{"protocolSection":{"identificationModule":{"nctId":"NCT01982630","orgStudyIdInfo":{"id":"8521-003"},"organization":{"fullName":"Merck Sharp & Dohme LLC","class":"INDUSTRY"},"briefTitle":"Study of the Safety and Efficacy of MK-8521 Compared to Placebo and a Diabetes Drug in Participants With Type 2 Diabetes Mellitus (MK-8521-003)","officialTitle":"A Phase Ib, Multicenter, Placebo and Active- Comparator-Controlled, Randomized, Double-Blind, Clinical Trial to Evaluate the Safety and Efficacy of MK-8521 Compared to Placebo and a Diabetes Drug in Subjects With Type 2 Diabetes Mellitus"},"statusModule":{"statusVerifiedDate":"2021-12","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2013-11-07","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2014-10-03","type":"ACTUAL"},"completionDateStruct":{"date":"2014-10-03","type":"ACTUAL"},"studyFirstSubmitDate":"2013-11-06","studyFirstSubmitQcDate":"2013-11-06","studyFirstPostDateStruct":{"date":"2013-11-13","type":"ESTIMATED"},"resultsFirstSubmitDate":"2021-12-16","resultsFirstSubmitQcDate":"2021-12-16","resultsFirstPostDateStruct":{"date":"2022-03-08","type":"ACTUAL"},"lastUpdateSubmitDate":"2021-12-16","lastUpdatePostDateStruct":{"date":"2022-03-08","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Merck Sharp & Dohme LLC","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"This study will evaluate the safety, efficacy, and pharmacokinetics of MK-8521 given once daily compared to placebo and another diabetes drug in participants with Type 2 diabetes mellitus (T2DM).\n\nThis study was modified by a protocol amendment to a 2-part trial to further test the safety and tolerability of MK-8521 at higher doses and to compare MK-8521 pharmacokinetics between participants with T2DM and healthy participants. An additional cohort of T2DM participants and a cohort of non-diabetic obese participants has been added."},"conditionsModule":{"conditions":["Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":87,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Part 1: MK-8521 64/120 μg/day","type":"EXPERIMENTAL","description":"Type 2 diabetes mellitus (T2DM) participants received once daily subcutaneous MK-8521 starting at 64 μg on Days 1 to 7 and escalated to 120 μg on Days 8 to 14.","interventionNames":["Drug: MK-8521"]},{"label":"Part 1: MK-8521 34/72 μg/day","type":"EXPERIMENTAL","description":"T2DM participants received once daily subcutaneous MK-8521 starting at 34 μg on Days 1 to 7 and escalated to 72 μg on Days 8 to 14.","interventionNames":["Drug: MK-8521"]},{"label":"Part 1: Liraglutide 0.6/1.2/1.8 mg/day","type":"ACTIVE_COMPARATOR","description":"T2DM participants received once daily subcutaneous liraglutide starting at 0.6 mg on Day 1 and 2, escalated to 1.2 mg on Days 3 to 7, and escalated to 1.8 mg on Days 8 to 14.","interventionNames":["Drug: Liraglutide"]},{"label":"Part 1: Placebo for MK-8521","type":"PLACEBO_COMPARATOR","description":"T2DM participants received once daily subcutaneous placebo for MK-8521 for 14 days.","interventionNames":["Drug: Placebo"]},{"label":"Part 2: MK-8521 64/120/180/240/300 µg/day-T2DM","type":"EXPERIMENTAL","description":"T2DM participants received once daily subcutaneous MK-8521 titrated to 300 µg starting at 64 µg and increasing to 120 µg on Day 8, 180 µg on Day 15, 240 µg on Day 20, and 300 µg on Day 25. The total number of dosing days was 29.","interventionNames":["Drug: MK-8521"]},{"label":"Part 2: Liraglutide 0.6/1.2/1.8 mg/day-T2DM","type":"ACTIVE_COMPARATOR","description":"T2DM participants received once daily subcutaneous liraglutide titrated to 1.8 mg starting at 0.6 mg and increasing to 1.2 mg on Day 8, and 1.8 mg on Day 15. The total number of dosing days was 29.","interventionNames":["Drug: Liraglutide"]},{"label":"Part 2: Placebo for MK-8521-T2DM","type":"PLACEBO_COMPARATOR","description":"T2DM participants received once daily subcutaneous placebo for MK-8521 for 29 days.","interventionNames":["Drug: Placebo"]},{"label":"Part 2: MK-8521 64/120 µg/day-Non-Diabetic Overweight/Obese","type":"EXPERIMENTAL","description":"Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 titrated to 120 µg starting at 64 µg and increasing to 120 µg on Day 8. The total number of dosing days was 14.","interventionNames":["Drug: MK-8521"]}],"interventions":[{"type":"DRUG","name":"MK-8521","armGroupLabels":["Part 1: MK-8521 34/72 μg/day","Part 1: MK-8521 64/120 μg/day","Part 2: MK-8521 64/120 µg/day-Non-Diabetic Overweight/Obese","Part 2: MK-8521 64/120/180/240/300 µg/day-T2DM"]},{"type":"DRUG","name":"Liraglutide","armGroupLabels":["Part 1: Liraglutide 0.6/1.2/1.8 mg/day","Part 2: Liraglutide 0.6/1.2/1.8 mg/day-T2DM"]},{"type":"DRUG","name":"Placebo","armGroupLabels":["Part 1: Placebo for MK-8521","Part 2: Placebo for MK-8521-T2DM"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number of Participants Experiencing Adverse Events (AEs) in Part 1","description":"An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. AEs are presented by individual dose received by participants during titration in an assigned study treatment sequence.","timeFrame":"Up to approximately 42 days"},{"measure":"Number of Participants Experiencing Adverse Events (AEs) in Part 2","description":"An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. AEs are presented by individual dose received by participants during titration in an assigned study treatment sequence.","timeFrame":"Up to approximately 57 days"},{"measure":"Number of Participants Discontinuing Study Drug Due to Adverse Events (AEs) in Part 1","description":"An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. Discontinuations are presented by individual dose received by participants during titration in an assigned study treatment sequence.","timeFrame":"Up to approximately 14 days"},{"measure":"Number of Participants Discontinuing Study Drug Due to Adverse Events (AEs) in Part 2","description":"An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. Discontinuations are presented by individual dose received by participants during titration in an assigned study treatment sequence.","timeFrame":"Up to approximately 29 days"},{"measure":"Change From Baseline in Time-weighted Average From 0 to 24 Hours (TWA0-24hr) of Heart Rate (HR) After 7 Days of Treatment in Type 2 Diabetes Mellitus (T2DM) Participants in Part 1","description":"Semi-recumbent heart rate was assessed at baseline on Day 1; Day 7 at predose, 2, 4, 6, 8, 12, 13, 14, 15, 16, 22 hours postdose; and prior to dosing on Day 8. Heart rate was measured in triplicate with at least a 1-2-minute interval between measurements. The repeated measurements were averaged before conducting the statistical analysis. TWA0-24hr was calculated as the area under the measurement-time curve (AUC) divided by the time period of over which the measurements were made (i.e. 24 hrs.). Change from baseline TWA0-24hr HR was calculated as the TWA0-24hr HR at Day 7 minus baseline where baseline was defined as predose on Day 1.","timeFrame":"Baseline (predose Day 1) and up to 24 hours post Day 7 dose"},{"measure":"Change From Baseline in Time-weighted Average From 0 to 24 Hours (TWA0-24hr) of Heart Rate (HR) After 7 Days of Treatment in Type 2 Diabetes Mellitus (T2DM) Participants in Part 2","description":"Semi-recumbent HR was measured in triplicate with at least a 1-2-minute interval between measurements at the following time points: baseline on Day 1; Day 7: predose, 2, 4, 6, 8, 12, and 16 hours postdose; and prior to dosing on Day 8. The repeated measurements were averaged before conducting the analysis. TWA0-24hr was calculated as the AUC divided by the time period of over which the measurements were made (i.e. 24 hrs.). Change from baseline TWA0-24hr HR was calculated as the TWA0-24hr HR at Day 7 minus baseline where baseline was defined as predose on Day 1.","timeFrame":"Baseline (predose Day 1) and up to 24 hours post Day 7 dose"},{"measure":"Change From Baseline in Time-weighted Average From 0 to 24 Hours (TWA0-24hr) of Heart Rate (HR) After 14 Days of Treatment in Type 2 Diabetes Mellitus (T2DM) Participants in Part 1","description":"Semi-recumbent HR was measured in triplicate with at least a 1-2-minute interval between measurements at the following time points: baseline on Day 1; Day 14: predose, 2, 4, 6, 8, 12, 13, 14, 15, 16, 22 hours postdose and prior to dosing on Day 15. The repeated measurements were averaged before conducting the analysis. TWA0-24hr was calculated as the AUC divided by the time period of over which the measurements were made (i.e. 24 hrs.). Change from baseline TWA0-24hr HR was calculated as the TWA0-24hr HR at Day 14 minus baseline where baseline was defined as predose on Day 1.","timeFrame":"Baseline (predose Day 1) and up to 24 hours post Day 14 dose"},{"measure":"Change From Baseline in Time-weighted Average From 0 to 24 Hours (TWA0-24hr) of Heart Rate (HR) After 14 Days of Treatment in Type 2 Diabetes Mellitus (T2DM) Participants in Part 2","description":"Semi-recumbent HR was measured in triplicate with at least a 1-2-minute interval between measurements at the following time points: baseline on Day 1; Day 14: predose, 2, 4, 6, 8, 12, 16, hours postdose; and prior to dosing on Day 15. The repeated measurements were averaged before conducting the analysis. TWA0-24hr was calculated as the AUC divided by the time period of over which the measurements were made (i.e. 24 hrs.). Change from baseline TWA0-24hr HR was calculated as the TWA0-24hr HR at Day 14 minus baseline where baseline was defined as predose on Day 1.","timeFrame":"Baseline (predose Day 1) and up to 24 hours post Day 14 dose"},{"measure":"Change From Baseline in Time-weighted Average From 0 to 24 Hours (TWA0-24hr) of Heart Rate (HR) After 19 Days of Treatment in Type 2 Diabetes Mellitus (T2DM) Participants in Part 2","description":"Semi-recumbent HR was measured in triplicate with at least a 1-2-minute interval between measurements at the following time points: baseline on Day 1; Day 19: predose, 2, 4, 6, 8, 12, 16, hours post dose; and prior to dosing on Day 20. The repeated measurements were averaged before conducting the analysis. TWA0-24hr was calculated as the AUC divided by the time period of over which the measurements were made (i.e. 24 hrs.). Change from baseline TWA0-24hr HR was calculated as the TWA0-24hr HR at Day 19 minus baseline where baseline was defined as predose on Day 1.","timeFrame":"Baseline (predose Day 1) and up to 24 hours post Day 19 dose"},{"measure":"Change From Baseline in Time-weighted Average From 0 to 24 Hours (TWA0-24hr) of Heart Rate (HR) After 24 Days of Treatment in Type 2 Diabetes Mellitus (T2DM) Participants in Part 2","description":"Semi-recumbent HR was measured in triplicate with at least a 1-2-minute interval between measurements at the following time points: baseline on Day 1; Day 24: predose, 2, 4, 6, 8, 12, 16, hours postdose; and prior to dosing on Day 25. The repeated measurements were averaged before conducting the analysis. TWA0-24hr was calculated as the AUC divided by the time period of over which the measurements were made (i.e. 24 hrs.). Change from baseline TWA0-24hr HR was calculated as the TWA0-24hr HR at Day 24 minus baseline where baseline was defined as predose on Day 1.","timeFrame":"Baseline (predose Day 1) and up to 24 hours post Day 24 dose"},{"measure":"Change From Baseline in Time-weighted Average From 0 to 24 Hours (TWA0-24hr) of Heart Rate (HR) After 29 Days of Treatment in Type 2 Diabetes Mellitus (T2DM) Participants in Part 2","description":"Semi-recumbent HR was measured in triplicate with at least a 1-2-minute interval between measurements at the following time points: baseline on Day 1; and Day 29: predose, 2, 4, 6, 8, 12, 16 and 24 hours postdose. The repeated measurements were averaged before conducting the analysis. TWA0-24hr was calculated as the AUC divided by the time period of over which the measurements were made (i.e. 24 hrs.). Change from baseline TWA0-24hr HR was calculated as the TWA0-24hr HR at Day 29 minus baseline where baseline was defined as predose on Day 1.","timeFrame":"Baseline (predose Day 1) and up to 24 hours post Day 29 dose"},{"measure":"Change From Baseline in Peak Heart Rate (PHR) at Day 7 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 2","description":"PHR was defined as the maximum time matched baseline adjusted heart rate over 24 hours. Semi-recumbent PHR was measured in triplicate with at least a 1-2-minute interval between measurements at the following time points: baseline on Day 1; Day 7: predose, 2, 4, 6, 8, 12, and 16 hours postdose; and prior to dosing on Day 8. The repeated measurements were averaged before conducting the analysis. Change from baseline PHR was calculated as the peak heart rate at Day 7 minus baseline where baseline was defined as predose on Day 1.","timeFrame":"Baseline (predose Day 1) and up to 24 hours post Day 7 dose"},{"measure":"Change From Baseline in Peak Heart Rate (PHR) at Day 14 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 2","description":"PHR was defined as the maximum time matched baseline adjusted heart rate over 24 hours. Semi-recumbent PHR was measured in triplicate with at least a 1-2-minute interval between measurements at the following time points: baseline on Day 1; Day 14: predose, 2, 4, 6, 8, 12, and 16 hours postdose; and prior to dosing on Day 15. The repeated measurements were averaged before conducting the analysis. Change from baseline PHR was calculated as the peak heart rate at Day 14 minus baseline where baseline was defined as predose on Day 1.","timeFrame":"Baseline (predose Day 1) and up to 24 hours post Day 14 dose"},{"measure":"Change From Baseline in Peak Heart Rate (PHR) at Day 19 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 2","description":"PHR was defined as the maximum time matched baseline adjusted heart rate over 24 hours. Semi-recumbent PHR was measured in triplicate with at least a 1-2-minute interval between measurements at the following time points: baseline on Day 1; Day 19: predose, 2, 4, 6, 8, 12, and 16 hours postdose; and prior to dosing on Day 20. The repeated measurements were averaged before conducting the analysis. Change from baseline PHR was calculated as the peak heart rate at Day 19 minus baseline where baseline was defined as predose on Day 1.","timeFrame":"Baseline (predose Day 1) and up to 24 hours post Day 19 dose"},{"measure":"Change From Baseline in Peak Heart Rate (PHR) at Day 24 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 2","description":"PHR was defined as the maximum time matched baseline adjusted heart rate over 24 hours. Semi-recumbent PHR was measured in triplicate with at least a 1-2-minute interval between measurements at the following time points: baseline on Day 1; Day 24: predose, 2, 4, 6, 8, 12, and 16 hours postdose; and prior to dosing on Day 25. The repeated measurements were averaged before conducting the analysis. Change from baseline PHR was calculated as the peak heart rate at Day 24 minus baseline where baseline was defined as predose on Day 1.","timeFrame":"Baseline (predose Day 1) and up to 24 hours post Day 24 dose"},{"measure":"Change From Baseline in Peak Heart Rate (PHR) at Day 29 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 2","description":"PHR was defined as the maximum time matched baseline adjusted heart rate over 24 hours. Semi-recumbent PHR was measured in triplicate with at least a 1-2-minute interval between measurements at the following time points: baseline on Day 1; and Day 29: predose 2, 4, 6, 8, 12, 16, and 24 hours post dose. The repeated measurements were averaged before conducting the analysis. Change from baseline PHR was calculated as the peak heart rate at Day 29 minus baseline where baseline was defined as predose on Day 1.","timeFrame":"Baseline (predose Day 1) and up to 24 hours post Day 29 dose"},{"measure":"Change From Baseline in Resting Morning Heart Rate (RMHR) After the Day 7 Dose for Type 2 Diabetes Mellitus (T2DM) Participants in Part 2","description":"Semi-recumbent RMHR was measured in triplicate with at least a 1-2-minute interval between measurements. The repeated measurements were averaged for each time point. Change from baseline RMHR was calculated as the RMHR 24 hours after the Day 7 dose (predose Day 8) minus baseline. Baseline was an average of 2 readings prior to dosing on Day 1.","timeFrame":"Baseline (predose Day 1) and Day 8 (24 hours after Day 7)"},{"measure":"Change From Baseline in Resting Morning Heart Rate (RMHR) After the Day 14 Dose for Type 2 Diabetes Mellitus (T2DM) Participants in Part 2","description":"Semi-recumbent RMHR was measured in triplicate with at least a 1-2-minute interval between measurements. The repeated measurements were averaged for each time point. Change from baseline RMHR was calculated as the RMHR 24 hours after the Day 14 dose (predose Day 15) minus baseline. Baseline was an average of 2 readings prior to dosing on Day 1.","timeFrame":"Baseline (predose Day 1) and Day 15 (24 hours after Day 14)"},{"measure":"Change From Baseline in Resting Morning Heart Rate (RMHR) After the Day 19 Dose for Type 2 Diabetes Mellitus (T2DM) Participants in Part 2","description":"Semi-recumbent RMHR was measured in triplicate with at least a 1-2-minute interval between measurements. The repeated measurements were averaged for each time point. Change from baseline RMHR was calculated as the RMHR 24 hours after the Day 19 dose (predose Day 20) minus baseline. Baseline was an average of 2 readings prior to dosing on Day 1.","timeFrame":"Baseline (predose Day 1) and Day 20 (24 hours after Day 19)"},{"measure":"Change From Baseline in Resting Morning Heart Rate (RMHR) After the Day 24 Dose for Type 2 Diabetes Mellitus (T2DM) Participants in Part 2","description":"Semi-recumbent RMHR was measured in triplicate with at least a 1-2-minute interval between measurements. The repeated measurements were averaged for each time point. Change from baseline RMHR was calculated as the RMHR 24 hours after the Day 24 dose (predose Day 25) minus baseline. Baseline was an average of 2 readings prior to dosing on Day 1.","timeFrame":"Baseline (predose Day 1) and Day 25 (24 hours after Day 24)"},{"measure":"Change From Baseline in Resting Morning Heart Rate (RMHR) After the Day 29 Dose for Type 2 Diabetes Mellitus (T2DM) Participants in Part 2","description":"Semi-recumbent RMHR was measured in triplicate with at least a 1-2-minute interval between measurements. The repeated measurements were averaged for each time point. Change from baseline RMHR was calculated as the RMHR 24 hours after the Day 29 dose minus baseline. Baseline was an average of 2 readings prior to dosing on Day 1.","timeFrame":"Baseline (predose Day 1) and Day 30 (24 hours after Day 29)"},{"measure":"Area Under the Concentration-time Curve From 0 to 24 Hours (AUC0-24hr) of MK-8521 on Days 1, 7, and 14 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 1","description":"AUC0-24hr was the area under the concentration-time curve of MK-8521 from time zero to 24 hours after administration. Plasma samples were collected from predose to 24 hours postdose for determination of AUC0-24hr. Individual values were natural log-transformed and evaluated with a linear-mixed effects model containing fixed effects for treatment, day, and treatment by day interaction, and a random effect for participant. Kenward and Roger's method was used to calculate the degree of freedom for the fixed effects. AUC0-24hr is presented as geometric mean and percent coefficient of variation of geometric mean.","timeFrame":"Predose and 1, 2, 4, 6, 8, 10, 12, 16, and 24 hours post-dose on Days 1, 7, and 14"},{"measure":"Maximum Concentration (Cmax) of MK-8521 on Days 1 and 7 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 1","description":"Cmax was the maximum observed concentration of MK-8521 in plasma after administration. Plasma samples were collected from predose to 24 hours postdose for determination of Cmax. Individual values were natural log-transformed and evaluated with a linear-mixed effects model containing fixed effects for treatment, day, and treatment by day interaction, and a random effect for participant. Kenward and Roger's method was used to calculate the degree of freedom for the fixed effects. Cmax is presented as geometric mean and percent coefficient of variation of geometric mean.","timeFrame":"Predose and 1, 2, 4, 6, 8, 10, 12, 16, and 24 hours post-dose on Days 1 and 7"},{"measure":"Maximum Concentration (Cmax) of MK-8521 on Day 14 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 1","description":"Cmax was the maximum observed concentration of MK-8521 in plasma after administration on Day 14. Plasma samples were collected from predose to 120 hours postdose for determination of Cmax. Individual values were natural log-transformed and evaluated with a linear-mixed effects model containing fixed effects for treatment, day, and treatment by day interaction, and a random effect for participant. Kenward and Roger's method was used to calculate the degree of freedom for the fixed effects. Cmax is presented as geometric mean and percent coefficient of variation of geometric mean.","timeFrame":"Predose and 1, 2, 4, 6, 8, 10, 12, 16, 24, 72, 96, and 120 hours post-dose on Day 14"},{"measure":"Trough Concentration (Ctrough) of MK-8521 on Days 1, 7, and 14 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 1","description":"Ctrough was the lowest observed concentration of MK-8521 in plasma. Plasma samples were collected predose on Day 2 (sampled after the Day 1 dose and prior to Day 2 dose), 7, and 14 for determination of Ctrough. Individual values were natural log-transformed and evaluated with a linear-mixed effects model containing fixed effects for treatment, day, and treatment by day interaction, and a random effect for participant. Kenward and Roger's method was used to calculate the degree of freedom for the fixed effects. Ctrough is presented as geometric mean and percent coefficient of variation of geometric mean.","timeFrame":"Predose on Days 2, 7, and 14"},{"measure":"Time to Maximum Concentration (Tmax) of MK-8521 on Days 1 and 7 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 1","description":"Tmax was the time required to reach the maximum concentration of MK-8521 in plasma. Plasma samples were collected from predose to 24 hours postdose for determination of Tmax. Tmax is presented as median with a full range.","timeFrame":"Predose and 1, 2, 4, 6, 8, 10, 12, 16, and 24 hours post-dose on Days 1 and 7"},{"measure":"Time to Maximum Concentration (Tmax) of MK-8521 on Day 14 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 1","description":"Tmax was the time required to reach the maximum concentration of MK-8521 in plasma. Plasma samples were collected from predose to 120 hours postdose for determination of Tmax. Tmax is presented as median with a full range.","timeFrame":"Predose and 1, 2, 4, 6, 8, 10, 12, 16, 24, 72, 96, and 120 hours post-dose on Day 14"},{"measure":"Apparent Terminal Half Life (t1/2) of MK-8521 on Days 1 and 7 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 1","description":"t1/2 was the time required to divide the MK-8521 concentration by half after reaching pseudo-equilibrium. Plasma samples were collected from predose to 24 hours postdose for determination of t1/2. t1/2 is presented as geometric mean and percent coefficient of variation of geometric mean.","timeFrame":"Predose and 1, 2, 4, 6, 8, 10, 12, 16, and 24 hours post-dose on Days 1 and 7"},{"measure":"Apparent Terminal Half Life (t1/2) of MK-8521 on Day 14 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 1","description":"t1/2 was the time required to divide the MK-8521 concentration by half after reaching pseudo-equilibrium. Plasma samples were collected from predose to 120 hours postdose for determination of t1/2. t1/2 was measured on Day 14 which is the longest time point for sampling for T2DM participants in Part 1. t1/2 is presented as geometric mean and percent coefficient of variation of geometric mean.","timeFrame":"Predose and 1, 2, 4, 6, 8, 10, 12, 16, 24, 72, 96, and 120 hours post-dose on Day 14"},{"measure":"Accumulation Ratio of the Area Under the Concentration-time Curve From 0 to 24 Hours (AUC0-24hr) of MK-8521 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 1","description":"Plasma samples were collected from predose to 24 hours postdose for determination of the accumulation ratio of AUC0-24hr. The geometric mean accumulation ratio was calculated as Day 7 AUC0-24hr/Day 1 AUC0-24hr and presented as geometric mean ratio with a full range.","timeFrame":"Predose and 1, 2, 4, 6, 8, 10, 12, 16, and 24 hours post-dose on Days 1 and 7"},{"measure":"Accumulation Ratio of the Maximum Concentration (Cmax) of MK-8521 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 1","description":"Plasma samples were collected from predose to 24 hours postdose for determination of the accumulation ratio of Cmax. The geometric mean accumulation ratio was calculated as Day 7 Cmax/Day 1 Cmax and presented as geometric mean ratio with a full range.","timeFrame":"Predose and 1, 2, 4, 6, 8, 10, 12, 16, and 24 hours post-dose on Days 1 and 7"},{"measure":"Accumulation Ratio of the Trough Concentration (Ctrough) of MK-8521 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 1","description":"Plasma samples were collected predose on Days 2 (sampled after the Day 1 dose and prior to Day 2 dose) and 7 for determination of the accumulation ratio of Ctrough. The geometric mean accumulation ratio was calculated as Day 7 Ctrough/Day 1 Ctrough (sampled after the Day 1 dose and prior to Day 2 dose) and presented as geometric mean ratio with a full range.","timeFrame":"Predose on Days 2 and 7"},{"measure":"Area Under the Concentration-time Curve From 0 to 24 Hours (AUC0-24hr) of MK-8521 on Days 1, 7, and 14 for Type 2 Diabetes Mellitus (T2DM) and Non-Diabetic Overweight/Obese Participants in Part 2","description":"AUC0-24hr was the area under the concentration-time curve of MK-8521 from time zero to 24 hours after administration. Plasma samples were collected from predose to 24 hours postdose for determination of AUC0-24hr. Individual values were natural log-transformed and evaluated with a linear-mixed effects model containing fixed effects for treatment, day, and treatment by day interaction, and a random effect for participant. Kenward and Roger's method was used to calculate the degree of freedom for the fixed effects. AUC0-24hr is presented as geometric mean and percent coefficient of variation of geometric mean.","timeFrame":"Predose and 1, 2, 6, 10, 16, and 24 hours postdose on Days 1, 7, and 14"},{"measure":"Accumulation Ratio of the Area Under the Concentration-time Curve From 0 to 24 Hours (AUC0-24hr) of MK-8521 for Type 2 Diabetes Mellitus (T2DM) and Non-Diabetic Overweight/Obese Participants in Part 2","description":"Plasma samples were collected from predose to 24 hours postdose for determination of the accumulation ratio of AUC0-24hr. The geometric mean accumulation ratio was calculated as Day 7 AUC0-24hr/Day 1 AUC0-24hr and presented as geometric mean ratio and percent geometric coefficient of variation.","timeFrame":"Predose and 1, 2, 6, 10, 16, and 24 hours post-dose on Days 1 and 7"}],"secondaryOutcomes":[{"measure":"Change From Baseline in Fasting Plasma Glucose (FPG) at Day 7 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 1","description":"FPG was measured predose on Days 1 and 7. The change from baseline of FPG was calculated as the difference between the predose measurement on Day 1 (baseline) and the measurement obtained predose on Day 7. FPG is presented as mean change from baseline with a standard error.","timeFrame":"Predose on Days 1 (baseline) and 7"},{"measure":"Change From Baseline in Fasting Plasma Glucose (FPG) at Day 14 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 1","description":"FPG was measured predose on Days 1 and 14. The change from baseline of FPG was calculated as the difference between the predose measurement on Day 1 (baseline) and the measurement obtained predose on Day 14. FPG is presented as mean change from baseline with a standard error.","timeFrame":"Predose on Days 1 (baseline) and 14"},{"measure":"Change From Baseline in 24-hour Weighted Mean Glucose (WMG) at Day 7 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 1","description":"The 24-hour WMG was calculated as the area under the 24-hour glucose curve (AUC0-24hr) divided by 24 hours. Blood samples for glucose were collected immediately prior to, and after each meal. The change from baseline value for 24-hour WMG was calculated where baseline was the WMG before food and prior to treatment on Day 1. Blood for plasma glucose concentrations was obtained at predose Day 1 at pre meal (breakfast), 0.5, 1, 2, 3, 4 (pre lunch), 4.5, 5, 6, 7, 10 (pre dinner), 10.5, 11, 12, 13, 15 and 23 hours post breakfast meal; and on Day 7 at 1 (pre breakfast), 1.5, 2, 3, 4, 5 (pre lunch), 5.5, 6, 7, 8, 11 (pre dinner), 11.5, 12, 13, 14, 16, 24 hours post dose. Individual change from baseline 24-hour WMG was analyzed in a linear mixed effects model with fixed effects for treatment, day and treatment by day interaction, a random effect for participant, and baseline 24-hour WMG as a covariate. WMG is presented as least squares mean with a 95% confidence interval.","timeFrame":"Baseline (predose and before food on Day 1) and up to 24 hours post Day 7 dose"},{"measure":"Change From Baseline in 24-hour Weighted Mean Glucose (WMG) at Day 14 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 1","description":"The 24-hour WMG was calculated as the area under the 24-hour glucose curve (AUC0-24hr) divided by 24 hours. Blood samples for glucose were collected immediately prior to and after each meal. The change from baseline value for 24-hour WMG was calculated where baseline was the WMG before food and prior to treatment on Day 1. Blood for plasma glucose concentrations was obtained on Day -1 at pre meal (breakfast), 0.5, 1, 2, 3, 4 (pre lunch), 4.5, 5, 6, 7, 10 (pre dinner), 10.5, 11, 12, 13, 15 and 23 hours post breakfast meal; and on Day 14 at 1 (pre breakfast), 1.5, 2, 3, 4, 5 (pre lunch), 5.5, 6, 7, 8, 11(pre dinner), 11.5, 12, 13, 14, 16, 24 hours post dose. Individual change from baseline 24-hour WMG was analyzed in a linear mixed effects model with fixed effects for treatment, day and treatment by day interaction, a random effect for participant, and baseline 24-hour WMG as a covariate. WMG is presented as least squares mean with a 95% confidence interval.","timeFrame":"Baseline (predose and before food on Day 1) and up to 24 hours post Day 14 dose"},{"measure":"Change From Baseline in Fasting Plasma Glucose (FPG) at Day 14 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 2","description":"FPG was measured predose on Days 1 and 14. The change from baseline of FPG was calculated as the difference between the predose measurement on Day 1 (baseline) and the measurement obtained predose on Day 14. FPG is presented as least squares mean change from baseline with a 95% confidence interval.","timeFrame":"Predose on Days 1 (baseline) and 14"},{"measure":"Change From Baseline in Fasting Plasma Glucose (FPG) at Day 19 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 2","description":"FPG was measured predose on Days 1 and 19. The change from baseline of FPG was calculated as the difference between the predose measurement on Day 1 (baseline) and the measurement obtained predose on Day 19. FPG is presented as least squares mean change from baseline with a 95% confidence interval.","timeFrame":"Predose on Days 1 (baseline) and 19"},{"measure":"Change From Baseline in Fasting Plasma Glucose (FPG) at Day 24 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 2","description":"FPG was measured predose on Days 1 and 24. The change from baseline of FPG was calculated as the difference between the predose measurement on Day 1 (baseline) and the measurement obtained predose on Day 24. FPG is presented as least squares mean change from baseline with a 95% confidence interval.","timeFrame":"Predose on Days 1 (baseline) and 24"},{"measure":"Change From Baseline in Fasting Plasma Glucose (FPG) at Day 29 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 2","description":"FPG was measured predose on Days 1 and 29. The change from baseline of FPG was calculated as the difference between the predose measurement on Day 1 (baseline) and the measurement obtained predose on Day 29. FPG is presented as least squares mean change from baseline with a 95% confidence interval.","timeFrame":"Predose on Days 1 (baseline) and 29"},{"measure":"Change From Baseline in 24-hour Weighted Mean Glucose (WMG) at Day 14 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 2","description":"The 24-hour WMG was calculated as the area under the 24-hour glucose curve (AUC0-24hr) divided by 24 hours. Plasma glucose concentrations were obtained on Day -1 at pre meal (breakfast), 1, 3, 4 (pre lunch), 5, 7, 10 (pre dinner), 11, 13, 15 and 23 hours post breakfast meal and Day 14 at 1 (pre breakfast), 2, 4, 5 (pre lunch), 6, 8, 11 (pre dinner), 12, 14, 16, 24 hours post dose. The timing of samples on Day -1 are relative to the breakfast meal. Day 14 samples are relative to dosing. The change from baseline value for 24-hour WMG was calculated where baseline was the WMG before food and prior to treatment on Day 1. Individual change from baseline 24-hour WMG was analyzed in a linear mixed effects model with group, day and group by day interaction as fixed effects, baseline 24-hour WMG as a covariate, and participant as a random effect. WMG is presented as least squares mean with a 95% confidence interval.","timeFrame":"Baseline (predose and before food on Day 1) and up to 24 hours post Day 14 dose"},{"measure":"Change From Baseline in 24-hour Weighted Mean Glucose (WMG) at Day 19 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 2","description":"The 24-hour WMG was calculated as the area under the 24-hour glucose curve (AUC0-24hr) divided by 24 hours. Plasma glucose concentrations were obtained on Day -1 at pre meal (breakfast), 1, 3, 4 (pre lunch), 5, 7, 10 (pre dinner), 11, 13, 15 and 23 hours post breakfast meal and Day 19 at 1 (pre breakfast), 2, 4, 5 (pre lunch), 6, 8, 11 (pre dinner), 12, 14, 16, 24 hours post dose. The timing of samples on Day -1 are relative to the breakfast meal. Day 19 samples are relative to dosing. The change from baseline value for 24-hour WMG was calculated where baseline was the WMG before food and prior to treatment on Day 1. Individual change from baseline 24-hour WMG was analyzed in a linear mixed effects model with group, day and group by day interaction as fixed effects, baseline 24-hour WMG as a covariate, and participant as a random effect. WMG is presented as least squares mean with a 95% confidence interval.","timeFrame":"Baseline (predose and before food on Day 1) and up to 24 hours post Day 19 dose"},{"measure":"Change From Baseline in 24-hour Weighted Mean Glucose (WMG) at Day 24 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 2","description":"The 24-hour WMG was calculated as the area under the 24-hour glucose curve (AUC0-24hr) divided by 24 hours. Plasma glucose concentrations were obtained on Day -1 at pre meal (breakfast), 1, 3, 4 (pre lunch), 5, 7, 10 (pre dinner), 11, 13, 15 and 23 hours post breakfast meal and Day 24 at 1 (pre breakfast), 2, 4, 5 (pre lunch), 6, 8, 11 (pre dinner), 12, 14, 16, 24 hours post dose. The timing of samples on Day -1 are relative to the breakfast meal. Day 24 samples are relative to dosing. The change from baseline value for 24-hour WMG was calculated where baseline was the WMG before food and prior to treatment on Day 1. Individual change from baseline 24-hour WMG was analyzed in a linear mixed effects model with group, day and group by day interaction as fixed effects, baseline 24-hour WMG as a covariate, and participant as a random effect. WMG is presented as least squares mean with a 95% confidence interval.","timeFrame":"Baseline (predose and before food on Day 1) and up to 24 hours post Day 24 dose"},{"measure":"Change From Baseline in 24-hour Weighted Mean Glucose (WMG) at Day 29 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 2","description":"The 24-hour WMG was calculated as the area under the 24-hour glucose curve (AUC0-24hr) divided by 24 hours. Plasma glucose concentrations were obtained on Day -1 at pre meal (breakfast), 1, 3, 4 (pre lunch), 5, 7, 10 (pre dinner), 11, 13, 15 and 23 hours post breakfast meal and Day 29 at 1 (pre breakfast), 2, 4, 5 (pre lunch), 6, 8, 11 (pre dinner), 12, 14, 16, 24 hours post dose. The timing of samples on Day -1 are relative to the breakfast meal. Day 29 samples are relative to dosing. The change from baseline value for 24-hour WMG was calculated where baseline was the WMG before food and prior to treatment on Day 1. Individual change from baseline 24-hour WMG was analyzed in a linear mixed effects model with group, day and group by day interaction as fixed effects, baseline 24-hour WMG as a covariate, and participant as a random effect. WMG is presented as least squares mean with a 95% confidence interval.","timeFrame":"Baseline (predose and before food on Day 1) and up to 24 hours post Day 29 dose"},{"measure":"Maximum Concentration (Cmax) of MK-8521 for Type 2 Diabetes Mellitus (T2DM) and Non-Diabetic Overweight/Obese Participants in Part 2","description":"Cmax was the maximum observed concentration of MK-8521 in plasma after administration. Plasma samples were collected from predose to 120 hours postdose for determination of Cmax. Per protocol, Cmax in the non-diabetic overweight/obese participants was not measured on Days 19, 24, and 29 because they only received 14 days of treatment. Individual values were natural log-transformed and evaluated with a linear-mixed effects model containing fixed effects for treatment, day, and treatment by day interaction, and a random effect for participant. Kenward and Roger's method was used to calculate the degree of freedom for the fixed effects. Cmax is presented as geometric mean and percent coefficient of variation of geometric mean.","timeFrame":"Predose and 1, 2, 6, 10, 16, 24 hours post dose on Days 1, 7, 14, 19, 24 (T2DM) and Days 1 and 7 (Non-Diabetic Overweight/Obese); predose and 1, 2, 6, 10, 16, 24, 72, 96. and 120 hours post dose on Day 14 (Non-Diabetic Overweight/Obese) and Day 29 (T2DM)."},{"measure":"Trough Concentration (Ctrough) of MK-8521 for Type 2 Diabetes Mellitus (T2DM) and Non-Diabetic Overweight/Obese Participants in Part 2","description":"Ctrough was the lowest observed concentration of MK-8521 in plasma. Plasma samples were collected predose on Day 2 (sampled after the Day 1 dose and prior to Day 2 dose), 7, 14, 19, 24, and 29 for determination of Ctrough. Per protocol, Ctrough in the non-diabetic overweight/obese participants was not measured on Days 19, 24, and 29 because they only received 14 days of treatment. Individual values were natural log-transformed and evaluated with a linear-mixed effects model containing fixed effects for treatment, day, and treatment by day interaction, and a random effect for participant. Kenward and Roger's method was used to calculate the degree of freedom for the fixed effects. Ctrough is presented as geometric mean and percent coefficient of variation of geometric mean.","timeFrame":"Predose on Days 2 (sampled 24 hours after Day 1 dose) and 7, 14, 19, 24, and 29"},{"measure":"Time to Maximum Concentration (Tmax) of MK-8521 for Type 2 Diabetes Mellitus (T2DM) and Non-Diabetic Overweight/Obese Participants in Part 2","description":"Tmax was the time required to reach the maximum concentration of MK-8521 in plasma. Plasma samples were collected from predose to 120 hours postdose for determination of Tmax. Per protocol, Tmax in the non-diabetic overweight/obese participants was not measured on Days 19, 24, and 29 because they only received 14 days of treatment. Tmax is presented as median with a full range.","timeFrame":"Predose and 1, 2, 6, 10, 16, 24 hours post dose on Days 1, 7, 14, 19, 24 (T2DM) and Days 1 and 7 (Non-Diabetic Overweight/Obese); predose and 1, 2, 6, 10, 16, 24, 72, 96. and 120 hours post dose on Day 14 (Non-Diabetic Overweight/Obese) and Day 29 (T2DM)."},{"measure":"Apparent Terminal Half Life (t1/2) of MK-8521 on Day 29 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 2","description":"t1/2 was the time required to divide the MK-8521 concentration by half after reaching pseudo-equilibrium. Plasma samples were collected from predose to 120 hours postdose for determination of t1/2. Per protocol, t1/2 was measured on Day 29 which is the longest time point for sampling for T2DM participants 1/2 is presented as geometric mean and percent coefficient of variation of geometric mean.","timeFrame":"Predose and 1, 2, 6, 10, 16, 24, 72, 96 and 120 hours post dose on Day 29"},{"measure":"Apparent Terminal Half Life (t1/2) of MK-8521 on Day 14 for Non-Diabetic Overweight/Obese Participants in Part 2","description":"t1/2 was the time required to divide the MK-8521 concentration by half after reaching pseudo-equilibrium. Plasma samples were collected from predose to 24 hours postdose for determination of t1/2. Per protocol, t1/2 was measured on Day 14 which is the longest time point for sampling for non-diabetic overweight/obese participants 1/2 is presented as geometric mean and percent coefficient of variation of geometric mean.","timeFrame":"Predose and 1, 2, 6, 10, 16, and 24 hours post dose on Day 14"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male, or female of non-childbearing potential with Type 2 diabetes mellitus (Parts 1 and 2) or non-diabetic (Part 2)\n* Body mass index (BMI) between: ≥27 and ≤40 kg/m\\^2\n* A1C (average blood sugar for the past 2 to 3 months) value ≥7.0 and ≤11.0 % (Part 1) or ≥ 6.5 and ≤11.0 % (Part 2) at the time of screening (T2DM participants)\n* A1C value \\<5.7 at the time of screening (non-diabetic subjects in Part 2 only)\n* On a stable dose of metformin (≥1000 mg total daily dose) for at least 12 weeks at the time of screening (T2DM participants)\n\nExclusion Criteria:\n\n* Mentally or legally incapacitated\n* History of clinically significant psychiatric disorder of the last 5 years. Participants with situational depression may be enrolled in the trial at the discretion of the Investigator\n* History of Type 1 diabetes mellitus or a history of ketoacidosis\n* History of clinically significant gastrointestinal, hematological, hepatic, immunological, renal, respiratory, genitourinary or major neurological abnormalities or diseases\n* History of cardiovascular disease or cardiac conduction disorder\n* History of cancer (malignancy). Exceptions may include adequately treated non-melanomatous skin carcinoma or carcinoma in situ of the cervix or other malignancies which have been successfully treated ≥10 years prior to the pre-screening visit\n* History of proliferative diabetic retinopathy or maculopathy\n* Clinically significant diabetic autonomic neuropathy\n* QTc interval ≥470 msec (for males) or ≥480 msec (for females)\n* Clinical significant electrocardiogram (ECG) abnormality\n* Positive for hepatitis B surface antigen, hepatitis C antibodies, or human immunodeficiency virus (HIV)\n* On a weight loss program and is not weight-stable (weight stable is defined history of \\<5% change in body weight in the last 3 months\n* On a weight loss medication or has undergone bariatric surgery\n* Major surgery, donated or lost 1 unit of blood (approximately 500 mL) within 4 weeks prior to the pretrial (screening) visit\n* Participated in another investigational trial within 4 weeks prior to the pretrial (screening) visit\n* History of acute or chronic pancreatitis of any etiology\n* Mean value for triplicate semi-recumbent systolic blood pressure \\>160 mm Hg and/or diastolic blood pressure \\>90 mm Hg (after at least a 10-minute seated rest) and blood pressure is considered unlikely to be below these limits by Day-1 (Randomization) with initiation or adjustment of antihypertensive medication\n* Event of severe hypoglycemia with seizure or loss of consciousness in the past 12 months\n* Treated with anti-hyperglycemic agents other than metformin within the last 12 weeks\n* Previous exposure to any glucagon-like peptide-1 (GLP-1) receptor agonist (e.g. Byetta™, Victoza™ or investigational agents)","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Medical Director","affiliation":"Merck Sharp & Dohme LLC","role":"STUDY_DIRECTOR"}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf","url":"http://engagezone.msd.com/ds_documentation.php"}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Participant flow, baseline characteristic, and outcome measure data are presented by study treatment sequence. Adverse events are presented by the individual doses contained in the study treatment sequence.","recruitmentDetails":"This study had 2 parts: Part 1 evaluated MK-8521, placebo, and liraglutide in participants with Type 2 diabetes mellitus (T2DM); Part 2 evaluated MK-8521 at higher doses, liraglutide, and placebo in participants with T2DM and MK-8521 in non-diabetic, obese participants.","groups":[{"id":"FG000","title":"Part 1: MK-8521 64/120 μg/Day","description":"Type 2 diabetes mellitus (T2DM) participants received once daily subcutaneous MK-8521 starting at 64 μg on Days 1 to 7 and escalated to 120 μg on Days 8 to 14."},{"id":"FG001","title":"Part 1: MK-8521 34/72 μg/Day","description":"T2DM participants received once daily subcutaneous MK-8521 starting at 34 μg on Days 1 to 7 and escalated to 72 μg on Days 8 to 14."},{"id":"FG002","title":"Part 1: Liraglutide 0.6/1.2/1.8 mg/Day","description":"T2DM participants received once daily subcutaneous liraglutide starting at 0.6 mg on Day 1 and 2, escalated to 1.2 mg on Days 3 to 7, and escalated to 1.8 mg on Days 8 to 14."},{"id":"FG003","title":"Part 1: Placebo for MK-8521","description":"T2DM participants received once daily subcutaneous placebo for MK-8521 for 14 days."},{"id":"FG004","title":"Part 2: MK-8521 64/120/180/240/300 µg/Day-T2DM","description":"T2DM participants received once daily subcutaneous MK-8521 titrated to 300 µg starting at 64 µg and increasing to 120 µg on Day 8, 180 µg on Day 15, 240 µg on Day 20, and 300 µg on Day 25. The total number of dosing days was 29."},{"id":"FG005","title":"Part 2: Liraglutide 0.6/1.2/1.8 mg/Day-T2DM","description":"T2DM participants received once daily subcutaneous liraglutide titrated to 1.8 mg starting at 0.6 mg and increasing to 1.2 mg on Day 8, and 1.8 mg on Day 15. The total number of dosing days was 29."},{"id":"FG006","title":"Part 2: Placebo for MK-8521-T2DM","description":"T2DM participants received once daily subcutaneous placebo for MK-8521 for 29 days."},{"id":"FG007","title":"Part 2: MK-8521 64/120 µg/Day-Non-Diabetic Overweight/Obese","description":"Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 titrated to 120 µg starting at 64 µg and increasing to 120 µg on Day 8. The total number of dosing days was 14."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"10"},{"groupId":"FG001","numSubjects":"8"},{"groupId":"FG002","numSubjects":"13"},{"groupId":"FG003","numSubjects":"9"},{"groupId":"FG004","numSubjects":"19"},{"groupId":"FG005","numSubjects":"14"},{"groupId":"FG006","numSubjects":"6"},{"groupId":"FG007","numSubjects":"8"}]},{"type":"Treated","achievements":[{"groupId":"FG000","numSubjects":"9"},{"groupId":"FG001","numSubjects":"8"},{"groupId":"FG002","numSubjects":"11"},{"groupId":"FG003","numSubjects":"9"},{"groupId":"FG004","numSubjects":"18"},{"groupId":"FG005","numSubjects":"14"},{"groupId":"FG006","numSubjects":"6"},{"groupId":"FG007","numSubjects":"8"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"8"},{"groupId":"FG002","numSubjects":"8"},{"groupId":"FG003","numSubjects":"8"},{"groupId":"FG004","numSubjects":"16"},{"groupId":"FG005","numSubjects":"11"},{"groupId":"FG006","numSubjects":"5"},{"groupId":"FG007","numSubjects":"8"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"5"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"3"},{"groupId":"FG005","numSubjects":"3"},{"groupId":"FG006","numSubjects":"1"},{"groupId":"FG007","numSubjects":"0"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"1"},{"groupId":"FG005","numSubjects":"2"},{"groupId":"FG006","numSubjects":"1"},{"groupId":"FG007","numSubjects":"0"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"2"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"}]},{"type":"Did Not Receive Drug-Technical Issues","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"1"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"All randomized participants. Baseline characteristic data presented by treatment group.","groups":[{"id":"BG000","title":"Part 1: MK-8521 64/120 μg/Day","description":"Type 2 diabetes mellitus (T2DM) participants received once daily subcutaneous MK-8521 starting at 64 μg on Days 1 to 7 and escalated to 120 μg on Days 8 to 14."},{"id":"BG001","title":"Part 1: MK-8521 34/72 μg/Day","description":"T2DM participants received once daily subcutaneous MK-8521 starting at 34 μg on Days 1 to 7 and escalated to 72 μg on Days 8 to 14."},{"id":"BG002","title":"Part 1: Liraglutide 0.6/1.2/1.8 mg/Day","description":"T2DM participants received once daily subcutaneous liraglutide starting at 0.6 mg on Day 1 and 2, escalated to 1.2 mg on Days 3 to 7, and escalated to 1.8 mg on Days 8 to 14."},{"id":"BG003","title":"Part 1: Placebo for MK-8521","description":"T2DM participants received once daily subcutaneous placebo for MK-8521 for 14 days."},{"id":"BG004","title":"Part 2: MK-8521 64/120/180/240/300 µg/Day-T2DM","description":"T2DM participants received once daily subcutaneous MK-8521 titrated to 300 µg starting at 64 µg and increasing to 120 µg on Day 8, 180 µg on Day 15, 240 µg on Day 20, and 300 µg on Day 25. The total number of dosing days was 29."},{"id":"BG005","title":"Part 2: Liraglutide 0.6/1.2/1.8 mg/Day-T2DM","description":"T2DM participants received once daily subcutaneous liraglutide titrated to 1.8 mg starting at 0.6 mg and increasing to 1.2 mg on Day 8, and 1.8 mg on Day 15. The total number of dosing days was 29."},{"id":"BG006","title":"Part 2: Placebo for MK-8521-T2DM","description":"T2DM participants received once daily subcutaneous placebo for MK-8521 for 29 days."},{"id":"BG007","title":"Part 2: MK-8521 64/120 µg/Day-Non-Diabetic Overweight/Obese","description":"Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 titrated to 120 µg starting at 64 µg and increasing to 120 µg on Day 8. The total number of dosing days was 14."},{"id":"BG008","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"13"},{"groupId":"BG003","value":"9"},{"groupId":"BG004","value":"19"},{"groupId":"BG005","value":"14"},{"groupId":"BG006","value":"6"},{"groupId":"BG007","value":"8"},{"groupId":"BG008","value":"87"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"52.1","spread":"8.6"},{"groupId":"BG001","value":"55.0","spread":"6.4"},{"groupId":"BG002","value":"54.5","spread":"8.8"},{"groupId":"BG003","value":"51.3","spread":"9.0"},{"groupId":"BG004","value":"54.6","spread":"6.0"},{"groupId":"BG005","value":"54.6","spread":"7.9"},{"groupId":"BG006","value":"52.8","spread":"6.9"},{"groupId":"BG007","value":"37.9","spread":"14.1"},{"groupId":"BG008","value":"52.3","spread":"9.4"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"5"},{"groupId":"BG003","value":"6"},{"groupId":"BG004","value":"11"},{"groupId":"BG005","value":"9"},{"groupId":"BG006","value":"2"},{"groupId":"BG007","value":"2"},{"groupId":"BG008","value":"42"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"8"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"8"},{"groupId":"BG005","value":"5"},{"groupId":"BG006","value":"4"},{"groupId":"BG007","value":"6"},{"groupId":"BG008","value":"45"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"12"},{"groupId":"BG003","value":"8"},{"groupId":"BG004","value":"11"},{"groupId":"BG005","value":"8"},{"groupId":"BG006","value":"4"},{"groupId":"BG007","value":"4"},{"groupId":"BG008","value":"63"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"8"},{"groupId":"BG005","value":"6"},{"groupId":"BG006","value":"2"},{"groupId":"BG007","value":"4"},{"groupId":"BG008","value":"23"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"1"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"1"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"4"},{"groupId":"BG006","value":"1"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"13"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"13"},{"groupId":"BG003","value":"8"},{"groupId":"BG004","value":"17"},{"groupId":"BG005","value":"10"},{"groupId":"BG006","value":"5"},{"groupId":"BG007","value":"8"},{"groupId":"BG008","value":"73"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants Experiencing Adverse Events (AEs) in Part 1","description":"An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. AEs are presented by individual dose received by participants during titration in an assigned study treatment sequence.","populationDescription":"The analysis population included all participants in Part 1 who received at least one dose of study drug.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to approximately 42 days","groups":[{"id":"OG000","title":"Part 1: MK-8521 64 μg/Day","description":"Type 2 Diabetes Mellitus (T2DM) participants received once daily subcutaneous MK-8521 64 μg/day on Days 1 to 7 as part of the MK-8521 64/120 μg/day treatment group schedule."},{"id":"OG001","title":"Part 1: MK-8521 120 μg/Day","description":"T2DM participants received once daily subcutaneous MK-8521 120 μg/day on Days 8 to 14 as part of the MK-8521 64/120 μg/day treatment group schedule."},{"id":"OG002","title":"Part 1: MK-8521 34 μg/Day","description":"T2DM participants received once daily subcutaneous MK-8521 34 μg/day on Days 1 to 7 as part of the MK-8521 34/72 μg/day treatment group schedule."},{"id":"OG003","title":"Part 1: MK-8521 72 μg/Day","description":"T2DM participants received once daily subcutaneous MK-8521 72 μg/day on Days 8 to 14 as part of the MK-8521 34/72 μg/day treatment group schedule."},{"id":"OG004","title":"Part 1: Liraglutide 0.6 mg/Day","description":"T2DM participants received once daily subcutaneous liraglutide 0.6 mg on Day 1 and 2 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule."},{"id":"OG005","title":"Part 1: Liraglutide 1.2 mg/Day","description":"T2DM participants received once daily subcutaneous liraglutide 1.2 mg on Days 3 to 7 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule."},{"id":"OG006","title":"Part 1: Liraglutide 1.8 mg/Day","description":"T2DM participants received once daily subcutaneous liraglutide 1.8 mg on Days 8 to 14 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule."},{"id":"OG007","title":"Part 1: Placebo for MK-8521","description":"T2DM participants received once daily subcutaneous placebo for MK-8521 for 14 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"11"},{"groupId":"OG005","value":"11"},{"groupId":"OG006","value":"8"},{"groupId":"OG007","value":"8"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"7"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"5"}]}]}]},{"type":"PRIMARY","title":"Number of Participants Experiencing Adverse Events (AEs) in Part 2","description":"An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. AEs are presented by individual dose received by participants during titration in an assigned study treatment sequence.","populationDescription":"The analysis population included all participants in Part 2 who received at least one dose of study drug.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to approximately 57 days","groups":[{"id":"OG000","title":"Part 2: MK-8521 64 μg/Day","description":"Type 2 Diabetes Mellitus (T2DM) participants received once daily subcutaneous MK-8521 64 µg/day on Days 1 to 7 as part of the MK-8521 64/120/180/240/300 µg/day treatment group schedule."},{"id":"OG001","title":"Part 2: MK-8521 120 μg/Day","description":"T2DM participants received once daily subcutaneous MK-8521 120 µg/day on Days 8 to 14 as part of the MK-8521 64/120/180/240/300 µg/day treatment group schedule."},{"id":"OG002","title":"Part 2: MK-8521 180 μg/Day","description":"T2DM participants received once daily subcutaneous MK-8521 180 µg/day on Days 15 to 19 as part of the MK-8521 64/120/180/240/300 µg/day treatment group schedule."},{"id":"OG003","title":"Part 2: MK-8521 240 μg/Day","description":"T2DM participants received once daily subcutaneous MK-8521 240 µg/day on Days 20 to 24 as part of the MK-8521 64/120/180/240/300 µg/day treatment group schedule."},{"id":"OG004","title":"Part 2: MK-8521 300 μg/Day","description":"T2DM participants received once daily subcutaneous MK-8521 300 µg/day on Days 25 to 29 as part of the MK-8521 64/120/180/240/300 µg/day treatment group schedule."},{"id":"OG005","title":"Part 2: Liraglutide 0.6 mg/Day","description":"T2DM participants received once daily subcutaneous liraglutide 0.6 mg on Days 1 to 7 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule."},{"id":"OG006","title":"Part 2: Liraglutide 1.2 mg/Day","description":"T2DM participants received once daily subcutaneous liraglutide 1.2 mg on Days 8 to 14 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule."},{"id":"OG007","title":"Part 2: Liraglutide 1.8 mg/Day","description":"T2DM participants received once daily subcutaneous liraglutide 1.8 mg on Days 15 to 29 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule."},{"id":"OG008","title":"Part 2: Placebo for MK-8521-T2DM","description":"T2DM participants received once daily subcutaneous placebo for MK-8521 for 29 days."},{"id":"OG009","title":"Part 2: MK-8521 64 µg/Day-Non-Diabetic Overweight/Obese","description":"Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 64 µg/day on Days 1 to 7 as part of the MK-8521 64/120 µg/day treatment group schedule."},{"id":"OG010","title":"Part 2: MK-8521 120 µg/Day-Non-Diabetic Overweight/Obese","description":"Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 120 µg/day hon Days 8 to 14 as part of the MK-8521 64/120 µg/day treatment group schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"18"},{"groupId":"OG003","value":"18"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"14"},{"groupId":"OG006","value":"13"},{"groupId":"OG007","value":"13"},{"groupId":"OG008","value":"6"},{"groupId":"OG009","value":"8"},{"groupId":"OG010","value":"8"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"13"},{"groupId":"OG004","value":"8"},{"groupId":"OG005","value":"8"},{"groupId":"OG006","value":"8"},{"groupId":"OG007","value":"12"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"2"},{"groupId":"OG010","value":"4"}]}]}]},{"type":"PRIMARY","title":"Number of Participants Discontinuing Study Drug Due to Adverse Events (AEs) in Part 1","description":"An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. Discontinuations are presented by individual dose received by participants during titration in an assigned study treatment sequence.","populationDescription":"The analysis population included all participants in Part 1 who received at least one dose of study drug.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to approximately 14 days","groups":[{"id":"OG000","title":"Part 1: MK-8521 64 μg/Day","description":"Type 2 Diabetes Mellitus (T2DM) participants received once daily subcutaneous MK-8521 64 μg/day on Days 1 to 7 as part of the MK-8521 64/120 μg/day treatment group schedule."},{"id":"OG001","title":"Part 1: MK-8521 120 μg/Day","description":"T2DM participants received once daily subcutaneous MK-8521 120 μg/day on Days 8 to 14 as part of the MK-8521 64/120 μg/day treatment group schedule."},{"id":"OG002","title":"Part 1: MK-8521 34 μg/Day","description":"T2DM participants received once daily subcutaneous MK-8521 34 μg/day on Days 1 to 7 as part of the MK-8521 34/72 μg/day treatment group schedule."},{"id":"OG003","title":"Part 1: MK-8521 72 μg/Day","description":"T2DM participants received once daily subcutaneous MK-8521 72 μg/day on Days 8 to 14 as part of the MK-8521 34/72 μg/day treatment group schedule."},{"id":"OG004","title":"Part 1: Liraglutide 0.6 mg/Day","description":"T2DM participants received once daily subcutaneous liraglutide 0.6 mg on Day 1 and 2 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule."},{"id":"OG005","title":"Part 1: Liraglutide 1.2 mg/Day","description":"T2DM participants received once daily subcutaneous liraglutide 1.2 mg on Days 3 to 7 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule."},{"id":"OG006","title":"Part 1: Liraglutide 1.8 mg/Day","description":"T2DM participants received once daily subcutaneous liraglutide 1.8 mg on Days 8 to 14 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule."},{"id":"OG007","title":"Part 1: Placebo for MK-8521","description":"T2DM participants received once daily subcutaneous placebo for MK-8521 for 14 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"11"},{"groupId":"OG005","value":"11"},{"groupId":"OG006","value":"8"},{"groupId":"OG007","value":"8"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"}]}]}]},{"type":"PRIMARY","title":"Number of Participants Discontinuing Study Drug Due to Adverse Events (AEs) in Part 2","description":"An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. Discontinuations are presented by individual dose received by participants during titration in an assigned study treatment sequence.","populationDescription":"The analysis population included all participants in Part 2 who received at least one dose of study drug.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to approximately 29 days","groups":[{"id":"OG000","title":"Part 2: MK-8521 64 μg/Day","description":"Type 2 Diabetes Mellitus (T2DM) participants received once daily subcutaneous MK-8521 64 µg/day on Days 1 to 7 as part of the MK-8521 64/120/180/240/300 µg/day treatment group schedule."},{"id":"OG001","title":"Part 2: MK-8521 120 μg/Day","description":"T2DM participants received once daily subcutaneous MK-8521 120 µg/day on Days 8 to 14 as part of the MK-8521 64/120/180/240/300 µg/day treatment group schedule."},{"id":"OG002","title":"Part 2: MK-8521 180 μg/Day","description":"T2DM participants received once daily subcutaneous MK-8521 180 µg/day on Days 15 to 19 as part of the MK-8521 64/120/180/240/300 µg/day treatment group schedule."},{"id":"OG003","title":"Part 2: MK-8521 240 μg/Day","description":"T2DM participants received once daily subcutaneous MK-8521 240 µg/day on Days 20 to 24 as part of the MK-8521 64/120/180/240/300 µg/day treatment group schedule."},{"id":"OG004","title":"Part 2: MK-8521 300 μg/Day","description":"T2DM participants received once daily subcutaneous MK-8521 300 µg/day on Days 25 to 29 as part of the MK-8521 64/120/180/240/300 µg/day treatment group schedule."},{"id":"OG005","title":"Part 2: Liraglutide 0.6 mg/Day","description":"T2DM participants received once daily subcutaneous liraglutide 0.6 mg on Days 1 to 7 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule."},{"id":"OG006","title":"Part 2: Liraglutide 1.2 mg/Day","description":"T2DM participants received once daily subcutaneous liraglutide 1.2 mg on Days 8 to 14 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule."},{"id":"OG007","title":"Part 2: Liraglutide 1.8 mg/Day","description":"Participants received once daily subcutaneous liraglutide 1.8 mg on Days 15 to 29 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule."},{"id":"OG008","title":"Part 2: Placebo for MK-8521-T2DM","description":"T2DM participants received once daily subcutaneous placebo for MK-8521 for 29 days."},{"id":"OG009","title":"Part 2: MK-8521 64 µg/Day-Non-Diabetic Overweight/Obese","description":"Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 64 µg/day on Days 1 to 7 as part of the MK-8521 64/120 µg/day treatment group schedule."},{"id":"OG010","title":"Part 2: MK-8521 120 µg/Day-Non-Diabetic Overweight/Obese","description":"Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 120 µg/day hon Days 8 to 14 as part of the MK-8521 64/120 µg/day treatment group schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"18"},{"groupId":"OG003","value":"18"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"14"},{"groupId":"OG006","value":"13"},{"groupId":"OG007","value":"13"},{"groupId":"OG008","value":"6"},{"groupId":"OG009","value":"8"},{"groupId":"OG010","value":"8"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"1"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in Time-weighted Average From 0 to 24 Hours (TWA0-24hr) of Heart Rate (HR) After 7 Days of Treatment in Type 2 Diabetes Mellitus (T2DM) Participants in Part 1","description":"Semi-recumbent heart rate was assessed at baseline on Day 1; Day 7 at predose, 2, 4, 6, 8, 12, 13, 14, 15, 16, 22 hours postdose; and prior to dosing on Day 8. Heart rate was measured in triplicate with at least a 1-2-minute interval between measurements. The repeated measurements were averaged before conducting the statistical analysis. TWA0-24hr was calculated as the area under the measurement-time curve (AUC) divided by the time period of over which the measurements were made (i.e. 24 hrs.). Change from baseline TWA0-24hr HR was calculated as the TWA0-24hr HR at Day 7 minus baseline where baseline was defined as predose on Day 1.","populationDescription":"The analysis population included a subset of participants who complied with the protocol sufficiently to ensure that their data exhibited the effects of treatment according to the underlying scientific model and had data available for the analysis of the endpoint.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Beats per minute","timeFrame":"Baseline (predose Day 1) and up to 24 hours post Day 7 dose","groups":[{"id":"OG000","title":"Part 1: MK-8521 64/120 μg/Day","description":"Type 2 diabetes mellitus (T2DM) participants received once daily subcutaneous MK-8521 starting at 64 μg on Days 1 to 7 and escalated to 120 μg on Days 8 to 14."},{"id":"OG001","title":"Part 1: MK-8521 34/72 μg/Day","description":"T2DM participants received once daily subcutaneous MK-8521 starting at 34 μg on Days 1 to 7 and escalated to 72 μg on Days 8 to 14."},{"id":"OG002","title":"Part 1: Liraglutide 0.6/1.2/1.8 mg/Day","description":"T2DM participants received once daily subcutaneous liraglutide starting at 0.6 mg on Day 1 and 2, escalated to 1.2 mg on Days 3 to 7, and escalated to 1.8 mg on Days 8 to 14."},{"id":"OG003","title":"Part 1: Placebo for MK-8521","description":"T2DM participants received once daily subcutaneous placebo for MK-8521 for 14 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"8"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.19","lowerLimit":"3.48","upperLimit":"10.89"},{"groupId":"OG001","value":"1.17","lowerLimit":"-2.21","upperLimit":"4.55"},{"groupId":"OG002","value":"7.42","lowerLimit":"3.74","upperLimit":"11.09"},{"groupId":"OG003","value":"5.69","lowerLimit":"2.39","upperLimit":"8.99"}]}]}],"analyses":[{"groupIds":["OG000","OG002"],"nonInferiorityType":"OTHER","statisticalMethod":"Linear Mixed Effects Model","statisticalComment":"Fixed effects for treatment, day and treatment by day interaction, a random effect for participant and baseline TWA0-24hr of heart rate as a covariate","paramType":"Difference of Least Squares Means","paramValue":"-0.23","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-4.59","ciUpperLimit":"4.13"},{"groupIds":["OG001","OG002"],"nonInferiorityType":"OTHER","statisticalMethod":"Linear Mixed Effects Model","statisticalComment":"Fixed effects for treatment, day and treatment by day interaction, a random effect for participant and baseline TWA0-24hr of heart rate as a covariate","paramType":"Difference of Least Squares Means","paramValue":"-6.25","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-10.48","ciUpperLimit":"-2.01"},{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","statisticalMethod":"Linear Mixed Effects Model","statisticalComment":"Fixed effects for treatment, day and treatment by day interaction, a random effect for participant and baseline TWA0-24hr of heart rate as a covariate","paramType":"Difference of Least Squares Means","paramValue":"6.02","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.81","ciUpperLimit":"10.22"},{"groupIds":["OG000","OG003"],"nonInferiorityType":"OTHER","statisticalMethod":"Linear Mixed Effects Model","statisticalComment":"Fixed effects for treatment, day and treatment by day interaction, a random effect for participant and baseline TWA0-24hr of heart rate as a covariate","paramType":"Difference of Least Squares Means","paramValue":"1.50","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-2.65","ciUpperLimit":"5.64"},{"groupIds":["OG001","OG003"],"nonInferiorityType":"OTHER","statisticalMethod":"Linear Mixed Effects Model","statisticalComment":"Fixed effects for treatment, day and treatment by day interaction, a random effect for participant and baseline TWA0-24hr of heart rate as a covariate","paramType":"Difference of Least Squares Means","paramValue":"-4.52","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-8.52","ciUpperLimit":"-0.52"},{"groupIds":["OG002","OG003"],"nonInferiorityType":"OTHER","statisticalMethod":"Linear Mixed Effects Model","statisticalComment":"Fixed effects for treatment, day and treatment by day interaction, a random effect for participant and baseline TWA0-24hr of heart rate as a covariate","paramType":"Difference of Least Squares Means","paramValue":"1.73","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-2.38","ciUpperLimit":"5.83"}]},{"type":"PRIMARY","title":"Change From Baseline in Time-weighted Average From 0 to 24 Hours (TWA0-24hr) of Heart Rate (HR) After 7 Days of Treatment in Type 2 Diabetes Mellitus (T2DM) Participants in Part 2","description":"Semi-recumbent HR was measured in triplicate with at least a 1-2-minute interval between measurements at the following time points: baseline on Day 1; Day 7: predose, 2, 4, 6, 8, 12, and 16 hours postdose; and prior to dosing on Day 8. The repeated measurements were averaged before conducting the analysis. TWA0-24hr was calculated as the AUC divided by the time period of over which the measurements were made (i.e. 24 hrs.). Change from baseline TWA0-24hr HR was calculated as the TWA0-24hr HR at Day 7 minus baseline where baseline was defined as predose on Day 1.","populationDescription":"The analysis population included a subset of participants who complied with the protocol sufficiently to ensure that their data exhibited the effects of treatment according to the underlying scientific model and had data available for the analysis of the endpoint. Per-protocol, non-diabetic overweight/obese participants were not planned for the TWA0-24hr analysis of heart rate.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Beats per minute","timeFrame":"Baseline (predose Day 1) and up to 24 hours post Day 7 dose","groups":[{"id":"OG000","title":"Part 2: MK-8521 64/120/180/240/300 µg/Day-T2DM","description":"Type 2 diabetes mellitus (T2DM) participants received once daily subcutaneous MK-8521 titrated to 300 µg starting at 64 µg and increasing to 120 µg on Day 8, 180 µg on Day 15, 240 µg on Day 20, and 300 µg on Day 25. The total number of dosing days was 29."},{"id":"OG001","title":"Part 2: Liraglutide 0.6/1.2/1.8 mg/Day-T2DM","description":"T2DM participants received once daily subcutaneous liraglutide titrated to 1.8 mg starting at 0.6 mg and increasing to 1.2 mg on Day 8, and 1.8 mg on Day 15. The total number of dosing days was 29."},{"id":"OG002","title":"Part 2: Placebo for MK-8521-T2DM","description":"T2DM participants received once daily subcutaneous placebo for MK-8521 for 29 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"6"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.99","lowerLimit":"0.10","upperLimit":"3.88"},{"groupId":"OG001","value":"4.10","lowerLimit":"1.87","upperLimit":"6.34"},{"groupId":"OG002","value":"-0.54","lowerLimit":"-3.80","upperLimit":"2.73"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","statisticalMethod":"Linear Mixed Effects Model","statisticalComment":"Fixed effects for treatment, day and treatment by day interaction, a random effect for participant and baseline TWA0-24hr of heart rate as a covariate","paramType":"Difference of Least Squares Means","paramValue":"-2.11","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-4.55","ciUpperLimit":"0.32"},{"groupIds":["OG000","OG002"],"nonInferiorityType":"OTHER","statisticalMethod":"Linear Mixed Effects Model","statisticalComment":"Fixed effects for treatment, day and treatment by day interaction, a random effect for participant and baseline TWA0-24hr of heart rate as a covariate","paramType":"Difference of Least Squares Means","paramValue":"2.53","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.61","ciUpperLimit":"5.66"},{"groupIds":["OG001","OG002"],"nonInferiorityType":"OTHER","statisticalMethod":"Linear Mixed Effects Model","statisticalComment":"Fixed effects for treatment, day and treatment by day interaction, a random effect for participant and baseline TWA0-24hr of heart rate as a covariate","paramType":"Difference of Least Squares Means","paramValue":"4.64","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.35","ciUpperLimit":"7.93"}]},{"type":"PRIMARY","title":"Change From Baseline in Time-weighted Average From 0 to 24 Hours (TWA0-24hr) of Heart Rate (HR) After 14 Days of Treatment in Type 2 Diabetes Mellitus (T2DM) Participants in Part 1","description":"Semi-recumbent HR was measured in triplicate with at least a 1-2-minute interval between measurements at the following time points: baseline on Day 1; Day 14: predose, 2, 4, 6, 8, 12, 13, 14, 15, 16, 22 hours postdose and prior to dosing on Day 15. The repeated measurements were averaged before conducting the analysis. TWA0-24hr was calculated as the AUC divided by the time period of over which the measurements were made (i.e. 24 hrs.). Change from baseline TWA0-24hr HR was calculated as the TWA0-24hr HR at Day 14 minus baseline where baseline was defined as predose on Day 1.","populationDescription":"The analysis population included a subset of participants who complied with the protocol sufficiently to ensure that their data exhibited the effects of treatment according to the underlying scientific model and had data available for the analysis of the endpoint.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Beats per minute","timeFrame":"Baseline (predose Day 1) and up to 24 hours post Day 14 dose","groups":[{"id":"OG000","title":"Part 1: MK-8521 64/120 μg/Day","description":"Type 2 diabetes mellitus (T2DM) participants received once daily subcutaneous MK-8521 starting at 64 μg on Days 1 to 7 and escalated to 120 μg on Days 8 to 14."},{"id":"OG001","title":"Part 1: MK-8521 34/72 μg/Day","description":"T2DM participants received once daily subcutaneous MK-8521 starting at 34 μg on Days 1 to 7 and escalated to 72 μg on Days 8 to 14."},{"id":"OG002","title":"Part 1: Liraglutide 0.6/1.2/1.8 mg/Day","description":"T2DM participants received once daily subcutaneous liraglutide starting at 0.6 mg on Day 1 and 2, escalated to 1.2 mg on Days 3 to 7, and escalated to 1.8 mg on Days 8 to 14."},{"id":"OG003","title":"Part 1: Placebo for MK-8521","description":"T2DM participants received once daily subcutaneous placebo for MK-8521 for 14 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"8"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.67","lowerLimit":"5.97","upperLimit":"13.37"},{"groupId":"OG001","value":"3.90","lowerLimit":"0.52","upperLimit":"7.28"},{"groupId":"OG002","value":"10.32","lowerLimit":"6.65","upperLimit":"14.00"},{"groupId":"OG003","value":"9.81","lowerLimit":"6.51","upperLimit":"13.12"}]}]}],"analyses":[{"groupIds":["OG000","OG002"],"nonInferiorityType":"OTHER","statisticalMethod":"Linear Mixed Effects Model","statisticalComment":"Fixed effects for treatment, day and treatment by day interaction, a random effect for participant and baseline TWA0-24hr of heart rate as a covariate","paramType":"Difference of Least Squares Means","paramValue":"-0.65","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-5.01","ciUpperLimit":"3.71"},{"groupIds":["OG001","OG002"],"nonInferiorityType":"OTHER","statisticalMethod":"Linear Mixed Effects Model","statisticalComment":"Fixed effects for treatment, day and treatment by day interaction, a random effect for participant and baseline TWA0-24hr of heart rate as a covariate","paramType":"Difference of Least Squares Means","paramValue":"-6.42","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-10.66","ciUpperLimit":"-2.19"},{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","statisticalMethod":"Linear Mixed Effects Model","statisticalComment":"Fixed effects for treatment, day and treatment by day interaction, a random effect for participant and baseline TWA0-24hr of heart rate as a covariate","paramType":"Difference of Least Squares Means","paramValue":"5.77","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.57","ciUpperLimit":"9.97"},{"groupIds":["OG000","OG003"],"nonInferiorityType":"OTHER","statisticalMethod":"Linear Mixed Effects Model","statisticalComment":"Fixed effects for treatment, day and treatment by day interaction, a random effect for participant and baseline TWA0-24hr of heart rate as a covariate","paramType":"Difference of Least Squares Means","paramValue":"-0.15","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-4.29","ciUpperLimit":"4.00"},{"groupIds":["OG001","OG003"],"nonInferiorityType":"OTHER","statisticalMethod":"Linear Mixed Effects Model","statisticalComment":"Fixed effects for treatment, day and treatment by day interaction, a random effect for participant and baseline TWA0-24hr of heart rate as a covariate","paramType":"Difference of Least Squares Means","paramValue":"-5.91","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-9.91","ciUpperLimit":"-1.92"},{"groupIds":["OG002","OG003"],"nonInferiorityType":"OTHER","statisticalMethod":"Linear Mixed Effects Model","statisticalComment":"Fixed effects for treatment, day and treatment by day interaction, a random effect for participant and baseline TWA0-24hr of heart rate as a covariate","paramType":"Difference of Least Squares Means","paramValue":"0.51","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-3.60","ciUpperLimit":"4.62"}]},{"type":"PRIMARY","title":"Change From Baseline in Time-weighted Average From 0 to 24 Hours (TWA0-24hr) of Heart Rate (HR) After 14 Days of Treatment in Type 2 Diabetes Mellitus (T2DM) Participants in Part 2","description":"Semi-recumbent HR was measured in triplicate with at least a 1-2-minute interval between measurements at the following time points: baseline on Day 1; Day 14: predose, 2, 4, 6, 8, 12, 16, hours postdose; and prior to dosing on Day 15. The repeated measurements were averaged before conducting the analysis. TWA0-24hr was calculated as the AUC divided by the time period of over which the measurements were made (i.e. 24 hrs.). Change from baseline TWA0-24hr HR was calculated as the TWA0-24hr HR at Day 14 minus baseline where baseline was defined as predose on Day 1.","populationDescription":"The analysis population included a subset of participants who complied with the protocol sufficiently to ensure that their data exhibited the effects of treatment according to the underlying scientific model and had data available for the analysis of the endpoint. Per-protocol, non-diabetic overweight/obese participants were not planned for the TWA0-24hr analysis of heart rate.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Beats per minute","timeFrame":"Baseline (predose Day 1) and up to 24 hours post Day 14 dose","groups":[{"id":"OG000","title":"Part 2: MK-8521 64/120/180/240/300 µg/Day-T2DM","description":"Type 2 diabetes mellitus (T2DM) participants received once daily subcutaneous MK-8521 titrated to 300 µg starting at 64 µg and increasing to 120 µg on Day 8, 180 µg on Day 15, 240 µg on Day 20, and 300 µg on Day 25. The total number of dosing days was 29."},{"id":"OG001","title":"Part 2: Liraglutide 0.6/1.2/1.8 mg/Day-T2DM","description":"T2DM participants received once daily subcutaneous liraglutide titrated to 1.8 mg starting at 0.6 mg and increasing to 1.2 mg on Day 8, and 1.8 mg on Day 15. The total number of dosing days was 29."},{"id":"OG002","title":"Part 2: Placebo for MK-8521-T2DM","description":"T2DM participants received once daily subcutaneous placebo for MK-8521 for 29 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"5"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.05","lowerLimit":"2.79","upperLimit":"7.30"},{"groupId":"OG001","value":"5.93","lowerLimit":"3.27","upperLimit":"8.60"},{"groupId":"OG002","value":"-0.20","lowerLimit":"-4.32","upperLimit":"3.93"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","statisticalMethod":"Linear Mixed Effects Model","statisticalComment":"Fixed effects for treatment, day and treatment by day interaction, a random effect for participant and baseline TWA0-24hr of heart rate as a covariate","paramType":"Difference of Least Squares Means","paramValue":"-0.89","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-3.80","ciUpperLimit":"2.02"},{"groupIds":["OG000","OG002"],"nonInferiorityType":"OTHER","statisticalMethod":"Linear Mixed Effects Model","statisticalComment":"Fixed effects for treatment, day and treatment by day interaction, a random effect for participant and baseline TWA0-24hr of heart rate as a covariate","paramType":"Difference of Least Squares Means","paramValue":"5.24","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.34","ciUpperLimit":"9.15"},{"groupIds":["OG001","OG002"],"nonInferiorityType":"OTHER","statisticalMethod":"Linear Mixed Effects Model","statisticalComment":"Fixed effects for treatment, day and treatment by day interaction, a random effect for participant and baseline TWA0-24hr of heart rate as a covariate","paramType":"Difference of Least Squares Means","paramValue":"6.13","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"2.05","ciUpperLimit":"10.22"}]},{"type":"PRIMARY","title":"Change From Baseline in Time-weighted Average From 0 to 24 Hours (TWA0-24hr) of Heart Rate (HR) After 19 Days of Treatment in Type 2 Diabetes Mellitus (T2DM) Participants in Part 2","description":"Semi-recumbent HR was measured in triplicate with at least a 1-2-minute interval between measurements at the following time points: baseline on Day 1; Day 19: predose, 2, 4, 6, 8, 12, 16, hours post dose; and prior to dosing on Day 20. The repeated measurements were averaged before conducting the analysis. TWA0-24hr was calculated as the AUC divided by the time period of over which the measurements were made (i.e. 24 hrs.). Change from baseline TWA0-24hr HR was calculated as the TWA0-24hr HR at Day 19 minus baseline where baseline was defined as predose on Day 1.","populationDescription":"The analysis population included a subset of participants who complied with the protocol sufficiently to ensure that their data exhibited the effects of treatment according to the underlying scientific model and had data available for the analysis of the endpoint. Per-protocol, non-diabetic overweight/obese participants were not planned for the TWA0-24hr analysis of heart rate.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Beats per minute","timeFrame":"Baseline (predose Day 1) and up to 24 hours post Day 19 dose","groups":[{"id":"OG000","title":"Part 2: MK-8521 64/120/180/240/300 µg/Day-T2DM","description":"Type 2 diabetes mellitus (T2DM) participants received once daily subcutaneous MK-8521 titrated to 300 µg starting at 64 µg and increasing to 120 µg on Day 8, 180 µg on Day 15, 240 µg on Day 20, and 300 µg on Day 25. The total number of dosing days was 29."},{"id":"OG001","title":"Part 2: Liraglutide 0.6/1.2/1.8 mg/Day-T2DM","description":"T2DM participants received once daily subcutaneous liraglutide titrated to 1.8 mg starting at 0.6 mg and increasing to 1.2 mg on Day 8, and 1.8 mg on Day 15. The total number of dosing days was 29."},{"id":"OG002","title":"Part 2: Placebo for MK-8521-T2DM","description":"T2DM participants received once daily subcutaneous placebo for MK-8521 for 29 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"5"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.62","lowerLimit":"3.19","upperLimit":"8.05"},{"groupId":"OG001","value":"6.20","lowerLimit":"3.32","upperLimit":"9.07"},{"groupId":"OG002","value":"-2.14","lowerLimit":"-6.66","upperLimit":"2.37"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","statisticalMethod":"Linear Mixed Effects Model","statisticalComment":"Fixed effects for treatment, day and treatment by day interaction, a random effect for participant and baseline TWA0-24hr of heart rate as a covariate","paramType":"Difference of Least Squares Means","paramValue":"-0.57","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-3.71","ciUpperLimit":"2.57"},{"groupIds":["OG000","OG002"],"nonInferiorityType":"OTHER","statisticalMethod":"Linear Mixed Effects Model","statisticalComment":"Fixed effects for treatment, day and treatment by day interaction, a random effect for participant and baseline TWA0-24hr of heart rate as a covariate","paramType":"Difference of Least Squares Means","paramValue":"7.77","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"3.50","ciUpperLimit":"12.03"},{"groupIds":["OG001","OG002"],"nonInferiorityType":"OTHER","statisticalMethod":"Linear Mixed Effects Model","statisticalComment":"Fixed effects for treatment, day and treatment by day interaction, a random effect for participant and baseline TWA0-24hr of heart rate as a covariate","paramType":"Difference of Least Squares Means","paramValue":"8.34","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"3.89","ciUpperLimit":"12.79"}]},{"type":"PRIMARY","title":"Change From Baseline in Time-weighted Average From 0 to 24 Hours (TWA0-24hr) of Heart Rate (HR) After 24 Days of Treatment in Type 2 Diabetes Mellitus (T2DM) Participants in Part 2","description":"Semi-recumbent HR was measured in triplicate with at least a 1-2-minute interval between measurements at the following time points: baseline on Day 1; Day 24: predose, 2, 4, 6, 8, 12, 16, hours postdose; and prior to dosing on Day 25. The repeated measurements were averaged before conducting the analysis. TWA0-24hr was calculated as the AUC divided by the time period of over which the measurements were made (i.e. 24 hrs.). Change from baseline TWA0-24hr HR was calculated as the TWA0-24hr HR at Day 24 minus baseline where baseline was defined as predose on Day 1.","populationDescription":"The analysis population included a subset of participants who complied with the protocol sufficiently to ensure that their data exhibited the effects of treatment according to the underlying scientific model and had data available for the analysis of the endpoint. Per-protocol, non-diabetic overweight/obese participants were not planned for the TWA0-24hr analysis of heart rate.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Beats per minute","timeFrame":"Baseline (predose Day 1) and up to 24 hours post Day 24 dose","groups":[{"id":"OG000","title":"Part 2: MK-8521 64/120/180/240/300 µg/Day-T2DM","description":"Type 2 diabetes mellitus (T2DM) participants received once daily subcutaneous MK-8521 titrated to 300 µg starting at 64 µg and increasing to 120 µg on Day 8, 180 µg on Day 15, 240 µg on Day 20, and 300 µg on Day 25. The total number of dosing days was 29."},{"id":"OG001","title":"Part 2: Liraglutide 0.6/1.2/1.8 mg/Day-T2DM","description":"T2DM participants received once daily subcutaneous liraglutide titrated to 1.8 mg starting at 0.6 mg and increasing to 1.2 mg on Day 8, and 1.8 mg on Day 15. The total number of dosing days was 29."},{"id":"OG002","title":"Part 2: Placebo for MK-8521-T2DM","description":"T2DM participants received once daily subcutaneous placebo for MK-8521 for 29 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"5"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.30","lowerLimit":"4.43","upperLimit":"10.17"},{"groupId":"OG001","value":"5.95","lowerLimit":"2.50","upperLimit":"9.41"},{"groupId":"OG002","value":"-0.99","lowerLimit":"-6.28","upperLimit":"4.29"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","statisticalMethod":"Linear Mixed Effects Model","statisticalComment":"Fixed effects for treatment, day and treatment by day interaction, a random effect for participant and baseline TWA0-24hr of heart rate as a covariate","paramType":"Difference of Least Squares Means","paramValue":"1.35","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-2.40","ciUpperLimit":"5.09"},{"groupIds":["OG000","OG002"],"nonInferiorityType":"OTHER","statisticalMethod":"Linear Mixed Effects Model","statisticalComment":"Fixed effects for treatment, day and treatment by day interaction, a random effect for participant and baseline TWA0-24hr of heart rate as a covariate","paramType":"Difference of Least Squares Means","paramValue":"8.29","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"3.29","ciUpperLimit":"13.30"},{"groupIds":["OG001","OG002"],"nonInferiorityType":"OTHER","statisticalMethod":"Linear Mixed Effects Model","statisticalComment":"Fixed effects for treatment, day and treatment by day interaction, a random effect for participant and baseline TWA0-24hr of heart rate as a covariate","paramType":"Difference of Least Squares Means","paramValue":"6.95","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.69","ciUpperLimit":"12.20"}]},{"type":"PRIMARY","title":"Change From Baseline in Time-weighted Average From 0 to 24 Hours (TWA0-24hr) of Heart Rate (HR) After 29 Days of Treatment in Type 2 Diabetes Mellitus (T2DM) Participants in Part 2","description":"Semi-recumbent HR was measured in triplicate with at least a 1-2-minute interval between measurements at the following time points: baseline on Day 1; and Day 29: predose, 2, 4, 6, 8, 12, 16 and 24 hours postdose. The repeated measurements were averaged before conducting the analysis. TWA0-24hr was calculated as the AUC divided by the time period of over which the measurements were made (i.e. 24 hrs.). Change from baseline TWA0-24hr HR was calculated as the TWA0-24hr HR at Day 29 minus baseline where baseline was defined as predose on Day 1.","populationDescription":"The analysis population included a subset of participants who complied with the protocol sufficiently to ensure that their data exhibited the effects of treatment according to the underlying scientific model and had data available for the analysis of the endpoint. Per-protocol, non-diabetic overweight/obese participants were not planned for the TWA0-24hr analysis of heart rate.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Beats per minute","timeFrame":"Baseline (predose Day 1) and up to 24 hours post Day 29 dose","groups":[{"id":"OG000","title":"Part 2: MK-8521 64/120/180/240/300 µg/Day-T2DM","description":"Type 2 diabetes mellitus (T2DM) participants received once daily subcutaneous MK-8521 titrated to 300 µg starting at 64 µg and increasing to 120 µg on Day 8, 180 µg on Day 15, 240 µg on Day 20, and 300 µg on Day 25. The total number of dosing days was 29."},{"id":"OG001","title":"Part 2: Liraglutide 0.6/1.2/1.8 mg/Day-T2DM","description":"T2DM participants received once daily subcutaneous liraglutide titrated to 1.8 mg starting at 0.6 mg and increasing to 1.2 mg on Day 8, and 1.8 mg on Day 15. The total number of dosing days was 29."},{"id":"OG002","title":"Part 2: Placebo for MK-8521-T2DM","description":"T2DM participants received once daily subcutaneous placebo for MK-8521 for 29 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"5"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.30","lowerLimit":"5.31","upperLimit":"11.29"},{"groupId":"OG001","value":"5.84","lowerLimit":"2.26","upperLimit":"9.43"},{"groupId":"OG002","value":"-1.31","lowerLimit":"-6.81","upperLimit":"4.19"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","statisticalMethod":"Linear Mixed Effects Model","statisticalComment":"Fixed effects for treatment, day and treatment by day interaction, a random effect for participant and baseline TWA0-24hr of heart rate as a covariate","paramType":"Difference of Least Squares Means","paramValue":"2.46","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.42","ciUpperLimit":"6.34"},{"groupIds":["OG000","OG002"],"nonInferiorityType":"OTHER","statisticalMethod":"Linear Mixed Effects Model","statisticalComment":"Fixed effects for treatment, day and treatment by day interaction, a random effect for participant and baseline TWA0-24hr of heart rate as a covariate","paramType":"Difference of Least Squares Means","paramValue":"9.61","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"4.42","ciUpperLimit":"14.81"},{"groupIds":["OG001","OG002"],"nonInferiorityType":"OTHER","statisticalMethod":"Linear Mixed Effects Model","statisticalComment":"Fixed effects for treatment, day and treatment by day interaction, a random effect for participant and baseline TWA0-24hr of heart rate as a covariate","paramType":"Difference of Least Squares Means","paramValue":"7.15","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.70","ciUpperLimit":"12.60"}]},{"type":"PRIMARY","title":"Change From Baseline in Peak Heart Rate (PHR) at Day 7 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 2","description":"PHR was defined as the maximum time matched baseline adjusted heart rate over 24 hours. Semi-recumbent PHR was measured in triplicate with at least a 1-2-minute interval between measurements at the following time points: baseline on Day 1; Day 7: predose, 2, 4, 6, 8, 12, and 16 hours postdose; and prior to dosing on Day 8. The repeated measurements were averaged before conducting the analysis. Change from baseline PHR was calculated as the peak heart rate at Day 7 minus baseline where baseline was defined as predose on Day 1.","populationDescription":"The analysis population included a subset of participants who complied with the protocol sufficiently to ensure that their data exhibited the effects of treatment according to the underlying scientific model and had data available for the analysis of the endpoint. Per-protocol, non-diabetic overweight/obese participants were not planned for the analysis of peak heart rate.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Beats per minute","timeFrame":"Baseline (predose Day 1) and up to 24 hours post Day 7 dose","groups":[{"id":"OG000","title":"Part 2: MK-8521 64/120/180/240/300 µg/Day-T2DM","description":"Type 2 diabetes mellitus (T2DM) participants received once daily subcutaneous MK-8521 titrated to 300 µg starting at 64 µg and increasing to 120 µg on Day 8, 180 µg on Day 15, 240 µg on Day 20, and 300 µg on Day 25. The total number of dosing days was 29."},{"id":"OG001","title":"Part 2: Liraglutide 0.6/1.2/1.8 mg/Day-T2DM","description":"T2DM participants received once daily subcutaneous liraglutide titrated to 1.8 mg starting at 0.6 mg and increasing to 1.2 mg on Day 8, and 1.8 mg on Day 15. The total number of dosing days was 29."},{"id":"OG002","title":"Part 2: Placebo for MK-8521-T2DM","description":"T2DM participants received once daily subcutaneous placebo for MK-8521 for 29 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"6"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.94","lowerLimit":"5.76","upperLimit":"10.13"},{"groupId":"OG001","value":"11.91","lowerLimit":"9.30","upperLimit":"14.53"},{"groupId":"OG002","value":"8.65","lowerLimit":"4.86","upperLimit":"12.43"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","statisticalMethod":"Linear Mixed Effects Model","statisticalComment":"Fixed effects for treatment, day and treatment by day interaction, a random effect for participant and baseline peak heart rate as a covariate","paramType":"Difference of Least Squares Means","paramValue":"-3.97","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-6.80","ciUpperLimit":"-1.14"},{"groupIds":["OG000","OG002"],"nonInferiorityType":"OTHER","statisticalMethod":"Linear Mixed Effects Model","statisticalComment":"Fixed effects for treatment, day and treatment by day interaction, a random effect for participant and baseline peak heart rate as a covariate","paramType":"Difference of Least Squares Means","paramValue":"-0.70","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-4.33","ciUpperLimit":"2.93"},{"groupIds":["OG001","OG002"],"nonInferiorityType":"OTHER","statisticalMethod":"Linear Mixed Effects Model","statisticalComment":"Fixed effects for treatment, day and treatment by day interaction, a random effect for participant and baseline peak heart rate as a covariate","paramType":"Difference of Least Squares Means","paramValue":"3.26","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.54","ciUpperLimit":"7.06"}]},{"type":"PRIMARY","title":"Change From Baseline in Peak Heart Rate (PHR) at Day 14 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 2","description":"PHR was defined as the maximum time matched baseline adjusted heart rate over 24 hours. Semi-recumbent PHR was measured in triplicate with at least a 1-2-minute interval between measurements at the following time points: baseline on Day 1; Day 14: predose, 2, 4, 6, 8, 12, and 16 hours postdose; and prior to dosing on Day 15. The repeated measurements were averaged before conducting the analysis. Change from baseline PHR was calculated as the peak heart rate at Day 14 minus baseline where baseline was defined as predose on Day 1.","populationDescription":"The analysis population included a subset of participants who complied with the protocol sufficiently to ensure that their data exhibited the effects of treatment according to the underlying scientific model and had data available for the analysis of the endpoint. Per-protocol, non-diabetic overweight/obese participants were not planned for the analysis of peak heart rate.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Beats per minute","timeFrame":"Baseline (predose Day 1) and up to 24 hours post Day 14 dose","groups":[{"id":"OG000","title":"Part 2: MK-8521 64/120/180/240/300 µg/Day-T2DM","description":"Type 2 diabetes mellitus (T2DM) participants received once daily subcutaneous MK-8521 titrated to 300 µg starting at 64 µg and increasing to 120 µg on Day 8, 180 µg on Day 15, 240 µg on Day 20, and 300 µg on Day 25. The total number of dosing days was 29."},{"id":"OG001","title":"Part 2: Liraglutide 0.6/1.2/1.8 mg/Day-T2DM","description":"T2DM participants received once daily subcutaneous liraglutide titrated to 1.8 mg starting at 0.6 mg and increasing to 1.2 mg on Day 8, and 1.8 mg on Day 15. The total number of dosing days was 29."},{"id":"OG002","title":"Part 2: Placebo for MK-8521-T2DM","description":"T2DM participants received once daily subcutaneous placebo for MK-8521 for 29 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"6"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.41","lowerLimit":"8.50","upperLimit":"14.32"},{"groupId":"OG001","value":"13.00","lowerLimit":"9.58","upperLimit":"16.41"},{"groupId":"OG002","value":"8.90","lowerLimit":"3.87","upperLimit":"13.93"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","statisticalMethod":"Linear Mixed Effects Model","statisticalComment":"Fixed effects for treatment, day and treatment by day interaction, a random effect for participant and baseline peak heart rate as a covariate","paramType":"Difference of Least Squares Means","paramValue":"-1.58","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-5.31","ciUpperLimit":"2.15"},{"groupIds":["OG000","OG002"],"nonInferiorityType":"OTHER","statisticalMethod":"Linear Mixed Effects Model","statisticalComment":"Fixed effects for treatment, day and treatment by day interaction, a random effect for participant and baseline peak heart rate as a covariate","paramType":"Difference of Least Squares Means","paramValue":"2.52","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-2.32","ciUpperLimit":"7.35"},{"groupIds":["OG001","OG002"],"nonInferiorityType":"OTHER","statisticalMethod":"Linear Mixed Effects Model","statisticalComment":"Fixed effects for treatment, day and treatment by day interaction, a random effect for participant and baseline peak heart rate as a covariate","paramType":"Difference of Least Squares Means","paramValue":"4.10","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.96","ciUpperLimit":"9.16"}]},{"type":"PRIMARY","title":"Change From Baseline in Peak Heart Rate (PHR) at Day 19 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 2","description":"PHR was defined as the maximum time matched baseline adjusted heart rate over 24 hours. Semi-recumbent PHR was measured in triplicate with at least a 1-2-minute interval between measurements at the following time points: baseline on Day 1; Day 19: predose, 2, 4, 6, 8, 12, and 16 hours postdose; and prior to dosing on Day 20. The repeated measurements were averaged before conducting the analysis. Change from baseline PHR was calculated as the peak heart rate at Day 19 minus baseline where baseline was defined as predose on Day 1.","populationDescription":"The analysis population included a subset of participants who complied with the protocol sufficiently to ensure that their data exhibited the effects of treatment according to the underlying scientific model and had data available for the analysis of the endpoint. Per-protocol, non-diabetic overweight/obese participants were not planned for the analysis of peak heart rate.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Beats per minute","timeFrame":"Baseline (predose Day 1) and up to 24 hours post Day 19 dose","groups":[{"id":"OG000","title":"Part 2: MK-8521 64/120/180/240/300 µg/Day-T2DM","description":"Type 2 diabetes mellitus (T2DM) participants received once daily subcutaneous MK-8521 titrated to 300 µg starting at 64 µg and increasing to 120 µg on Day 8, 180 µg on Day 15, 240 µg on Day 20, and 300 µg on Day 25. The total number of dosing days was 29."},{"id":"OG001","title":"Part 2: Liraglutide 0.6/1.2/1.8 mg/Day-T2DM","description":"T2DM participants received once daily subcutaneous liraglutide titrated to 1.8 mg starting at 0.6 mg and increasing to 1.2 mg on Day 8, and 1.8 mg on Day 15. The total number of dosing days was 29."},{"id":"OG002","title":"Part 2: Placebo for MK-8521-T2DM","description":"T2DM participants received once daily subcutaneous placebo for MK-8521 for 29 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"5"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.26","lowerLimit":"8.28","upperLimit":"14.24"},{"groupId":"OG001","value":"14.75","lowerLimit":"11.25","upperLimit":"18.25"},{"groupId":"OG002","value":"7.30","lowerLimit":"2.00","upperLimit":"12.61"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","statisticalMethod":"Linear Mixed Effects Model","statisticalComment":"Fixed effects for treatment, day and treatment by day interaction, a random effect for participant and baseline peak heart rate as a covariate","paramType":"Difference of Least Squares Means","paramValue":"-3.48","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-7.31","ciUpperLimit":"0.34"},{"groupIds":["OG000","OG002"],"nonInferiorityType":"OTHER","statisticalMethod":"Linear Mixed Effects Model","statisticalComment":"Fixed effects for treatment, day and treatment by day interaction, a random effect for participant and baseline peak heart rate as a covariate","paramType":"Difference of Least Squares Means","paramValue":"3.96","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.11","ciUpperLimit":"9.03"},{"groupIds":["OG001","OG002"],"nonInferiorityType":"OTHER","statisticalMethod":"Linear Mixed Effects Model","statisticalComment":"Fixed effects for treatment, day and treatment by day interaction, a random effect for participant and baseline peak heart rate as a covariate","paramType":"Difference of Least Squares Means","paramValue":"7.44","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"2.16","ciUpperLimit":"12.73"}]},{"type":"PRIMARY","title":"Change From Baseline in Peak Heart Rate (PHR) at Day 24 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 2","description":"PHR was defined as the maximum time matched baseline adjusted heart rate over 24 hours. Semi-recumbent PHR was measured in triplicate with at least a 1-2-minute interval between measurements at the following time points: baseline on Day 1; Day 24: predose, 2, 4, 6, 8, 12, and 16 hours postdose; and prior to dosing on Day 25. The repeated measurements were averaged before conducting the analysis. Change from baseline PHR was calculated as the peak heart rate at Day 24 minus baseline where baseline was defined as predose on Day 1.","populationDescription":"The analysis population included a subset of participants who complied with the protocol sufficiently to ensure that their data exhibited the effects of treatment according to the underlying scientific model and had data available for the analysis of the endpoint. Per-protocol, non-diabetic overweight/obese participants were not planned for the analysis of peak heart rate.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Beats per minute","timeFrame":"Baseline (predose Day 1) and up to 24 hours post Day 24 dose","groups":[{"id":"OG000","title":"Part 2: MK-8521 64/120/180/240/300 µg/Day-T2DM","description":"Type 2 diabetes mellitus (T2DM) participants received once daily subcutaneous MK-8521 titrated to 300 µg starting at 64 µg and increasing to 120 µg on Day 8, 180 µg on Day 15, 240 µg on Day 20, and 300 µg on Day 25. The total number of dosing days was 29."},{"id":"OG001","title":"Part 2: Liraglutide 0.6/1.2/1.8 mg/Day-T2DM","description":"T2DM participants received once daily subcutaneous liraglutide titrated to 1.8 mg starting at 0.6 mg and increasing to 1.2 mg on Day 8, and 1.8 mg on Day 15. The total number of dosing days was 29."},{"id":"OG002","title":"Part 2: Placebo for MK-8521-T2DM","description":"T2DM participants received once daily subcutaneous placebo for MK-8521 for 29 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"5"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.09","lowerLimit":"10.60","upperLimit":"17.57"},{"groupId":"OG001","value":"14.06","lowerLimit":"9.85","upperLimit":"18.27"},{"groupId":"OG002","value":"9.39","lowerLimit":"3.03","upperLimit":"15.76"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","statisticalMethod":"Linear Mixed Effects Model","statisticalComment":"Fixed effects for treatment, day and treatment by day interaction, a random effect for participant and baseline peak heart rate as a covariate","paramType":"Difference of Least Squares Means","paramValue":"0.03","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-4.51","ciUpperLimit":"4.57"},{"groupIds":["OG000","OG002"],"nonInferiorityType":"OTHER","statisticalMethod":"Linear Mixed Effects Model","statisticalComment":"Fixed effects for treatment, day and treatment by day interaction, a random effect for participant and baseline peak heart rate as a covariate","paramType":"Difference of Least Squares Means","paramValue":"4.70","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.33","ciUpperLimit":"10.73"},{"groupIds":["OG001","OG002"],"nonInferiorityType":"OTHER","statisticalMethod":"Linear Mixed Effects Model","statisticalComment":"Fixed effects for treatment, day and treatment by day interaction, a random effect for participant and baseline peak heart rate as a covariate","paramType":"Difference of Least Squares Means","paramValue":"4.66","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.67","ciUpperLimit":"11.00"}]},{"type":"PRIMARY","title":"Change From Baseline in Peak Heart Rate (PHR) at Day 29 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 2","description":"PHR was defined as the maximum time matched baseline adjusted heart rate over 24 hours. Semi-recumbent PHR was measured in triplicate with at least a 1-2-minute interval between measurements at the following time points: baseline on Day 1; and Day 29: predose 2, 4, 6, 8, 12, 16, and 24 hours post dose. The repeated measurements were averaged before conducting the analysis. Change from baseline PHR was calculated as the peak heart rate at Day 29 minus baseline where baseline was defined as predose on Day 1.","populationDescription":"The analysis population included a subset of participants who complied with the protocol sufficiently to ensure that their data exhibited the effects of treatment according to the underlying scientific model and had data available for the analysis of the endpoint. Per-protocol, non-diabetic overweight/obese participants were not planned for the analysis of peak heart rate.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Beats per minute","timeFrame":"Baseline (predose Day 1) and up to 24 hours post Day 29 dose","groups":[{"id":"OG000","title":"Part 2: MK-8521 64/120/180/240/300 µg/Day-T2DM","description":"Type 2 diabetes mellitus (T2DM) participants received once daily subcutaneous MK-8521 titrated to 300 µg starting at 64 µg and increasing to 120 µg on Day 8, 180 µg on Day 15, 240 µg on Day 20, and 300 µg on Day 25. The total number of dosing days was 29."},{"id":"OG001","title":"Part 2: Liraglutide 0.6/1.2/1.8 mg/Day-T2DM","description":"T2DM participants received once daily subcutaneous liraglutide titrated to 1.8 mg starting at 0.6 mg and increasing to 1.2 mg on Day 8, and 1.8 mg on Day 15. The total number of dosing days was 29."},{"id":"OG002","title":"Part 2: Placebo for MK-8521-T2DM","description":"T2DM participants received once daily subcutaneous placebo for MK-8521 for 29 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"5"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.01","lowerLimit":"12.88","upperLimit":"19.13"},{"groupId":"OG001","value":"12.66","lowerLimit":"8.91","upperLimit":"16.41"},{"groupId":"OG002","value":"7.13","lowerLimit":"1.49","upperLimit":"12.76"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","statisticalMethod":"Linear Mixed Effects Model","statisticalComment":"Fixed effects for treatment, day and treatment by day interaction, a random effect for participant and baseline peak heart rate as a covariate","paramType":"Difference of Least Squares Means","paramValue":"3.34","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.70","ciUpperLimit":"7.39"},{"groupIds":["OG000","OG002"],"nonInferiorityType":"OTHER","statisticalMethod":"Linear Mixed Effects Model","statisticalComment":"Fixed effects for treatment, day and treatment by day interaction, a random effect for participant and baseline peak heart rate as a covariate","paramType":"Difference of Least Squares Means","paramValue":"8.88","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"3.53","ciUpperLimit":"14.23"},{"groupIds":["OG001","OG002"],"nonInferiorityType":"OTHER","statisticalMethod":"Linear Mixed Effects Model","statisticalComment":"Fixed effects for treatment, day and treatment by day interaction, a random effect for participant and baseline peak heart rate as a covariate","paramType":"Difference of Least Squares Means","paramValue":"5.54","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.08","ciUpperLimit":"11.15"}]},{"type":"PRIMARY","title":"Change From Baseline in Resting Morning Heart Rate (RMHR) After the Day 7 Dose for Type 2 Diabetes Mellitus (T2DM) Participants in Part 2","description":"Semi-recumbent RMHR was measured in triplicate with at least a 1-2-minute interval between measurements. The repeated measurements were averaged for each time point. Change from baseline RMHR was calculated as the RMHR 24 hours after the Day 7 dose (predose Day 8) minus baseline. Baseline was an average of 2 readings prior to dosing on Day 1.","populationDescription":"The analysis population included a subset of participants who complied with the protocol sufficiently to ensure that their data exhibited the effects of treatment according to the underlying scientific model and had data available for the analysis of the endpoint. Per-protocol, non-diabetic overweight/obese participants were not planned for the analysis of resting morning heart rate.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Beats per minute","timeFrame":"Baseline (predose Day 1) and Day 8 (24 hours after Day 7)","groups":[{"id":"OG000","title":"Part 2: MK-8521 64/120/180/240/300 µg/Day-T2DM","description":"Type 2 diabetes mellitus (T2DM) participants received once daily subcutaneous MK-8521 titrated to 300 µg starting at 64 µg and increasing to 120 µg on Day 8, 180 µg on Day 15, 240 µg on Day 20, and 300 µg on Day 25. The total number of dosing days was 29."},{"id":"OG001","title":"Part 2: Liraglutide 0.6/1.2/1.8 mg/Day-T2DM","description":"T2DM participants received once daily subcutaneous liraglutide titrated to 1.8 mg starting at 0.6 mg and increasing to 1.2 mg on Day 8, and 1.8 mg on Day 15. The total number of dosing days was 29."},{"id":"OG002","title":"Part 2: Placebo for MK-8521-T2DM","description":"T2DM participants received once daily subcutaneous placebo for MK-8521 for 29 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"6"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.65","lowerLimit":"-1.00","upperLimit":"4.29"},{"groupId":"OG001","value":"5.20","lowerLimit":"2.07","upperLimit":"8.33"},{"groupId":"OG002","value":"0.59","lowerLimit":"-3.99","upperLimit":"5.18"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","statisticalMethod":"Linear Mixed Effects Model","statisticalComment":"Fixed effects for treatment, day and treatment by day interaction, a random effect for participant and baseline RMHR as a covariate","paramType":"Difference of Least Squares Means","paramValue":"-3.55","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-6.98","ciUpperLimit":"-0.12"},{"groupIds":["OG000","OG002"],"nonInferiorityType":"OTHER","statisticalMethod":"Linear Mixed Effects Model","statisticalComment":"Fixed effects for treatment, day and treatment by day interaction, a random effect for participant and baseline RMHR as a covariate","paramType":"Difference of Least Squares Means","paramValue":"1.05","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-3.38","ciUpperLimit":"5.49"},{"groupIds":["OG001","OG002"],"nonInferiorityType":"OTHER","statisticalMethod":"Linear Mixed Effects Model","statisticalComment":"Fixed effects for treatment, day and treatment by day interaction, a random effect for participant and baseline RMHR as a covariate","paramType":"Difference of Least Squares Means","paramValue":"4.61","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.02","ciUpperLimit":"9.23"}]},{"type":"PRIMARY","title":"Change From Baseline in Resting Morning Heart Rate (RMHR) After the Day 14 Dose for Type 2 Diabetes Mellitus (T2DM) Participants in Part 2","description":"Semi-recumbent RMHR was measured in triplicate with at least a 1-2-minute interval between measurements. The repeated measurements were averaged for each time point. Change from baseline RMHR was calculated as the RMHR 24 hours after the Day 14 dose (predose Day 15) minus baseline. Baseline was an average of 2 readings prior to dosing on Day 1.","populationDescription":"The analysis population included a subset of participants who complied with the protocol sufficiently to ensure that their data exhibited the effects of treatment according to the underlying scientific model and had data available for the analysis of the endpoint. Per-protocol, non-diabetic overweight/obese participants were not planned for the analysis of resting morning heart rate.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Beats per minute","timeFrame":"Baseline (predose Day 1) and Day 15 (24 hours after Day 14)","groups":[{"id":"OG000","title":"Part 2: MK-8521 64/120/180/240/300 µg/Day-T2DM","description":"Type 2 diabetes mellitus (T2DM) participants received once daily subcutaneous MK-8521 titrated to 300 µg starting at 64 µg and increasing to 120 µg on Day 8, 180 µg on Day 15, 240 µg on Day 20, and 300 µg on Day 25. The total number of dosing days was 29."},{"id":"OG001","title":"Part 2: Liraglutide 0.6/1.2/1.8 mg/Day-T2DM","description":"T2DM participants received once daily subcutaneous liraglutide titrated to 1.8 mg starting at 0.6 mg and increasing to 1.2 mg on Day 8, and 1.8 mg on Day 15. The total number of dosing days was 29."},{"id":"OG002","title":"Part 2: Placebo for MK-8521-T2DM","description":"T2DM participants received once daily subcutaneous placebo for MK-8521 for 29 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"5"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.22","lowerLimit":"1.58","upperLimit":"6.87"},{"groupId":"OG001","value":"5.38","lowerLimit":"2.25","upperLimit":"8.51"},{"groupId":"OG002","value":"-4.42","lowerLimit":"-9.32","upperLimit":"0.47"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","statisticalMethod":"Linear Mixed Effects Model","statisticalComment":"Fixed effects for treatment, day and treatment by day interaction, a random effect for participant and baseline RMHR as a covariate","paramType":"Difference of Least Squares Means","paramValue":"-1.16","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-4.59","ciUpperLimit":"2.28"},{"groupIds":["OG000","OG002"],"nonInferiorityType":"OTHER","statisticalMethod":"Linear Mixed Effects Model","statisticalComment":"Fixed effects for treatment, day and treatment by day interaction, a random effect for participant and baseline RMHR as a covariate","paramType":"Difference of Least Squares Means","paramValue":"8.65","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"3.99","ciUpperLimit":"13.31"},{"groupIds":["OG001","OG002"],"nonInferiorityType":"OTHER","statisticalMethod":"Linear Mixed Effects Model","statisticalComment":"Fixed effects for treatment, day and treatment by day interaction, a random effect for participant and baseline RMHR as a covariate","paramType":"Difference of Least Squares Means","paramValue":"9.80","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"4.96","ciUpperLimit":"14.65"}]},{"type":"PRIMARY","title":"Change From Baseline in Resting Morning Heart Rate (RMHR) After the Day 19 Dose for Type 2 Diabetes Mellitus (T2DM) Participants in Part 2","description":"Semi-recumbent RMHR was measured in triplicate with at least a 1-2-minute interval between measurements. The repeated measurements were averaged for each time point. Change from baseline RMHR was calculated as the RMHR 24 hours after the Day 19 dose (predose Day 20) minus baseline. Baseline was an average of 2 readings prior to dosing on Day 1.","populationDescription":"The analysis population included a subset of participants who complied with the protocol sufficiently to ensure that their data exhibited the effects of treatment according to the underlying scientific model and had data available for the analysis of the endpoint. Per-protocol, non-diabetic overweight/obese participants were not planned for the analysis of resting morning heart rate.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Beats per minute","timeFrame":"Baseline (predose Day 1) and Day 20 (24 hours after Day 19)","groups":[{"id":"OG000","title":"Part 2: MK-8521 64/120/180/240/300 µg/Day-T2DM","description":"Type 2 diabetes mellitus (T2DM) participants received once daily subcutaneous MK-8521 titrated to 300 µg starting at 64 µg and increasing to 120 µg on Day 8, 180 µg on Day 15, 240 µg on Day 20, and 300 µg on Day 25. The total number of dosing days was 29."},{"id":"OG001","title":"Part 2: Liraglutide 0.6/1.2/1.8 mg/Day-T2DM","description":"T2DM participants received once daily subcutaneous liraglutide titrated to 1.8 mg starting at 0.6 mg and increasing to 1.2 mg on Day 8, and 1.8 mg on Day 15. The total number of dosing days was 29."},{"id":"OG002","title":"Part 2: Placebo for MK-8521-T2DM","description":"T2DM participants received once daily subcutaneous placebo for MK-8521 for 29 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"5"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.41","lowerLimit":"3.76","upperLimit":"9.05"},{"groupId":"OG001","value":"10.44","lowerLimit":"7.24","upperLimit":"13.65"},{"groupId":"OG002","value":"-3.82","lowerLimit":"-8.72","upperLimit":"1.07"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","statisticalMethod":"Linear Mixed Effects Model","statisticalComment":"Fixed effects for treatment, day and treatment by day interaction, a random effect for participant and baseline RMHR as a covariate","paramType":"Difference of Least Squares Means","paramValue":"-4.04","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-7.52","ciUpperLimit":"-0.56"},{"groupIds":["OG000","OG002"],"nonInferiorityType":"OTHER","statisticalMethod":"Linear Mixed Effects Model","statisticalComment":"Fixed effects for treatment, day and treatment by day interaction, a random effect for participant and baseline RMHR as a covariate","paramType":"Difference of Least Squares Means","paramValue":"10.23","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"5.57","ciUpperLimit":"14.89"},{"groupIds":["OG001","OG002"],"nonInferiorityType":"OTHER","statisticalMethod":"Linear Mixed Effects Model","statisticalComment":"Fixed effects for treatment, day and treatment by day interaction, a random effect for participant and baseline RMHR as a covariate","paramType":"Difference of Least Squares Means","paramValue":"14.27","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"9.38","ciUpperLimit":"19.15"}]},{"type":"PRIMARY","title":"Change From Baseline in Resting Morning Heart Rate (RMHR) After the Day 24 Dose for Type 2 Diabetes Mellitus (T2DM) Participants in Part 2","description":"Semi-recumbent RMHR was measured in triplicate with at least a 1-2-minute interval between measurements. The repeated measurements were averaged for each time point. Change from baseline RMHR was calculated as the RMHR 24 hours after the Day 24 dose (predose Day 25) minus baseline. Baseline was an average of 2 readings prior to dosing on Day 1.","populationDescription":"The analysis population included a subset of participants who complied with the protocol sufficiently to ensure that their data exhibited the effects of treatment according to the underlying scientific model and had data available for the analysis of the endpoint. Per-protocol, non-diabetic overweight/obese participants were not planned for the analysis of resting morning heart rate.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Beats per minute","timeFrame":"Baseline (predose Day 1) and Day 25 (24 hours after Day 24)","groups":[{"id":"OG000","title":"Part 2: MK-8521 64/120/180/240/300 µg/Day-T2DM","description":"Type 2 diabetes mellitus (T2DM) participants received once daily subcutaneous MK-8521 titrated to 300 µg starting at 64 µg and increasing to 120 µg on Day 8, 180 µg on Day 15, 240 µg on Day 20, and 300 µg on Day 25. The total number of dosing days was 29."},{"id":"OG001","title":"Part 2: Liraglutide 0.6/1.2/1.8 mg/Day-T2DM","description":"T2DM participants received once daily subcutaneous liraglutide titrated to 1.8 mg starting at 0.6 mg and increasing to 1.2 mg on Day 8, and 1.8 mg on Day 15. The total number of dosing days was 29."},{"id":"OG002","title":"Part 2: Placebo for MK-8521-T2DM","description":"T2DM participants received once daily subcutaneous placebo for MK-8521 for 29 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"5"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.51","lowerLimit":"4.77","upperLimit":"10.25"},{"groupId":"OG001","value":"9.63","lowerLimit":"6.35","upperLimit":"12.91"},{"groupId":"OG002","value":"-5.82","lowerLimit":"-10.72","upperLimit":"-0.93"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","statisticalMethod":"Linear Mixed Effects Model","statisticalComment":"Fixed effects for treatment, day and treatment by day interaction, a random effect for participant and baseline RMHR as a covariate","paramType":"Difference of Least Squares Means","paramValue":"-2.12","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-5.70","ciUpperLimit":"1.47"},{"groupIds":["OG000","OG002"],"nonInferiorityType":"OTHER","statisticalMethod":"Linear Mixed Effects Model","statisticalComment":"Fixed effects for treatment, day and treatment by day interaction, a random effect for participant and baseline RMHR as a covariate","paramType":"Difference of Least Squares Means","paramValue":"13.34","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"8.64","ciUpperLimit":"18.03"},{"groupIds":["OG001","OG002"],"nonInferiorityType":"OTHER","statisticalMethod":"Linear Mixed Effects Model","statisticalComment":"Fixed effects for treatment, day and treatment by day interaction, a random effect for participant and baseline RMHR as a covariate","paramType":"Difference of Least Squares Means","paramValue":"15.45","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"10.53","ciUpperLimit":"20.38"}]},{"type":"PRIMARY","title":"Change From Baseline in Resting Morning Heart Rate (RMHR) After the Day 29 Dose for Type 2 Diabetes Mellitus (T2DM) Participants in Part 2","description":"Semi-recumbent RMHR was measured in triplicate with at least a 1-2-minute interval between measurements. The repeated measurements were averaged for each time point. Change from baseline RMHR was calculated as the RMHR 24 hours after the Day 29 dose minus baseline. Baseline was an average of 2 readings prior to dosing on Day 1.","populationDescription":"The analysis population included a subset of participants who complied with the protocol sufficiently to ensure that their data exhibited the effects of treatment according to the underlying scientific model and had data available for the analysis of the endpoint. Per-protocol, non-diabetic overweight/obese participants were not planned for the analysis of resting morning heart rate.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Beats per minute","timeFrame":"Baseline (predose Day 1) and Day 30 (24 hours after Day 29)","groups":[{"id":"OG000","title":"Part 2: MK-8521 64/120/180/240/300 µg/Day-T2DM","description":"Type 2 diabetes mellitus (T2DM) participants received once daily subcutaneous MK-8521 titrated to 300 µg starting at 64 µg and increasing to 120 µg on Day 8, 180 µg on Day 15, 240 µg on Day 20, and 300 µg on Day 25. The total number of dosing days was 29."},{"id":"OG001","title":"Part 2: Liraglutide 0.6/1.2/1.8 mg/Day-T2DM","description":"T2DM participants received once daily subcutaneous liraglutide titrated to 1.8 mg starting at 0.6 mg and increasing to 1.2 mg on Day 8, and 1.8 mg on Day 15. The total number of dosing days was 29."},{"id":"OG002","title":"Part 2: Placebo for MK-8521-T2DM","description":"T2DM participants received once daily subcutaneous placebo for MK-8521 for 29 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"5"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.41","lowerLimit":"6.67","upperLimit":"12.15"},{"groupId":"OG001","value":"7.30","lowerLimit":"4.01","upperLimit":"10.58"},{"groupId":"OG002","value":"-1.02","lowerLimit":"-5.92","upperLimit":"3.87"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","statisticalMethod":"Linear Mixed Effects Model","statisticalComment":"Fixed effects for treatment, day and treatment by day interaction, a random effect for participant and baseline RMHR as a covariate","paramType":"Difference of Least Squares Means","paramValue":"2.11","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.47","ciUpperLimit":"5.70"},{"groupIds":["OG000","OG002"],"nonInferiorityType":"OTHER","statisticalMethod":"Linear Mixed Effects Model","statisticalComment":"Fixed effects for treatment, day and treatment by day interaction, a random effect for participant and baseline RMHR as a covariate","paramType":"Difference of Least Squares Means","paramValue":"10.43","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"5.73","ciUpperLimit":"15.13"},{"groupIds":["OG001","OG002"],"nonInferiorityType":"OTHER","statisticalMethod":"Linear Mixed Effects Model","statisticalComment":"Fixed effects for treatment, day and treatment by day interaction, a random effect for participant and baseline RMHR as a covariate","paramType":"Difference of Least Squares Means","paramValue":"8.32","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"3.40","ciUpperLimit":"13.24"}]},{"type":"PRIMARY","title":"Area Under the Concentration-time Curve From 0 to 24 Hours (AUC0-24hr) of MK-8521 on Days 1, 7, and 14 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 1","description":"AUC0-24hr was the area under the concentration-time curve of MK-8521 from time zero to 24 hours after administration. Plasma samples were collected from predose to 24 hours postdose for determination of AUC0-24hr. Individual values were natural log-transformed and evaluated with a linear-mixed effects model containing fixed effects for treatment, day, and treatment by day interaction, and a random effect for participant. Kenward and Roger's method was used to calculate the degree of freedom for the fixed effects. AUC0-24hr is presented as geometric mean and percent coefficient of variation of geometric mean.","populationDescription":"The analysis population included a subset of participants who complied with the protocol sufficiently to ensure that their data exhibited the effects of treatment according to the underlying scientific model and had data available for the analysis of the endpoint.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"nM•hour","timeFrame":"Predose and 1, 2, 4, 6, 8, 10, 12, 16, and 24 hours post-dose on Days 1, 7, and 14","groups":[{"id":"OG000","title":"Part 1: MK-8521 64/120 μg/Day","description":"Type 2 diabetes mellitus (T2DM) participants received once daily subcutaneous MK-8521 starting at 64 μg on Days 1 to 7 and escalated to 120 μg on Days 8 to 14."},{"id":"OG001","title":"Part 1: MK-8521 34/72 μg/Day","description":"T2DM participants received once daily subcutaneous MK-8521 starting at 34 μg on Days 1 to 7 and escalated to 72 μg on Days 8 to 14."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"8"}]}],"classes":[{"title":"Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.11","spread":"47.6"},{"groupId":"OG001","value":"2.25","spread":"27.5"}]}]},{"title":"Day 7","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"14.4","spread":"55.9"},{"groupId":"OG001","value":"5.63","spread":"24.6"}]}]},{"title":"Day 14","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"32.8","spread":"42.8"},{"groupId":"OG001","value":"12.6","spread":"26.6"}]}]}]},{"type":"PRIMARY","title":"Maximum Concentration (Cmax) of MK-8521 on Days 1 and 7 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 1","description":"Cmax was the maximum observed concentration of MK-8521 in plasma after administration. Plasma samples were collected from predose to 24 hours postdose for determination of Cmax. Individual values were natural log-transformed and evaluated with a linear-mixed effects model containing fixed effects for treatment, day, and treatment by day interaction, and a random effect for participant. Kenward and Roger's method was used to calculate the degree of freedom for the fixed effects. Cmax is presented as geometric mean and percent coefficient of variation of geometric mean.","populationDescription":"The analysis population included a subset of participants who complied with the protocol sufficiently to ensure that their data exhibited the effects of treatment according to the underlying scientific model and had data available for the analysis of the endpoint.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"nM","timeFrame":"Predose and 1, 2, 4, 6, 8, 10, 12, 16, and 24 hours post-dose on Days 1 and 7","groups":[{"id":"OG000","title":"Part 1: MK-8521 64/120 μg/Day","description":"Type 2 diabetes mellitus (T2DM) participants received once daily subcutaneous MK-8521 starting at 64 μg on Days 1 to 7 and escalated to 120 μg on Days 8 to 14."},{"id":"OG001","title":"Part 1: MK-8521 34/72 μg/Day","description":"T2DM participants received once daily subcutaneous MK-8521 starting at 34 μg on Days 1 to 7 and escalated to 72 μg on Days 8 to 14."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"8"}]}],"classes":[{"title":"Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.350","spread":"41.4"},{"groupId":"OG001","value":"0.128","spread":"21.4"}]}]},{"title":"Day 7","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.710","spread":"57.6"},{"groupId":"OG001","value":"0.275","spread":"31.2"}]}]}]},{"type":"PRIMARY","title":"Maximum Concentration (Cmax) of MK-8521 on Day 14 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 1","description":"Cmax was the maximum observed concentration of MK-8521 in plasma after administration on Day 14. Plasma samples were collected from predose to 120 hours postdose for determination of Cmax. Individual values were natural log-transformed and evaluated with a linear-mixed effects model containing fixed effects for treatment, day, and treatment by day interaction, and a random effect for participant. Kenward and Roger's method was used to calculate the degree of freedom for the fixed effects. Cmax is presented as geometric mean and percent coefficient of variation of geometric mean.","populationDescription":"The analysis population included a subset of participants who complied with the protocol sufficiently to ensure that their data exhibited the effects of treatment according to the underlying scientific model and had data available for the analysis of the endpoint.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"nM","timeFrame":"Predose and 1, 2, 4, 6, 8, 10, 12, 16, 24, 72, 96, and 120 hours post-dose on Day 14","groups":[{"id":"OG000","title":"Part 1: MK-8521 64/120 μg/Day","description":"Type 2 diabetes mellitus (T2DM) participants received once daily subcutaneous MK-8521 starting at 64 μg on Days 1 to 7 and escalated to 120 μg on Days 8 to 14."},{"id":"OG001","title":"Part 1: MK-8521 34/72 μg/Day","description":"T2DM participants received once daily subcutaneous MK-8521 starting at 34 μg on Days 1 to 7 and escalated to 72 μg on Days 8 to 14."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"8"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.70","spread":"38.4"},{"groupId":"OG001","value":"0.619","spread":"27.0"}]}]}]},{"type":"PRIMARY","title":"Trough Concentration (Ctrough) of MK-8521 on Days 1, 7, and 14 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 1","description":"Ctrough was the lowest observed concentration of MK-8521 in plasma. Plasma samples were collected predose on Day 2 (sampled after the Day 1 dose and prior to Day 2 dose), 7, and 14 for determination of Ctrough. Individual values were natural log-transformed and evaluated with a linear-mixed effects model containing fixed effects for treatment, day, and treatment by day interaction, and a random effect for participant. Kenward and Roger's method was used to calculate the degree of freedom for the fixed effects. Ctrough is presented as geometric mean and percent coefficient of variation of geometric mean.","populationDescription":"The analysis population included a subset of participants who complied with the protocol sufficiently to ensure that their data exhibited the effects of treatment according to the underlying scientific model and had data available for the analysis of the endpoint.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"nM","timeFrame":"Predose on Days 2, 7, and 14","groups":[{"id":"OG000","title":"Part 1: MK-8521 64/120 μg/Day","description":"Type 2 diabetes mellitus (T2DM) participants received once daily subcutaneous MK-8521 starting at 64 μg on Days 1 to 7 and escalated to 120 μg on Days 8 to 14."},{"id":"OG001","title":"Part 1: MK-8521 34/72 μg/Day","description":"T2DM participants received once daily subcutaneous MK-8521 starting at 34 μg on Days 1 to 7 and escalated to 72 μg on Days 8 to 14."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"8"}]}],"classes":[{"title":"Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.322","spread":"33.2"},{"groupId":"OG001","value":"0.119","spread":"20.6"}]}]},{"title":"Day 7","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.442","spread":"83.6"},{"groupId":"OG001","value":"0.207","spread":"21.8"}]}]},{"title":"Day 14","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.16","spread":"43.3"},{"groupId":"OG001","value":"0.506","spread":"27.5"}]}]}]},{"type":"PRIMARY","title":"Time to Maximum Concentration (Tmax) of MK-8521 on Days 1 and 7 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 1","description":"Tmax was the time required to reach the maximum concentration of MK-8521 in plasma. Plasma samples were collected from predose to 24 hours postdose for determination of Tmax. Tmax is presented as median with a full range.","populationDescription":"The analysis population included a subset of participants who complied with the protocol sufficiently to ensure that their data exhibited the effects of treatment according to the underlying scientific model and had data available for the analysis of the endpoint.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"Hours","timeFrame":"Predose and 1, 2, 4, 6, 8, 10, 12, 16, and 24 hours post-dose on Days 1 and 7","groups":[{"id":"OG000","title":"Part 1: MK-8521 64/120 μg/Day","description":"Type 2 diabetes mellitus (T2DM) participants received once daily subcutaneous MK-8521 starting at 64 μg on Days 1 to 7 and escalated to 120 μg on Days 8 to 14."},{"id":"OG001","title":"Part 1: MK-8521 34/72 μg/Day","description":"T2DM participants received once daily subcutaneous MK-8521 starting at 34 μg on Days 1 to 7 and escalated to 72 μg on Days 8 to 14."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"8"}]}],"classes":[{"title":"Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"16","lowerLimit":"10","upperLimit":"24"},{"groupId":"OG001","value":"16","lowerLimit":"10","upperLimit":"24"}]}]},{"title":"Day 7","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7","lowerLimit":"6","upperLimit":"10"},{"groupId":"OG001","value":"6","lowerLimit":"1","upperLimit":"10"}]}]}]},{"type":"PRIMARY","title":"Time to Maximum Concentration (Tmax) of MK-8521 on Day 14 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 1","description":"Tmax was the time required to reach the maximum concentration of MK-8521 in plasma. Plasma samples were collected from predose to 120 hours postdose for determination of Tmax. Tmax is presented as median with a full range.","populationDescription":"The analysis population included a subset of participants who complied with the protocol sufficiently to ensure that their data exhibited the effects of treatment according to the underlying scientific model and had data available for the analysis of the endpoint.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"Hours","timeFrame":"Predose and 1, 2, 4, 6, 8, 10, 12, 16, 24, 72, 96, and 120 hours post-dose on Day 14","groups":[{"id":"OG000","title":"Part 1: MK-8521 64/120 μg/Day","description":"Type 2 diabetes mellitus (T2DM) participants received once daily subcutaneous MK-8521 starting at 64 μg on Days 1 to 7 and escalated to 120 μg on Days 8 to 14."},{"id":"OG001","title":"Part 1: MK-8521 34/72 μg/Day","description":"T2DM participants received once daily subcutaneous MK-8521 starting at 34 μg on Days 1 to 7 and escalated to 72 μg on Days 8 to 14."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"8"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","lowerLimit":"1","upperLimit":"8"},{"groupId":"OG001","value":"6","lowerLimit":"4","upperLimit":"12"}]}]}]},{"type":"PRIMARY","title":"Apparent Terminal Half Life (t1/2) of MK-8521 on Days 1 and 7 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 1","description":"t1/2 was the time required to divide the MK-8521 concentration by half after reaching pseudo-equilibrium. Plasma samples were collected from predose to 24 hours postdose for determination of t1/2. t1/2 is presented as geometric mean and percent coefficient of variation of geometric mean.","populationDescription":"The analysis population included a subset of participants who complied with the protocol sufficiently to ensure that their data exhibited the effects of treatment according to the underlying scientific model and had data available for the analysis of the endpoint. t1/2 was not measured for Days 1 and 7 since terminal phase was not adequately captured with sampling times up to 24 hours post dose.","reportingStatus":"POSTED","timeFrame":"Predose and 1, 2, 4, 6, 8, 10, 12, 16, and 24 hours post-dose on Days 1 and 7","groups":[{"id":"OG000","title":"Part 1: MK-8521 64/120 μg/Day","description":"Type 2 diabetes mellitus (T2DM) participants received once daily subcutaneous MK-8521 starting at 64 μg on Days 1 to 7 and escalated to 120 μg on Days 8 to 14."},{"id":"OG001","title":"Part 1: MK-8521 34/72 μg/Day","description":"T2DM participants received once daily subcutaneous MK-8521 starting at 34 μg on Days 1 to 7 and escalated to 72 μg on Days 8 to 14."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}],"classes":[{"title":"Day 1"},{"title":"Day 7"}]},{"type":"PRIMARY","title":"Apparent Terminal Half Life (t1/2) of MK-8521 on Day 14 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 1","description":"t1/2 was the time required to divide the MK-8521 concentration by half after reaching pseudo-equilibrium. Plasma samples were collected from predose to 120 hours postdose for determination of t1/2. t1/2 was measured on Day 14 which is the longest time point for sampling for T2DM participants in Part 1. t1/2 is presented as geometric mean and percent coefficient of variation of geometric mean.","populationDescription":"The analysis population included a subset of participants who complied with the protocol sufficiently to ensure that their data exhibited the effects of treatment according to the underlying scientific model and had data available for the analysis of the endpoint.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"Hours","timeFrame":"Predose and 1, 2, 4, 6, 8, 10, 12, 16, 24, 72, 96, and 120 hours post-dose on Day 14","groups":[{"id":"OG000","title":"Part 1: MK-8521 64/120 μg/Day","description":"Type 2 diabetes mellitus (T2DM) participants received once daily subcutaneous MK-8521 starting at 64 μg on Days 1 to 7 and escalated to 120 μg on Days 8 to 14."},{"id":"OG001","title":"Part 1: MK-8521 34/72 μg/Day","description":"T2DM participants received once daily subcutaneous MK-8521 starting at 34 μg on Days 1 to 7 and escalated to 72 μg on Days 8 to 14."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"8"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.6","spread":"16.1"},{"groupId":"OG001","value":"17.2","spread":"17.0"}]}]}]},{"type":"PRIMARY","title":"Accumulation Ratio of the Area Under the Concentration-time Curve From 0 to 24 Hours (AUC0-24hr) of MK-8521 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 1","description":"Plasma samples were collected from predose to 24 hours postdose for determination of the accumulation ratio of AUC0-24hr. The geometric mean accumulation ratio was calculated as Day 7 AUC0-24hr/Day 1 AUC0-24hr and presented as geometric mean ratio with a full range.","populationDescription":"The analysis population included a subset of participants who complied with the protocol sufficiently to ensure that their data exhibited the effects of treatment according to the underlying scientific model and had data available for the analysis of the endpoint.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Full Range","unitOfMeasure":"Ratio","timeFrame":"Predose and 1, 2, 4, 6, 8, 10, 12, 16, and 24 hours post-dose on Days 1 and 7","groups":[{"id":"OG000","title":"Part 1: MK-8521 64/120 μg/Day","description":"Type 2 diabetes mellitus (T2DM) participants received once daily subcutaneous MK-8521 starting at 64 μg on Days 1 to 7 and escalated to 120 μg on Days 8 to 14."},{"id":"OG001","title":"Part 1: MK-8521 34/72 μg/Day","description":"T2DM participants received once daily subcutaneous MK-8521 starting at 34 μg on Days 1 to 7 and escalated to 72 μg on Days 8 to 14."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"8"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.31","lowerLimit":"1.85","upperLimit":"2.66"},{"groupId":"OG001","value":"2.50","lowerLimit":"1.80","upperLimit":"3.73"}]}]}]},{"type":"PRIMARY","title":"Accumulation Ratio of the Maximum Concentration (Cmax) of MK-8521 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 1","description":"Plasma samples were collected from predose to 24 hours postdose for determination of the accumulation ratio of Cmax. The geometric mean accumulation ratio was calculated as Day 7 Cmax/Day 1 Cmax and presented as geometric mean ratio with a full range.","populationDescription":"The analysis population included a subset of participants who complied with the protocol sufficiently to ensure that their data exhibited the effects of treatment according to the underlying scientific model and had data available for the analysis of the endpoint.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Full Range","unitOfMeasure":"Ratio","timeFrame":"Predose and 1, 2, 4, 6, 8, 10, 12, 16, and 24 hours post-dose on Days 1 and 7","groups":[{"id":"OG000","title":"Part 1: MK-8521 64/120 μg/Day","description":"Type 2 diabetes mellitus (T2DM) participants received once daily subcutaneous MK-8521 starting at 64 μg on Days 1 to 7 and escalated to 120 μg on Days 8 to 14."},{"id":"OG001","title":"Part 1: MK-8521 34/72 μg/Day","description":"T2DM participants received once daily subcutaneous MK-8521 starting at 34 μg on Days 1 to 7 and escalated to 72 μg on Days 8 to 14."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"8"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.00","lowerLimit":"1.41","upperLimit":"2.35"},{"groupId":"OG001","value":"2.14","lowerLimit":"1.61","upperLimit":"2.83"}]}]}]},{"type":"PRIMARY","title":"Accumulation Ratio of the Trough Concentration (Ctrough) of MK-8521 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 1","description":"Plasma samples were collected predose on Days 2 (sampled after the Day 1 dose and prior to Day 2 dose) and 7 for determination of the accumulation ratio of Ctrough. The geometric mean accumulation ratio was calculated as Day 7 Ctrough/Day 1 Ctrough (sampled after the Day 1 dose and prior to Day 2 dose) and presented as geometric mean ratio with a full range.","populationDescription":"The analysis population included a subset of participants who complied with the protocol sufficiently to ensure that their data exhibited the effects of treatment according to the underlying scientific model and had data available for the analysis of the endpoint.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Full Range","unitOfMeasure":"Ratio","timeFrame":"Predose on Days 2 and 7","groups":[{"id":"OG000","title":"Part 1: MK-8521 64/120 μg/Day","description":"Type 2 diabetes mellitus (T2DM) participants received once daily subcutaneous MK-8521 starting at 64 μg on Days 1 to 7 and escalated to 120 μg on Days 8 to 14."},{"id":"OG001","title":"Part 1: MK-8521 34/72 μg/Day","description":"T2DM participants received once daily subcutaneous MK-8521 starting at 34 μg on Days 1 to 7 and escalated to 72 μg on Days 8 to 14."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"8"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.37","lowerLimit":"0.39","upperLimit":"2.13"},{"groupId":"OG001","value":"1.73","lowerLimit":"1.46","upperLimit":"1.93"}]}]}]},{"type":"PRIMARY","title":"Area Under the Concentration-time Curve From 0 to 24 Hours (AUC0-24hr) of MK-8521 on Days 1, 7, and 14 for Type 2 Diabetes Mellitus (T2DM) and Non-Diabetic Overweight/Obese Participants in Part 2","description":"AUC0-24hr was the area under the concentration-time curve of MK-8521 from time zero to 24 hours after administration. Plasma samples were collected from predose to 24 hours postdose for determination of AUC0-24hr. Individual values were natural log-transformed and evaluated with a linear-mixed effects model containing fixed effects for treatment, day, and treatment by day interaction, and a random effect for participant. Kenward and Roger's method was used to calculate the degree of freedom for the fixed effects. AUC0-24hr is presented as geometric mean and percent coefficient of variation of geometric mean.","populationDescription":"The analysis population included a subset of participants who complied with the protocol sufficiently to ensure that their data exhibited the effects of treatment according to the underlying scientific model and had data available for the analysis of the endpoint.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"nM•hour","timeFrame":"Predose and 1, 2, 6, 10, 16, and 24 hours postdose on Days 1, 7, and 14","groups":[{"id":"OG000","title":"Part 2: MK-8521 64/120/180/240/300 µg/Day-T2DM","description":"Type 2 diabetes mellitus (T2DM) participants received once daily subcutaneous MK-8521 titrated to 300 µg starting at 64 µg and increasing to 120 µg on Day 8, 180 µg on Day 15, 240 µg on Day 20, and 300 µg on Day 25. The total number of dosing days was 29."},{"id":"OG001","title":"Part 2: MK-8521 64/120 µg/Day-Non-Diabetic Overweight/Obese","description":"Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 titrated to 120 µg starting at 64 µg and increasing to 120 µg on Day 8. The total number of dosing days was 14."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"8"}]}],"classes":[{"title":"Day 1","categories":[{"measurements":[{"groupId":"OG000","value":"6.46","spread":"49.5"},{"groupId":"OG001","value":"7.68","spread":"34.8"}]}]},{"title":"Day 7","categories":[{"measurements":[{"groupId":"OG000","value":"15.1","spread":"35.6"},{"groupId":"OG001","value":"15.0","spread":"35.9"}]}]},{"title":"Day 14","categories":[{"measurements":[{"groupId":"OG000","value":"30.0","spread":"35.8"},{"groupId":"OG001","value":"34.4","spread":"19.5"}]}]}]},{"type":"PRIMARY","title":"Accumulation Ratio of the Area Under the Concentration-time Curve From 0 to 24 Hours (AUC0-24hr) of MK-8521 for Type 2 Diabetes Mellitus (T2DM) and Non-Diabetic Overweight/Obese Participants in Part 2","description":"Plasma samples were collected from predose to 24 hours postdose for determination of the accumulation ratio of AUC0-24hr. The geometric mean accumulation ratio was calculated as Day 7 AUC0-24hr/Day 1 AUC0-24hr and presented as geometric mean ratio and percent geometric coefficient of variation.","populationDescription":"The analysis population included a subset of participants who complied with the protocol sufficiently to ensure that their data exhibited the effects of treatment according to the underlying scientific model and had data available for the analysis of the endpoint.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"Ratio","timeFrame":"Predose and 1, 2, 6, 10, 16, and 24 hours post-dose on Days 1 and 7","groups":[{"id":"OG000","title":"Part 2: MK-8521 64/120/180/240/300 µg/Day-T2DM","description":"Type 2 diabetes mellitus (T2DM) participants received once daily subcutaneous MK-8521 titrated to 300 µg starting at 64 µg and increasing to 120 µg on Day 8, 180 µg on Day 15, 240 µg on Day 20, and 300 µg on Day 25. The total number of dosing days was 29."},{"id":"OG001","title":"Part 2: MK-8521 64/120 µg/Day-Non-Diabetic Overweight/Obese","description":"Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 titrated to 120 µg starting at 64 µg and increasing to 120 µg on Day 8. The total number of dosing days was 14."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"8"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.33","spread":"22.2"},{"groupId":"OG001","value":"1.95","spread":"28.6"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Plasma Glucose (FPG) at Day 7 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 1","description":"FPG was measured predose on Days 1 and 7. The change from baseline of FPG was calculated as the difference between the predose measurement on Day 1 (baseline) and the measurement obtained predose on Day 7. FPG is presented as mean change from baseline with a standard error.","populationDescription":"The analysis population included a subset of participants who complied with the protocol sufficiently to ensure that their data exhibited the effects of treatment according to the underlying scientific model and had data available for the analysis of the endpoint.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Error","unitOfMeasure":"mg/dL","timeFrame":"Predose on Days 1 (baseline) and 7","groups":[{"id":"OG000","title":"Part 1: MK-8521 64/120 μg/Day","description":"Type 2 diabetes mellitus (T2DM) participants received once daily subcutaneous MK-8521 starting at 64 μg on Days 1 to 7 and escalated to 120 μg on Days 8 to 14."},{"id":"OG001","title":"Part 1: MK-8521 34/72 μg/Day","description":"T2DM participants received once daily subcutaneous MK-8521 starting at 34 μg on Days 1 to 7 and escalated to 72 μg on Days 8 to 14."},{"id":"OG002","title":"Part 1: Liraglutide 0.6/1.2/1.8 mg/Day","description":"T2DM participants received once daily subcutaneous liraglutide starting at 0.6 mg on Day 1 and 2, escalated to 1.2 mg on Days 3 to 7, and escalated to 1.8 mg on Days 8 to 14."},{"id":"OG003","title":"Part 1: Placebo for MK-8521","description":"Participants received once daily subcutaneous placebo for MK-8521 for 14 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"8"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-23.57","spread":"10.75"},{"groupId":"OG001","value":"-39.00","spread":"8.44"},{"groupId":"OG002","value":"-59.11","spread":"7.09"},{"groupId":"OG003","value":"-11.13","spread":"7.26"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Plasma Glucose (FPG) at Day 14 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 1","description":"FPG was measured predose on Days 1 and 14. The change from baseline of FPG was calculated as the difference between the predose measurement on Day 1 (baseline) and the measurement obtained predose on Day 14. FPG is presented as mean change from baseline with a standard error.","populationDescription":"The analysis population included a subset of participants who complied with the protocol sufficiently to ensure that their data exhibited the effects of treatment according to the underlying scientific model and had data available for the analysis of the endpoint.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Error","unitOfMeasure":"mg/dL","timeFrame":"Predose on Days 1 (baseline) and 14","groups":[{"id":"OG000","title":"Part 1: MK-8521 64/120 μg/Day","description":"Type 2 diabetes mellitus (T2DM) participants received once daily subcutaneous MK-8521 starting at 64 μg on Days 1 to 7 and escalated to 120 μg on Days 8 to 14."},{"id":"OG001","title":"Part 1: MK-8521 34/72 μg/Day","description":"T2DM participants received once daily subcutaneous MK-8521 starting at 34 μg on Days 1 to 7 and escalated to 72 μg on Days 8 to 14."},{"id":"OG002","title":"Part 1: Liraglutide 0.6/1.2/1.8 mg/Day","description":"T2DM participants received once daily subcutaneous liraglutide starting at 0.6 mg on Day 1 and 2, escalated to 1.2 mg on Days 3 to 7, and escalated to 1.8 mg on Days 8 to 14."},{"id":"OG003","title":"Part 1: Placebo for MK-8521","description":"Participants received once daily subcutaneous placebo for MK-8521 for 14 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"8"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-41.29","spread":"11.22"},{"groupId":"OG001","value":"-48.50","spread":"13.21"},{"groupId":"OG002","value":"-59.25","spread":"4.98"},{"groupId":"OG003","value":"-13.50","spread":"9.54"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in 24-hour Weighted Mean Glucose (WMG) at Day 7 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 1","description":"The 24-hour WMG was calculated as the area under the 24-hour glucose curve (AUC0-24hr) divided by 24 hours. Blood samples for glucose were collected immediately prior to, and after each meal. The change from baseline value for 24-hour WMG was calculated where baseline was the WMG before food and prior to treatment on Day 1. Blood for plasma glucose concentrations was obtained at predose Day 1 at pre meal (breakfast), 0.5, 1, 2, 3, 4 (pre lunch), 4.5, 5, 6, 7, 10 (pre dinner), 10.5, 11, 12, 13, 15 and 23 hours post breakfast meal; and on Day 7 at 1 (pre breakfast), 1.5, 2, 3, 4, 5 (pre lunch), 5.5, 6, 7, 8, 11 (pre dinner), 11.5, 12, 13, 14, 16, 24 hours post dose. Individual change from baseline 24-hour WMG was analyzed in a linear mixed effects model with fixed effects for treatment, day and treatment by day interaction, a random effect for participant, and baseline 24-hour WMG as a covariate. WMG is presented as least squares mean with a 95% confidence interval.","populationDescription":"The analysis population included a subset of participants who complied with the protocol sufficiently to ensure that their data exhibited the effects of treatment according to the underlying scientific model and had data available for the analysis of the endpoint.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"mg/dL","timeFrame":"Baseline (predose and before food on Day 1) and up to 24 hours post Day 7 dose","groups":[{"id":"OG000","title":"Part 1: MK-8521 64/120 μg/Day","description":"Type 2 diabetes mellitus (T2DM) participants received once daily subcutaneous MK-8521 starting at 64 μg on Days 1 to 7 and escalated to 120 μg on Days 8 to 14."},{"id":"OG001","title":"Part 1: MK-8521 34/72 μg/Day","description":"T2DM participants received once daily subcutaneous MK-8521 starting at 34 μg on Days 1 to 7 and escalated to 72 μg on Days 8 to 14."},{"id":"OG002","title":"Part 1: Liraglutide 0.6/1.2/1.8 mg/Day","description":"T2DM participants received once daily subcutaneous liraglutide starting at 0.6 mg on Day 1 and 2, escalated to 1.2 mg on Days 3 to 7, and escalated to 1.8 mg on Days 8 to 14."},{"id":"OG003","title":"Part 1: Placebo for MK-8521","description":"Participants received once daily subcutaneous placebo for MK-8521 for 14 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"8"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-24.08","lowerLimit":"-45.46","upperLimit":"-2.71"},{"groupId":"OG001","value":"-27.54","lowerLimit":"-46.39","upperLimit":"-8.69"},{"groupId":"OG002","value":"-53.64","lowerLimit":"-75.20","upperLimit":"-32.08"},{"groupId":"OG003","value":"2.36","lowerLimit":"-16.20","upperLimit":"20.92"}]}]}],"analyses":[{"groupIds":["OG000","OG002"],"nonInferiorityType":"OTHER","statisticalMethod":"Linear Mixed Effects Model","statisticalComment":"Fixed effects for treatment, day and treatment by day interaction, a random effect for participant and baseline 24-hour WMG as a covariate","paramType":"Difference of Least Squares Means","paramValue":"29.56","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"4.34","ciUpperLimit":"54.77"},{"groupIds":["OG001","OG002"],"nonInferiorityType":"OTHER","statisticalMethod":"Linear Mixed Effects Model","statisticalComment":"Fixed effects for treatment, day and treatment by day interaction, a random effect for participant and baseline 24-hour WMG as a covariate","paramType":"Difference of Least Squares Means","paramValue":"26.10","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"2.02","ciUpperLimit":"50.19"},{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","statisticalMethod":"Linear Mixed Effects Model","statisticalComment":"Fixed effects for treatment, day and treatment by day interaction, a random effect for participant and baseline 24-hour WMG as a covariate","paramType":"Difference of Least Squares Means","paramValue":"3.45","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-20.23","ciUpperLimit":"27.14"},{"groupIds":["OG000","OG003"],"nonInferiorityType":"OTHER","statisticalMethod":"Linear Mixed Effects Model","statisticalComment":"Fixed effects for treatment, day and treatment by day interaction, a random effect for participant and baseline 24-hour WMG as a covariate","paramType":"Difference of Least Squares Means","paramValue":"-26.45","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-49.96","ciUpperLimit":"-2.93"},{"groupIds":["OG001","OG003"],"nonInferiorityType":"OTHER","statisticalMethod":"Linear Mixed Effects Model","statisticalComment":"Fixed effects for treatment, day and treatment by day interaction, a random effect for participant and baseline 24-hour WMG as a covariate","paramType":"Difference of Least Squares Means","paramValue":"-29.90","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-52.04","ciUpperLimit":"-7.77"},{"groupIds":["OG002","OG003"],"nonInferiorityType":"OTHER","statisticalMethod":"Linear Mixed Effects Model","statisticalComment":"Fixed effects for treatment, day and treatment by day interaction, a random effect for participant and baseline 24-hour WMG as a covariate","paramType":"Difference of Least Squares Means","paramValue":"-56.00","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-79.53","ciUpperLimit":"-32.48"}]},{"type":"SECONDARY","title":"Change From Baseline in 24-hour Weighted Mean Glucose (WMG) at Day 14 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 1","description":"The 24-hour WMG was calculated as the area under the 24-hour glucose curve (AUC0-24hr) divided by 24 hours. Blood samples for glucose were collected immediately prior to and after each meal. The change from baseline value for 24-hour WMG was calculated where baseline was the WMG before food and prior to treatment on Day 1. Blood for plasma glucose concentrations was obtained on Day -1 at pre meal (breakfast), 0.5, 1, 2, 3, 4 (pre lunch), 4.5, 5, 6, 7, 10 (pre dinner), 10.5, 11, 12, 13, 15 and 23 hours post breakfast meal; and on Day 14 at 1 (pre breakfast), 1.5, 2, 3, 4, 5 (pre lunch), 5.5, 6, 7, 8, 11(pre dinner), 11.5, 12, 13, 14, 16, 24 hours post dose. Individual change from baseline 24-hour WMG was analyzed in a linear mixed effects model with fixed effects for treatment, day and treatment by day interaction, a random effect for participant, and baseline 24-hour WMG as a covariate. WMG is presented as least squares mean with a 95% confidence interval.","populationDescription":"The analysis population included a subset of participants who complied with the protocol sufficiently to ensure that their data exhibited the effects of treatment according to the underlying scientific model and had data available for the analysis of the endpoint.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"mg/dL","timeFrame":"Baseline (predose and before food on Day 1) and up to 24 hours post Day 14 dose","groups":[{"id":"OG000","title":"Part 1: MK-8521 64/120 μg/Day","description":"Type 2 diabetes mellitus (T2DM) participants received once daily subcutaneous MK-8521 starting at 64 μg on Days 1 to 7 and escalated to 120 μg on Days 8 to 14."},{"id":"OG001","title":"Part 1: MK-8521 34/72 μg/Day","description":"T2DM participants received once daily subcutaneous MK-8521 starting at 34 μg on Days 1 to 7 and escalated to 72 μg on Days 8 to 14."},{"id":"OG002","title":"Part 1: Liraglutide 0.6/1.2/1.8 mg/Day","description":"T2DM participants received once daily subcutaneous liraglutide starting at 0.6 mg on Day 1 and 2, escalated to 1.2 mg on Days 3 to 7, and escalated to 1.8 mg on Days 8 to 14."},{"id":"OG003","title":"Part 1: Placebo for MK-8521","description":"Participants received once daily subcutaneous placebo for MK-8521 for 14 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"8"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-37.24","lowerLimit":"-58.61","upperLimit":"-15.86"},{"groupId":"OG001","value":"-45.63","lowerLimit":"-64.49","upperLimit":"-26.78"},{"groupId":"OG002","value":"-52.20","lowerLimit":"-73.76","upperLimit":"-30.64"},{"groupId":"OG003","value":"-2.00","lowerLimit":"-20.56","upperLimit":"16.56"}]}]}],"analyses":[{"groupIds":["OG000","OG002"],"nonInferiorityType":"OTHER","statisticalMethod":"Linear Mixed Effects Model","statisticalComment":"Fixed effects for treatment, day and treatment by day interaction, a random effect for participant and baseline 24-hour WMG as a covariate","paramType":"Difference of Least Squares Means","paramValue":"14.96","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-10.25","ciUpperLimit":"40.18"},{"groupIds":["OG001","OG002"],"nonInferiorityType":"OTHER","statisticalMethod":"Linear Mixed Effects Model","statisticalComment":"Fixed effects for treatment, day and treatment by day interaction, a random effect for participant and baseline 24-hour WMG as a covariate","paramType":"Difference of Least Squares Means","paramValue":"6.57","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-17.52","ciUpperLimit":"30.65"},{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","statisticalMethod":"Linear Mixed Effects Model","statisticalComment":"Fixed effects for treatment, day and treatment by day interaction, a random effect for participant and baseline 24-hour WMG as a covariate","paramType":"Difference of Least Squares Means","paramValue":"8.40","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-15.29","ciUpperLimit":"32.08"},{"groupIds":["OG000","OG003"],"nonInferiorityType":"OTHER","statisticalMethod":"Linear Mixed Effects Model","statisticalComment":"Fixed effects for treatment, day and treatment by day interaction, a random effect for participant and baseline 24-hour WMG as a covariate","paramType":"Difference of Least Squares Means","paramValue":"-35.23","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-58.75","ciUpperLimit":"-11.72"},{"groupIds":["OG001","OG003"],"nonInferiorityType":"OTHER","statisticalMethod":"Linear Mixed Effects Model","statisticalComment":"Fixed effects for treatment, day and treatment by day interaction, a random effect for participant and baseline 24-hour WMG as a covariate","paramType":"Difference of Least Squares Means","paramValue":"-43.63","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-65.77","ciUpperLimit":"-21.50"},{"groupIds":["OG002","OG003"],"nonInferiorityType":"OTHER","statisticalMethod":"Linear Mixed Effects Model","statisticalComment":"Fixed effects for treatment, day and treatment by day interaction, a random effect for participant and baseline 24-hour WMG as a covariate","paramType":"Difference of Least Squares Means","paramValue":"-50.20","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-73.72","ciUpperLimit":"-26.68"}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Plasma Glucose (FPG) at Day 14 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 2","description":"FPG was measured predose on Days 1 and 14. The change from baseline of FPG was calculated as the difference between the predose measurement on Day 1 (baseline) and the measurement obtained predose on Day 14. FPG is presented as least squares mean change from baseline with a 95% confidence interval.","populationDescription":"The analysis population included a subset of participants who complied with the protocol sufficiently to ensure that their data exhibited the effects of treatment according to the underlying scientific model and had data available for the analysis of the endpoint.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"mg/dL","timeFrame":"Predose on Days 1 (baseline) and 14","groups":[{"id":"OG000","title":"Part 2: MK-8521 64/120/180/240/300 µg/Day-T2DM","description":"Type 2 diabetes mellitus (T2DM) participants received once daily subcutaneous MK-8521 titrated to 300 µg starting at 64 µg and increasing to 120 µg on Day 8, 180 µg on Day 15, 240 µg on Day 20, and 300 µg on Day 25. The total number of dosing days was 29."},{"id":"OG001","title":"Part 2: Liraglutide 0.6/1.2/1.8 mg/Day-T2DM","description":"T2DM participants received once daily subcutaneous liraglutide titrated to 1.8 mg starting at 0.6 mg and increasing to 1.2 mg on Day 8, and 1.8 mg on Day 15. The total number of dosing days was 29."},{"id":"OG002","title":"Part 2: Placebo for MK-8521-T2DM","description":"T2DM participants received once daily subcutaneous placebo for MK-8521 for 29 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"5"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-45.89","lowerLimit":"-56.44","upperLimit":"-35.33"},{"groupId":"OG001","value":"-39.80","lowerLimit":"-48.27","upperLimit":"-31.33"},{"groupId":"OG002","value":"-14.69","lowerLimit":"-43.93","upperLimit":"14.55"}]}]}],"analyses":[{"groupIds":["OG000","OG002"],"nonInferiorityType":"OTHER","statisticalMethod":"Linear Mixed Effects Model","statisticalComment":"Fixed effects for treatment, day and treatment by day interaction, a random effect for participant and baseline FPG as a covariate","paramType":"Difference of Least Squares Means","paramValue":"-31.20","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-56.59","ciUpperLimit":"-5.81"},{"groupIds":["OG001","OG002"],"nonInferiorityType":"OTHER","statisticalMethod":"Linear Mixed Effects Model","statisticalComment":"Fixed effects for treatment, day and treatment by day interaction, a random effect for participant and baseline FPG as a covariate","paramType":"Difference of Least Squares Means","paramValue":"-25.12","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-50.25","ciUpperLimit":"0.01"},{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","statisticalMethod":"Linear Mixed Effects Model","statisticalComment":"Fixed effects for treatment, day and treatment by day interaction, a random effect for participant and baseline FPG as a covariate","paramType":"Difference of Least Squares Means","paramValue":"-6.08","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-17.31","ciUpperLimit":"5.14"}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Plasma Glucose (FPG) at Day 19 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 2","description":"FPG was measured predose on Days 1 and 19. The change from baseline of FPG was calculated as the difference between the predose measurement on Day 1 (baseline) and the measurement obtained predose on Day 19. FPG is presented as least squares mean change from baseline with a 95% confidence interval.","populationDescription":"The analysis population included a subset of participants who complied with the protocol sufficiently to ensure that their data exhibited the effects of treatment according to the underlying scientific model and had data available for the analysis of the endpoint.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"mg/dL","timeFrame":"Predose on Days 1 (baseline) and 19","groups":[{"id":"OG000","title":"Part 2: MK-8521 64/120/180/240/300 µg/Day-T2DM","description":"Type 2 diabetes mellitus (T2DM) participants received once daily subcutaneous MK-8521 titrated to 300 µg starting at 64 µg and increasing to 120 µg on Day 8, 180 µg on Day 15, 240 µg on Day 20, and 300 µg on Day 25. The total number of dosing days was 29."},{"id":"OG001","title":"Part 2: Liraglutide 0.6/1.2/1.8 mg/Day-T2DM","description":"T2DM participants received once daily subcutaneous liraglutide titrated to 1.8 mg starting at 0.6 mg and increasing to 1.2 mg on Day 8, and 1.8 mg on Day 15. The total number of dosing days was 29."},{"id":"OG002","title":"Part 2: Placebo for MK-8521-T2DM","description":"T2DM participants received once daily subcutaneous placebo for MK-8521 for 29 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"5"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-44.22","lowerLimit":"-54.77","upperLimit":"-33.66"},{"groupId":"OG001","value":"-47.33","lowerLimit":"-55.80","upperLimit":"-38.86"},{"groupId":"OG002","value":"-16.74","lowerLimit":"-45.98","upperLimit":"12.51"}]}]}],"analyses":[{"groupIds":["OG000","OG002"],"nonInferiorityType":"OTHER","statisticalMethod":"Linear Mixed Effects Model","statisticalComment":"Fixed effects for treatment, day and treatment by day interaction, a random effect for participant and baseline FPG as a covariate","paramType":"Difference of Least Squares Means","paramValue":"-27.48","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-52.87","ciUpperLimit":"-2.09"},{"groupIds":["OG001","OG002"],"nonInferiorityType":"OTHER","statisticalMethod":"Linear Mixed Effects Model","statisticalComment":"Fixed effects for treatment, day and treatment by day interaction, a random effect for participant and baseline FPG as a covariate","paramType":"Difference of Least Squares Means","paramValue":"-30.59","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-55.72","ciUpperLimit":"-5.46"},{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","statisticalMethod":"Linear Mixed Effects Model","statisticalComment":"Fixed effects for treatment, day and treatment by day interaction, a random effect for participant and baseline FPG as a covariate","paramType":"Difference of Least Squares Means","paramValue":"3.11","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-8.11","ciUpperLimit":"14.34"}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Plasma Glucose (FPG) at Day 24 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 2","description":"FPG was measured predose on Days 1 and 24. The change from baseline of FPG was calculated as the difference between the predose measurement on Day 1 (baseline) and the measurement obtained predose on Day 24. FPG is presented as least squares mean change from baseline with a 95% confidence interval.","populationDescription":"The analysis population included a subset of participants who complied with the protocol sufficiently to ensure that their data exhibited the effects of treatment according to the underlying scientific model and had data available for the analysis of the endpoint.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"mg/dL","timeFrame":"Predose on Days 1 (baseline) and 24","groups":[{"id":"OG000","title":"Part 2: MK-8521 64/120/180/240/300 µg/Day-T2DM","description":"Type 2 diabetes mellitus (T2DM) participants received once daily subcutaneous MK-8521 titrated to 300 µg starting at 64 µg and increasing to 120 µg on Day 8, 180 µg on Day 15, 240 µg on Day 20, and 300 µg on Day 25. The total number of dosing days was 29."},{"id":"OG001","title":"Part 2: Liraglutide 0.6/1.2/1.8 mg/Day-T2DM","description":"T2DM participants received once daily subcutaneous liraglutide titrated to 1.8 mg starting at 0.6 mg and increasing to 1.2 mg on Day 8, and 1.8 mg on Day 15. The total number of dosing days was 29."},{"id":"OG002","title":"Part 2: Placebo for MK-8521-T2DM","description":"T2DM participants received once daily subcutaneous placebo for MK-8521 for 29 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"5"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-40.14","lowerLimit":"-51.00","upperLimit":"-29.27"},{"groupId":"OG001","value":"-50.14","lowerLimit":"-59.30","upperLimit":"-40.99"},{"groupId":"OG002","value":"-44.73","lowerLimit":"-73.97","upperLimit":"-15.49"}]}]}],"analyses":[{"groupIds":["OG000","OG002"],"nonInferiorityType":"OTHER","statisticalMethod":"Linear Mixed Effects Model","statisticalComment":"Fixed effects for treatment, day and treatment by day interaction, a random effect for participant and baseline FPG as a covariate","paramType":"Difference of Least Squares Means","paramValue":"4.59","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-20.88","ciUpperLimit":"30.06"},{"groupIds":["OG001","OG002"],"nonInferiorityType":"OTHER","statisticalMethod":"Linear Mixed Effects Model","statisticalComment":"Fixed effects for treatment, day and treatment by day interaction, a random effect for participant and baseline FPG as a covariate","paramType":"Difference of Least Squares Means","paramValue":"-5.42","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-30.68","ciUpperLimit":"19.85"},{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","statisticalMethod":"Linear Mixed Effects Model","statisticalComment":"Fixed effects for treatment, day and treatment by day interaction, a random effect for participant and baseline FPG as a covariate","paramType":"Difference of Least Squares Means","paramValue":"10.01","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.77","ciUpperLimit":"21.78"}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Plasma Glucose (FPG) at Day 29 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 2","description":"FPG was measured predose on Days 1 and 29. The change from baseline of FPG was calculated as the difference between the predose measurement on Day 1 (baseline) and the measurement obtained predose on Day 29. FPG is presented as least squares mean change from baseline with a 95% confidence interval.","populationDescription":"The analysis population included a subset of participants who complied with the protocol sufficiently to ensure that their data exhibited the effects of treatment according to the underlying scientific model and had data available for the analysis of the endpoint.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"mg/dL","timeFrame":"Predose on Days 1 (baseline) and 29","groups":[{"id":"OG000","title":"Part 2: MK-8521 64/120/180/240/300 µg/Day-T2DM","description":"Type 2 diabetes mellitus (T2DM) participants received once daily subcutaneous MK-8521 titrated to 300 µg starting at 64 µg and increasing to 120 µg on Day 8, 180 µg on Day 15, 240 µg on Day 20, and 300 µg on Day 25. The total number of dosing days was 29."},{"id":"OG001","title":"Part 2: Liraglutide 0.6/1.2/1.8 mg/Day-T2DM","description":"T2DM participants received once daily subcutaneous liraglutide titrated to 1.8 mg starting at 0.6 mg and increasing to 1.2 mg on Day 8, and 1.8 mg on Day 15. The total number of dosing days was 29."},{"id":"OG002","title":"Part 2: Placebo for MK-8521-T2DM","description":"T2DM participants received once daily subcutaneous placebo for MK-8521 for 29 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"5"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-52.54","lowerLimit":"-63.74","upperLimit":"-41.33"},{"groupId":"OG001","value":"-52.06","lowerLimit":"-61.21","upperLimit":"-42.91"},{"groupId":"OG002","value":"-37.55","lowerLimit":"-66.80","upperLimit":"-8.31"}]}]}],"analyses":[{"groupIds":["OG000","OG002"],"nonInferiorityType":"OTHER","statisticalMethod":"Linear Mixed Effects Model","statisticalComment":"Fixed effects for treatment, day and treatment by day interaction, a random effect for participant and baseline FPG as a covariate","paramType":"Difference of Least Squares Means","paramValue":"-14.98","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-40.53","ciUpperLimit":"10.57"},{"groupIds":["OG001","OG002"],"nonInferiorityType":"OTHER","statisticalMethod":"Linear Mixed Effects Model","statisticalComment":"Fixed effects for treatment, day and treatment by day interaction, a random effect for participant and baseline FPG as a covariate","paramType":"Difference of Least Squares Means","paramValue":"-14.50","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-39.77","ciUpperLimit":"10.76"},{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","statisticalMethod":"Linear Mixed Effects Model","statisticalComment":"Fixed effects for treatment, day and treatment by day interaction, a random effect for participant and baseline FPG as a covariate","paramType":"Difference of Least Squares Means","paramValue":"-0.48","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-12.47","ciUpperLimit":"11.52"}]},{"type":"SECONDARY","title":"Change From Baseline in 24-hour Weighted Mean Glucose (WMG) at Day 14 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 2","description":"The 24-hour WMG was calculated as the area under the 24-hour glucose curve (AUC0-24hr) divided by 24 hours. Plasma glucose concentrations were obtained on Day -1 at pre meal (breakfast), 1, 3, 4 (pre lunch), 5, 7, 10 (pre dinner), 11, 13, 15 and 23 hours post breakfast meal and Day 14 at 1 (pre breakfast), 2, 4, 5 (pre lunch), 6, 8, 11 (pre dinner), 12, 14, 16, 24 hours post dose. The timing of samples on Day -1 are relative to the breakfast meal. Day 14 samples are relative to dosing. The change from baseline value for 24-hour WMG was calculated where baseline was the WMG before food and prior to treatment on Day 1. Individual change from baseline 24-hour WMG was analyzed in a linear mixed effects model with group, day and group by day interaction as fixed effects, baseline 24-hour WMG as a covariate, and participant as a random effect. WMG is presented as least squares mean with a 95% confidence interval.","populationDescription":"The analysis population included a subset of participants who complied with the protocol sufficiently to ensure that their data exhibited the effects of treatment according to the underlying scientific model and had data available for the analysis of the endpoint.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"mg/dL","timeFrame":"Baseline (predose and before food on Day 1) and up to 24 hours post Day 14 dose","groups":[{"id":"OG000","title":"Part 2: MK-8521 64/120/180/240/300 µg/Day-T2DM","description":"Type 2 diabetes mellitus (T2DM) participants received once daily subcutaneous MK-8521 titrated to 300 µg starting at 64 µg and increasing to 120 µg on Day 8, 180 µg on Day 15, 240 µg on Day 20, and 300 µg on Day 25. The total number of dosing days was 29."},{"id":"OG001","title":"Part 2: Liraglutide 0.6/1.2/1.8 mg/Day-T2DM","description":"T2DM participants received once daily subcutaneous liraglutide titrated to 1.8 mg starting at 0.6 mg and increasing to 1.2 mg on Day 8, and 1.8 mg on Day 15. The total number of dosing days was 29."},{"id":"OG002","title":"Part 2: Placebo for MK-8521-T2DM","description":"T2DM participants received once daily subcutaneous placebo for MK-8521 for 29 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"5"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-47.52","lowerLimit":"-56.82","upperLimit":"-38.22"},{"groupId":"OG001","value":"-51.24","lowerLimit":"-58.02","upperLimit":"-44.45"},{"groupId":"OG002","value":"-3.84","lowerLimit":"-30.31","upperLimit":"22.63"}]}]}],"analyses":[{"groupIds":["OG000","OG002"],"nonInferiorityType":"OTHER","statisticalMethod":"Linear Mixed Effects Model","statisticalComment":"Fixed effects for treatment, day and treatment by day interaction, a random effect for participant and baseline 24-hour WMG as a covariate","paramType":"Difference of Least Squares Means","paramValue":"-43.68","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-65.81","ciUpperLimit":"-21.55"},{"groupIds":["OG001","OG002"],"nonInferiorityType":"OTHER","statisticalMethod":"Linear Mixed Effects Model","statisticalComment":"Fixed effects for treatment, day and treatment by day interaction, a random effect for participant and baseline 24-hour WMG as a covariate","paramType":"Difference of Least Squares Means","paramValue":"-47.40","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-69.35","ciUpperLimit":"-25.45"},{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","statisticalMethod":"Linear Mixed Effects Model","statisticalComment":"Fixed effects for treatment, day and treatment by day interaction, a random effect for participant and baseline 24-hour WMG as a covariate","paramType":"Difference of Least Squares Means","paramValue":"3.72","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-5.76","ciUpperLimit":"13.19"}]},{"type":"SECONDARY","title":"Change From Baseline in 24-hour Weighted Mean Glucose (WMG) at Day 19 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 2","description":"The 24-hour WMG was calculated as the area under the 24-hour glucose curve (AUC0-24hr) divided by 24 hours. Plasma glucose concentrations were obtained on Day -1 at pre meal (breakfast), 1, 3, 4 (pre lunch), 5, 7, 10 (pre dinner), 11, 13, 15 and 23 hours post breakfast meal and Day 19 at 1 (pre breakfast), 2, 4, 5 (pre lunch), 6, 8, 11 (pre dinner), 12, 14, 16, 24 hours post dose. The timing of samples on Day -1 are relative to the breakfast meal. Day 19 samples are relative to dosing. The change from baseline value for 24-hour WMG was calculated where baseline was the WMG before food and prior to treatment on Day 1. Individual change from baseline 24-hour WMG was analyzed in a linear mixed effects model with group, day and group by day interaction as fixed effects, baseline 24-hour WMG as a covariate, and participant as a random effect. WMG is presented as least squares mean with a 95% confidence interval.","populationDescription":"The analysis population included a subset of participants who complied with the protocol sufficiently to ensure that their data exhibited the effects of treatment according to the underlying scientific model and had data available for the analysis of the endpoint.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"mg/dL","timeFrame":"Baseline (predose and before food on Day 1) and up to 24 hours post Day 19 dose","groups":[{"id":"OG000","title":"Part 2: MK-8521 64/120/180/240/300 µg/Day-T2DM","description":"Type 2 diabetes mellitus (T2DM) participants received once daily subcutaneous MK-8521 titrated to 300 µg starting at 64 µg and increasing to 120 µg on Day 8, 180 µg on Day 15, 240 µg on Day 20, and 300 µg on Day 25. The total number of dosing days was 29."},{"id":"OG001","title":"Part 2: Liraglutide 0.6/1.2/1.8 mg/Day-T2DM","description":"T2DM participants received once daily subcutaneous liraglutide titrated to 1.8 mg starting at 0.6 mg and increasing to 1.2 mg on Day 8, and 1.8 mg on Day 15. The total number of dosing days was 29."},{"id":"OG002","title":"Part 2: Placebo for MK-8521-T2DM","description":"T2DM participants received once daily subcutaneous placebo for MK-8521 for 29 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"5"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-52.23","lowerLimit":"-61.54","upperLimit":"-42.93"},{"groupId":"OG001","value":"-57.43","lowerLimit":"-64.21","upperLimit":"-50.64"},{"groupId":"OG002","value":"-18.22","lowerLimit":"-44.69","upperLimit":"8.25"}]}]}],"analyses":[{"groupIds":["OG000","OG002"],"nonInferiorityType":"OTHER","statisticalMethod":"Linear Mixed Effects Model","statisticalComment":"Fixed effects for treatment, day and treatment by day interaction, a random effect for participant and baseline 24-hour WMG as a covariate","paramType":"Difference of Least Squares Means","paramValue":"-34.01","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-56.14","ciUpperLimit":"-11.88"},{"groupIds":["OG001","OG002"],"nonInferiorityType":"OTHER","statisticalMethod":"Linear Mixed Effects Model","statisticalComment":"Fixed effects for treatment, day and treatment by day interaction, a random effect for participant and baseline 24-hour WMG as a covariate","paramType":"Difference of Least Squares Means","paramValue":"-39.20","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-61.15","ciUpperLimit":"-17.26"},{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","statisticalMethod":"Linear Mixed Effects Model","statisticalComment":"Fixed effects for treatment, day and treatment by day interaction, a random effect for participant and baseline 24-hour WMG as a covariate","paramType":"Difference of Least Squares Means","paramValue":"5.20","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-4.28","ciUpperLimit":"14.67"}]},{"type":"SECONDARY","title":"Change From Baseline in 24-hour Weighted Mean Glucose (WMG) at Day 24 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 2","description":"The 24-hour WMG was calculated as the area under the 24-hour glucose curve (AUC0-24hr) divided by 24 hours. Plasma glucose concentrations were obtained on Day -1 at pre meal (breakfast), 1, 3, 4 (pre lunch), 5, 7, 10 (pre dinner), 11, 13, 15 and 23 hours post breakfast meal and Day 24 at 1 (pre breakfast), 2, 4, 5 (pre lunch), 6, 8, 11 (pre dinner), 12, 14, 16, 24 hours post dose. The timing of samples on Day -1 are relative to the breakfast meal. Day 24 samples are relative to dosing. The change from baseline value for 24-hour WMG was calculated where baseline was the WMG before food and prior to treatment on Day 1. Individual change from baseline 24-hour WMG was analyzed in a linear mixed effects model with group, day and group by day interaction as fixed effects, baseline 24-hour WMG as a covariate, and participant as a random effect. WMG is presented as least squares mean with a 95% confidence interval.","populationDescription":"The analysis population included a subset of participants who complied with the protocol sufficiently to ensure that their data exhibited the effects of treatment according to the underlying scientific model and had data available for the analysis of the endpoint.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"mg/dL","timeFrame":"Baseline (predose and before food on Day 1) and up to 24 hours post Day 24 dose","groups":[{"id":"OG000","title":"Part 2: MK-8521 64/120/180/240/300 µg/Day-T2DM","description":"Type 2 diabetes mellitus (T2DM) participants received once daily subcutaneous MK-8521 titrated to 300 µg starting at 64 µg and increasing to 120 µg on Day 8, 180 µg on Day 15, 240 µg on Day 20, and 300 µg on Day 25. The total number of dosing days was 29."},{"id":"OG001","title":"Part 2: Liraglutide 0.6/1.2/1.8 mg/Day-T2DM","description":"T2DM participants received once daily subcutaneous liraglutide titrated to 1.8 mg starting at 0.6 mg and increasing to 1.2 mg on Day 8, and 1.8 mg on Day 15. The total number of dosing days was 29."},{"id":"OG002","title":"Part 2: Placebo for MK-8521-T2DM","description":"T2DM participants received once daily subcutaneous placebo for MK-8521 for 29 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"5"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-50.44","lowerLimit":"-59.89","upperLimit":"-40.99"},{"groupId":"OG001","value":"-60.66","lowerLimit":"-67.60","upperLimit":"-53.72"},{"groupId":"OG002","value":"-26.71","lowerLimit":"-53.18","upperLimit":"-0.24"}]}]}],"analyses":[{"groupIds":["OG000","OG002"],"nonInferiorityType":"OTHER","statisticalMethod":"Linear Mixed Effects Model","statisticalComment":"Fixed effects for treatment, day and treatment by day interaction, a random effect for participant and baseline 24-hour WMG as a covariate","paramType":"Difference of Least Squares Means","paramValue":"-23.73","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-45.89","ciUpperLimit":"-1.56"},{"groupIds":["OG001","OG002"],"nonInferiorityType":"OTHER","statisticalMethod":"Linear Mixed Effects Model","statisticalComment":"Fixed effects for treatment, day and treatment by day interaction, a random effect for participant and baseline 24-hour WMG as a covariate","paramType":"Difference of Least Squares Means","paramValue":"-33.95","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-55.93","ciUpperLimit":"-11.98"},{"groupIds":["OG001","OG002"],"nonInferiorityType":"OTHER","statisticalMethod":"Linear Mixed Effects Model","statisticalComment":"Fixed effects for treatment, day and treatment by day interaction, a random effect for participant and baseline 24-hour WMG as a covariate","paramType":"Difference of Least Squares Means","paramValue":"10.23","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.56","ciUpperLimit":"19.89"}]},{"type":"SECONDARY","title":"Change From Baseline in 24-hour Weighted Mean Glucose (WMG) at Day 29 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 2","description":"The 24-hour WMG was calculated as the area under the 24-hour glucose curve (AUC0-24hr) divided by 24 hours. Plasma glucose concentrations were obtained on Day -1 at pre meal (breakfast), 1, 3, 4 (pre lunch), 5, 7, 10 (pre dinner), 11, 13, 15 and 23 hours post breakfast meal and Day 29 at 1 (pre breakfast), 2, 4, 5 (pre lunch), 6, 8, 11 (pre dinner), 12, 14, 16, 24 hours post dose. The timing of samples on Day -1 are relative to the breakfast meal. Day 29 samples are relative to dosing. The change from baseline value for 24-hour WMG was calculated where baseline was the WMG before food and prior to treatment on Day 1. Individual change from baseline 24-hour WMG was analyzed in a linear mixed effects model with group, day and group by day interaction as fixed effects, baseline 24-hour WMG as a covariate, and participant as a random effect. WMG is presented as least squares mean with a 95% confidence interval.","populationDescription":"The analysis population included a subset of participants who complied with the protocol sufficiently to ensure that their data exhibited the effects of treatment according to the underlying scientific model and had data available for the analysis of the endpoint.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"mg/dL","timeFrame":"Baseline (predose and before food on Day 1) and up to 24 hours post Day 29 dose","groups":[{"id":"OG000","title":"Part 2: MK-8521 64/120/180/240/300 µg/Day-T2DM","description":"Type 2 diabetes mellitus (T2DM) participants received once daily subcutaneous MK-8521 titrated to 300 µg starting at 64 µg and increasing to 120 µg on Day 8, 180 µg on Day 15, 240 µg on Day 20, and 300 µg on Day 25. The total number of dosing days was 29."},{"id":"OG001","title":"Part 2: Liraglutide 0.6/1.2/1.8 mg/Day-T2DM","description":"T2DM participants received once daily subcutaneous liraglutide titrated to 1.8 mg starting at 0.6 mg and increasing to 1.2 mg on Day 8, and 1.8 mg on Day 15. The total number of dosing days was 29."},{"id":"OG002","title":"Part 2: Placebo for MK-8521-T2DM","description":"T2DM participants received once daily subcutaneous placebo for MK-8521 for 29 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"5"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-53.44","lowerLimit":"-62.89","upperLimit":"-43.99"},{"groupId":"OG001","value":"-59.72","lowerLimit":"-66.66","upperLimit":"-52.78"},{"groupId":"OG002","value":"-29.96","lowerLimit":"-56.43","upperLimit":"-3.49"}]}]}],"analyses":[{"groupIds":["OG000","OG002"],"nonInferiorityType":"OTHER","statisticalMethod":"Linear Mixed Effects Model","statisticalComment":"Fixed effects for treatment, day and treatment by day interaction, a random effect for participant and baseline 24-hour WMG as a covariate","paramType":"Difference of Least Squares Means","paramValue":"-23.49","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-45.65","ciUpperLimit":"-1.32"},{"groupIds":["OG001","OG002"],"nonInferiorityType":"OTHER","statisticalMethod":"Linear Mixed Effects Model","statisticalComment":"Fixed effects for treatment, day and treatment by day interaction, a random effect for participant and baseline 24-hour WMG as a covariate","paramType":"Difference of Least Squares Means","paramValue":"-29.76","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-51.74","ciUpperLimit":"-7.79"},{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","statisticalMethod":"Linear Mixed Effects Model","statisticalComment":"Fixed effects for treatment, day and treatment by day interaction, a random effect for participant and baseline 24-hour WMG as a covariate","paramType":"Difference of Least Squares Means","paramValue":"6.27","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-3.39","ciUpperLimit":"15.93"}]},{"type":"SECONDARY","title":"Maximum Concentration (Cmax) of MK-8521 for Type 2 Diabetes Mellitus (T2DM) and Non-Diabetic Overweight/Obese Participants in Part 2","description":"Cmax was the maximum observed concentration of MK-8521 in plasma after administration. Plasma samples were collected from predose to 120 hours postdose for determination of Cmax. Per protocol, Cmax in the non-diabetic overweight/obese participants was not measured on Days 19, 24, and 29 because they only received 14 days of treatment. Individual values were natural log-transformed and evaluated with a linear-mixed effects model containing fixed effects for treatment, day, and treatment by day interaction, and a random effect for participant. Kenward and Roger's method was used to calculate the degree of freedom for the fixed effects. Cmax is presented as geometric mean and percent coefficient of variation of geometric mean.","populationDescription":"The analysis population included a subset of participants who complied with the protocol sufficiently to ensure that their data exhibited the effects of treatment according to the underlying scientific model and had data available for the analysis of the endpoint.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"nM","timeFrame":"Predose and 1, 2, 6, 10, 16, 24 hours post dose on Days 1, 7, 14, 19, 24 (T2DM) and Days 1 and 7 (Non-Diabetic Overweight/Obese); predose and 1, 2, 6, 10, 16, 24, 72, 96. and 120 hours post dose on Day 14 (Non-Diabetic Overweight/Obese) and Day 29 (T2DM).","groups":[{"id":"OG000","title":"Part 2: MK-8521 64/120/180/240/300 μg/Day-T2DM","description":"Type 2 diabetes mellitus (T2DM) participants received once daily subcutaneous MK-8521 titrated to 300 μg starting at 64 μg and increasing to 120 μg on Day 8, 180 μg on Day 15, 240 μg on Day 20, and 300 μg on Day 25. The total number of dosing days was 29."},{"id":"OG001","title":"Part 2: MK-8521 64/120 μg/Day-Non-Diabetic Overweight/Obese","description":"Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 titrated to 120 μg starting at 64 μg and increasing to 120 μg on Day 8. The total number of dosing days was 14."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"8"}]}],"classes":[{"title":"Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.35","spread":"48.0"},{"groupId":"OG001","value":"0.411","spread":"32.1"}]}]},{"title":"Day 7","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.719","spread":"34.6"},{"groupId":"OG001","value":"0.742","spread":"38.7"}]}]},{"title":"Day 14","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.43","spread":"35.8"},{"groupId":"OG001","value":"1.72","spread":"20.0"}]}]},{"title":"Day 19","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.27","spread":"38.6"}]}]},{"title":"Day 24","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.85","spread":"33.1"}]}]},{"title":"Day 29","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.14","spread":"34.1"}]}]}]},{"type":"SECONDARY","title":"Trough Concentration (Ctrough) of MK-8521 for Type 2 Diabetes Mellitus (T2DM) and Non-Diabetic Overweight/Obese Participants in Part 2","description":"Ctrough was the lowest observed concentration of MK-8521 in plasma. Plasma samples were collected predose on Day 2 (sampled after the Day 1 dose and prior to Day 2 dose), 7, 14, 19, 24, and 29 for determination of Ctrough. Per protocol, Ctrough in the non-diabetic overweight/obese participants was not measured on Days 19, 24, and 29 because they only received 14 days of treatment. Individual values were natural log-transformed and evaluated with a linear-mixed effects model containing fixed effects for treatment, day, and treatment by day interaction, and a random effect for participant. Kenward and Roger's method was used to calculate the degree of freedom for the fixed effects. Ctrough is presented as geometric mean and percent coefficient of variation of geometric mean.","populationDescription":"The analysis population included a subset of participants who complied with the protocol sufficiently to ensure that their data exhibited the effects of treatment according to the underlying scientific model and had data available for the analysis of the endpoint.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"nM","timeFrame":"Predose on Days 2 (sampled 24 hours after Day 1 dose) and 7, 14, 19, 24, and 29","groups":[{"id":"OG000","title":"Part 2: MK-8521 64/120/180/240/300 μg/Day-T2DM","description":"Type 2 diabetes mellitus (T2DM) participants received once daily subcutaneous MK-8521 titrated to 300 μg starting at 64 μg and increasing to 120 μg on Day 8, 180 μg on Day 15, 240 μg on Day 20, and 300 μg on Day 25. The total number of dosing days was 29."},{"id":"OG001","title":"Part 2: MK-8521 64/120 μg/Day-Non-Diabetic Overweight/Obese","description":"Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 titrated to 120 μg starting at 64 μg and increasing to 120 μg on Day 8. The total number of dosing days was 14."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"8"}]}],"classes":[{"title":"Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.331","spread":"45.5"},{"groupId":"OG001","value":"0.388","spread":"32.8"}]}]},{"title":"Day 7","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.533","spread":"32.7"},{"groupId":"OG001","value":"0.492","spread":"29.1"}]}]},{"title":"Day 14","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.07","spread":"36.0"},{"groupId":"OG001","value":"1.12","spread":"21.8"}]}]},{"title":"Day 19","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.61","spread":"33.8"}]}]},{"title":"Day 24","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.02","spread":"30.6"}]}]},{"title":"Day 29","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.47","spread":"29.9"}]}]}]},{"type":"SECONDARY","title":"Time to Maximum Concentration (Tmax) of MK-8521 for Type 2 Diabetes Mellitus (T2DM) and Non-Diabetic Overweight/Obese Participants in Part 2","description":"Tmax was the time required to reach the maximum concentration of MK-8521 in plasma. Plasma samples were collected from predose to 120 hours postdose for determination of Tmax. Per protocol, Tmax in the non-diabetic overweight/obese participants was not measured on Days 19, 24, and 29 because they only received 14 days of treatment. Tmax is presented as median with a full range.","populationDescription":"The analysis population included a subset of participants who complied with the protocol sufficiently to ensure that their data exhibited the effects of treatment according to the underlying scientific model and had data available for the analysis of the endpoint.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"Hours","timeFrame":"Predose and 1, 2, 6, 10, 16, 24 hours post dose on Days 1, 7, 14, 19, 24 (T2DM) and Days 1 and 7 (Non-Diabetic Overweight/Obese); predose and 1, 2, 6, 10, 16, 24, 72, 96. and 120 hours post dose on Day 14 (Non-Diabetic Overweight/Obese) and Day 29 (T2DM).","groups":[{"id":"OG000","title":"Part 2: MK-8521 64/120/180/240/300 μg/Day-T2DM","description":"Type 2 diabetes mellitus (T2DM) participants received once daily subcutaneous MK-8521 titrated to 300 μg starting at 64 μg and increasing to 120 μg on Day 8, 180 μg on Day 15, 240 μg on Day 20, and 300 μg on Day 25. The total number of dosing days was 29."},{"id":"OG001","title":"Part 2: MK-8521 64/120 μg/Day-Non-Diabetic Overweight/Obese","description":"Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 titrated to 120 μg starting at 64 μg and increasing to 120 μg on Day 8. The total number of dosing days was 14."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"8"}]}],"classes":[{"title":"Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"16","lowerLimit":"10","upperLimit":"24"},{"groupId":"OG001","value":"16","lowerLimit":"10","upperLimit":"24"}]}]},{"title":"Day 7","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10","lowerLimit":"1","upperLimit":"16"},{"groupId":"OG001","value":"10","lowerLimit":"10","upperLimit":"10"}]}]},{"title":"Day 14","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6","lowerLimit":"1","upperLimit":"10"},{"groupId":"OG001","value":"6","lowerLimit":"6","upperLimit":"10"}]}]},{"title":"Day 19","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6","lowerLimit":"6","upperLimit":"10"}]}]},{"title":"Day 24","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6","lowerLimit":"6","upperLimit":"16"}]}]},{"title":"Day 29","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10","lowerLimit":"1","upperLimit":"24"}]}]}]},{"type":"SECONDARY","title":"Apparent Terminal Half Life (t1/2) of MK-8521 on Day 29 for Type 2 Diabetes Mellitus (T2DM) Participants in Part 2","description":"t1/2 was the time required to divide the MK-8521 concentration by half after reaching pseudo-equilibrium. Plasma samples were collected from predose to 120 hours postdose for determination of t1/2. Per protocol, t1/2 was measured on Day 29 which is the longest time point for sampling for T2DM participants 1/2 is presented as geometric mean and percent coefficient of variation of geometric mean.","populationDescription":"The analysis population included a subset of participants who complied with the protocol sufficiently to ensure that their data exhibited the effects of treatment according to the underlying scientific model and had data available for the analysis of the endpoint.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"Hours","timeFrame":"Predose and 1, 2, 6, 10, 16, 24, 72, 96 and 120 hours post dose on Day 29","groups":[{"id":"OG000","title":"Part 2: MK-8521 64/120/180/240/300 μg/Day-T2DM","description":"Type 2 diabetes mellitus (T2DM) participants received once daily subcutaneous MK-8521 titrated to 300 μg starting at 64 μg and increasing to 120 μg on Day 8, 180 μg on Day 15, 240 μg on Day 20, and 300 μg on Day 25. The total number of dosing days was 29."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.4","spread":"10.2"}]}]}]},{"type":"SECONDARY","title":"Apparent Terminal Half Life (t1/2) of MK-8521 on Day 14 for Non-Diabetic Overweight/Obese Participants in Part 2","description":"t1/2 was the time required to divide the MK-8521 concentration by half after reaching pseudo-equilibrium. Plasma samples were collected from predose to 24 hours postdose for determination of t1/2. Per protocol, t1/2 was measured on Day 14 which is the longest time point for sampling for non-diabetic overweight/obese participants 1/2 is presented as geometric mean and percent coefficient of variation of geometric mean.","populationDescription":"The analysis population included a subset of participants who complied with the protocol sufficiently to ensure that their data exhibited the effects of treatment according to the underlying scientific model and had data available for the analysis of the endpoint.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"Hours","timeFrame":"Predose and 1, 2, 6, 10, 16, and 24 hours post dose on Day 14","groups":[{"id":"OG000","title":"Part 2: MK-8521 64/120 μg/Day-Non-Diabetic Overweight/Obese","description":"Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 titrated to 120 μg starting at 64 μg and increasing to 120 μg on Day 8. The total number of dosing days was 14."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.4","spread":"10.8"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"0","timeFrame":"Up to approximately 42 days for Part 1 and up to approximately 57 days for Part 2","description":"All participants that received ≥1 dose of study drug for adverse events (AEs) and all randomized participants for all-cause mortality. AEs and all-cause mortality are presented by individual dose received by participants during titration in an assigned study treatment sequence.","eventGroups":[{"id":"EG000","title":"Part 1: MK-8521 64 μg/Day","description":"Type 2 Diabetes Mellitus (T2DM) participants received once daily subcutaneous MK-8521 64 μg/day on Days 1 to 7 as part of the MK-8521 64/120 μg/day treatment group schedule.","deathsNumAffected":0,"deathsNumAtRisk":10,"seriousNumAffected":1,"seriousNumAtRisk":9,"otherNumAffected":5,"otherNumAtRisk":9},{"id":"EG001","title":"Part 1: MK-8521 120 μg/Day","description":"T2DM participants received once daily subcutaneous MK-8521 120 μg/day on Days 8 to 14 as part of the MK-8521 64/120 μg/day treatment group schedule.","deathsNumAffected":0,"deathsNumAtRisk":7,"seriousNumAffected":0,"seriousNumAtRisk":7,"otherNumAffected":5,"otherNumAtRisk":7},{"id":"EG002","title":"Part 1: MK-8521 34 μg/Day","description":"T2DM participants received once daily subcutaneous MK-8521 34 μg/day on Days 1 to 7 as part of the MK-8521 34/72 μg/day treatment group schedule.","deathsNumAffected":0,"deathsNumAtRisk":8,"seriousNumAffected":0,"seriousNumAtRisk":8,"otherNumAffected":1,"otherNumAtRisk":8},{"id":"EG003","title":"Part 1: MK-8521 72 μg/Day","description":"T2DM participants received once daily subcutaneous MK-8521 72 μg/day on Days 8 to 14 as part of the MK-8521 34/72 μg/day treatment group schedule.","deathsNumAffected":0,"deathsNumAtRisk":8,"seriousNumAffected":0,"seriousNumAtRisk":8,"otherNumAffected":4,"otherNumAtRisk":8},{"id":"EG004","title":"Part 1: Liraglutide 0.6 mg/Day","description":"T2DM participants received once daily subcutaneous liraglutide 0.6 mg on Day 1 and 2 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.","deathsNumAffected":0,"deathsNumAtRisk":11,"seriousNumAffected":0,"seriousNumAtRisk":11,"otherNumAffected":2,"otherNumAtRisk":11},{"id":"EG005","title":"Part 1: Liraglutide 1.2 mg/Day","description":"T2DM participants received once daily subcutaneous liraglutide 1.2 mg on Days 3 to 7 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.","deathsNumAffected":0,"deathsNumAtRisk":11,"seriousNumAffected":0,"seriousNumAtRisk":11,"otherNumAffected":7,"otherNumAtRisk":11},{"id":"EG006","title":"Part 1: Liraglutide 1.8 mg/Day","description":"T2DM participants received once daily subcutaneous liraglutide 1.8 mg on Days 8 to 14 as part of the liraglutide 0.6/1.2/1.8 mg/day treatment group schedule.","deathsNumAffected":0,"deathsNumAtRisk":8,"seriousNumAffected":0,"seriousNumAtRisk":8,"otherNumAffected":2,"otherNumAtRisk":8},{"id":"EG007","title":"Part 1: Placebo for MK-8521","description":"T2DM participants received once daily subcutaneous placebo for MK-8521 for 14 days.","deathsNumAffected":0,"deathsNumAtRisk":8,"seriousNumAffected":0,"seriousNumAtRisk":8,"otherNumAffected":5,"otherNumAtRisk":8},{"id":"EG008","title":"Part 2: MK-8521 64 μg/Day T2DM","description":"Type 2 Diabetes Mellitus (T2DM) participants received once daily subcutaneous MK-8521 64 µg on Days 1 to 7 as part of the MK-8521 64/120/180/240/300 µg treatment sequence.","deathsNumAffected":0,"deathsNumAtRisk":18,"seriousNumAffected":0,"seriousNumAtRisk":18,"otherNumAffected":8,"otherNumAtRisk":18},{"id":"EG009","title":"Part 2: MK-8521 120 μg/Day T2DM","description":"T2DM participants received once daily subcutaneous MK-8521 120 µg on Days 8 to 14 as part of the MK-8521 64/120/180/240/300 µg treatment sequence.","deathsNumAffected":0,"deathsNumAtRisk":18,"seriousNumAffected":0,"seriousNumAtRisk":18,"otherNumAffected":14,"otherNumAtRisk":18},{"id":"EG010","title":"Part 2: MK-8521 180 μg/Day T2DM","description":"T2DM participants received once daily subcutaneous MK-8521 180 µg on Days 15 to 19 as part of the MK-8521 64/120/180/240/300 µg treatment sequence.","deathsNumAffected":0,"deathsNumAtRisk":18,"seriousNumAffected":0,"seriousNumAtRisk":18,"otherNumAffected":6,"otherNumAtRisk":18},{"id":"EG011","title":"Part 2: MK-8521 240 μg/Day T2DM","description":"T2DM participants received once daily subcutaneous MK-8521 240 µg on Days 20 to 24 as part of the MK-8521 64/120/180/240/300 µg treatment sequence.","deathsNumAffected":0,"deathsNumAtRisk":18,"seriousNumAffected":1,"seriousNumAtRisk":18,"otherNumAffected":13,"otherNumAtRisk":18},{"id":"EG012","title":"Part 2: MK-8521 300 μg/Day T2DM","description":"T2DM participants received once daily subcutaneous MK-8521 300 µg on Days 25 to 29 as part of the MK-8521 64/120/180/240/300 µg treatment sequence.","deathsNumAffected":0,"deathsNumAtRisk":15,"seriousNumAffected":0,"seriousNumAtRisk":15,"otherNumAffected":8,"otherNumAtRisk":15},{"id":"EG013","title":"Part 2: Liraglutide 0.6 mg/Day T2DM","description":"T2DM participants received once daily subcutaneous liraglutide 0.6 mg on Days 1 to 7 as part of the liraglutide 0.6/1.2/1.8 mg treatment sequence.","deathsNumAffected":0,"deathsNumAtRisk":14,"seriousNumAffected":0,"seriousNumAtRisk":14,"otherNumAffected":8,"otherNumAtRisk":14},{"id":"EG014","title":"Part 2: Liraglutide 1.2 mg/Day T2DM","description":"T2DM participants received once daily subcutaneous liraglutide 1.2 mg on Days 8 to 14 as part of the liraglutide 0.6/1.2/1.8 mg treatment sequence.","deathsNumAffected":0,"deathsNumAtRisk":13,"seriousNumAffected":0,"seriousNumAtRisk":13,"otherNumAffected":8,"otherNumAtRisk":13},{"id":"EG015","title":"Part 2: Liraglutide 1.8 mg/Day T2DM","description":"T2DM participants received once daily subcutaneous liraglutide 1.8 mg on Days 15 to 29 as part of the liraglutide 0.6/1.2/1.8 mg treatment sequence.","deathsNumAffected":0,"deathsNumAtRisk":13,"seriousNumAffected":0,"seriousNumAtRisk":13,"otherNumAffected":12,"otherNumAtRisk":13},{"id":"EG016","title":"Part 2: Placebo for MK-8521-T2DM","description":"T2DM participants received once daily subcutaneous placebo for MK-8521 for 29 days.","deathsNumAffected":0,"deathsNumAtRisk":6,"seriousNumAffected":0,"seriousNumAtRisk":6,"otherNumAffected":3,"otherNumAtRisk":6},{"id":"EG017","title":"Part 2: MK-8521 64 μg/Day-Non-Diabetic Overweight/Obese","description":"Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 64 µg on Days 1 to 7 as part of the MK-8521 64/120 µg treatment sequence.","deathsNumAffected":0,"deathsNumAtRisk":8,"seriousNumAffected":0,"seriousNumAtRisk":8,"otherNumAffected":2,"otherNumAtRisk":8},{"id":"EG018","title":"Part 2: MK-8521 120 μg/Day-Non-Diabetic Overweight/Obese","description":"Non-diabetic overweight/obese participants received once daily subcutaneous MK-8521 120 µg on Days 8 to 14 as part of the MK-8521 64/120 µg treatment sequence.","deathsNumAffected":0,"deathsNumAtRisk":8,"seriousNumAffected":0,"seriousNumAtRisk":8,"otherNumAffected":4,"otherNumAtRisk":8}],"seriousEvents":[{"term":"Sick sinus syndrome","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Supraventricular tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Convulsion","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Presyncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]}],"otherEvents":[{"term":"Palpitations","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG009","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Sinus tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Supraventricular tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":2,"numAffected":1,"numAtRisk":13},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":9},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG012","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Tachycardia paroxysmal","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Ventricular extrasystoles","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG014","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Ventricular tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Ear pain","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":2,"numAffected":2,"numAtRisk":13},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Vision blurred","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG016","numEvents":1,"numAffected":1,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Abdominal discomfort","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Abdominal distension","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG009","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG012","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":2,"numAffected":1,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG008","numEvents":2,"numAffected":2,"numAtRisk":18},{"groupId":"EG009","numEvents":2,"numAffected":2,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG014","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG015","numEvents":2,"numAffected":2,"numAtRisk":13},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG012","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG013","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":4,"numAffected":3,"numAtRisk":13},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":1,"numAffected":1,"numAtRisk":8}]},{"term":"Aphthous stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Change of bowel habit","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG013","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":1,"numAffected":1,"numAtRisk":8}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG009","numEvents":4,"numAffected":4,"numAtRisk":18},{"groupId":"EG010","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG013","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG014","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG015","numEvents":3,"numAffected":2,"numAtRisk":13},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":3,"numAffected":3,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG008","numEvents":6,"numAffected":4,"numAtRisk":18},{"groupId":"EG009","numEvents":6,"numAffected":6,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG012","numEvents":3,"numAffected":3,"numAtRisk":15},{"groupId":"EG013","numEvents":6,"numAffected":5,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":4,"numAffected":4,"numAtRisk":13},{"groupId":"EG016","numEvents":1,"numAffected":1,"numAtRisk":6},{"groupId":"EG017","numEvents":1,"numAffected":1,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Dry mouth","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":3,"numAffected":3,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":8},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":2,"numAffected":2,"numAtRisk":18},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Flatulence","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Gingival pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Haematochezia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Haemorrhoids","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG013","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Mouth ulceration","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":8},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":11},{"groupId":"EG005","numEvents":4,"numAffected":4,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG008","numEvents":4,"numAffected":2,"numAtRisk":18},{"groupId":"EG009","numEvents":4,"numAffected":4,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":6,"numAffected":5,"numAtRisk":18},{"groupId":"EG012","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG013","numEvents":7,"numAffected":5,"numAtRisk":14},{"groupId":"EG014","numEvents":3,"numAffected":2,"numAtRisk":13},{"groupId":"EG015","numEvents":6,"numAffected":5,"numAtRisk":13},{"groupId":"EG016","numEvents":1,"numAffected":1,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":1,"numAffected":1,"numAtRisk":8}]},{"term":"Regurgitation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Retching","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG013","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Toothache","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG016","numEvents":1,"numAffected":1,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":11},{"groupId":"EG005","numEvents":3,"numAffected":1,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG008","numEvents":2,"numAffected":1,"numAtRisk":18},{"groupId":"EG009","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG012","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG013","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":3,"numAffected":2,"numAtRisk":13},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Application site dermatitis","organSystem":"General disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":8},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG009","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG013","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":2,"numAffected":1,"numAtRisk":13},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Application site erythema","organSystem":"General disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG012","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Application site irritation","organSystem":"General disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":8},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG016","numEvents":1,"numAffected":1,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":1,"numAffected":1,"numAtRisk":8}]},{"term":"Application site pruritus","organSystem":"General disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG009","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG009","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Catheter site erythema","organSystem":"General disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Catheter site haemorrhage","organSystem":"General disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG014","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG015","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Catheter site oedema","organSystem":"General disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Early satiety","organSystem":"General disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG012","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Feeling cold","organSystem":"General disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Feeling hot","organSystem":"General disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG009","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Influenza like illness","organSystem":"General disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":8},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG009","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Injection site erythema","organSystem":"General disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG016","numEvents":1,"numAffected":1,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Injection site haemorrhage","organSystem":"General disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG009","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Injection site injury","organSystem":"General disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Injection site macule","organSystem":"General disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Peripheral swelling","organSystem":"General disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG012","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":8},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Vessel puncture site erythema","organSystem":"General disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":8},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Vessel puncture site haemorrhage","organSystem":"General disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":8},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Vessel puncture site pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":8},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Xerosis","organSystem":"General disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG009","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Hordeolum","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Localised infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG012","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Tooth infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG016","numEvents":1,"numAffected":1,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG012","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Viral infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG012","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Viral pharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Post-traumatic pain","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Skin abrasion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":3,"numAffected":2,"numAtRisk":13},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":1,"numAffected":1,"numAtRisk":8}]},{"term":"Lipase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":8},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG009","numEvents":4,"numAffected":4,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG012","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG008","numEvents":2,"numAffected":2,"numAtRisk":18},{"groupId":"EG009","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG013","numEvents":2,"numAffected":2,"numAtRisk":14},{"groupId":"EG014","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG016","numEvents":1,"numAffected":1,"numAtRisk":6},{"groupId":"EG017","numEvents":1,"numAffected":1,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG016","numEvents":1,"numAffected":1,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Hypertriglyceridaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG016","numEvents":1,"numAffected":1,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Hypoglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Increased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":2,"numAffected":2,"numAtRisk":18},{"groupId":"EG012","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Muscle spasms","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Musculoskeletal chest pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG009","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Neck pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG014","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG009","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG010","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG013","numEvents":2,"numAffected":1,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG016","numEvents":1,"numAffected":1,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Dysgeusia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG016","numEvents":1,"numAffected":1,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":4,"numAffected":3,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":8},{"groupId":"EG008","numEvents":3,"numAffected":3,"numAtRisk":18},{"groupId":"EG009","numEvents":5,"numAffected":4,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG012","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG013","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG014","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG015","numEvents":4,"numAffected":3,"numAtRisk":13},{"groupId":"EG016","numEvents":1,"numAffected":1,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Hypoaesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Paraesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Sinus headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Somnolence","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG016","numEvents":1,"numAffected":1,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Tremor","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG009","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Dysthymic disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Dysuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG012","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":1,"numAffected":1,"numAtRisk":8}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Hiccups","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Nasal congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Oropharyngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG013","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":2,"numAffected":1,"numAtRisk":13},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Paranasal sinus discomfort","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Rhinitis allergic","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Dermatitis contact","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Dry skin","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG014","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Ecchymosis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":8},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG017","numEvents":1,"numAffected":1,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Erythema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":2,"numAffected":1,"numAtRisk":8},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Hyperhidrosis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG013","numEvents":1,"numAffected":1,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Nail ridging","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG009","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":2,"numAffected":1,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":2,"numAffected":2,"numAtRisk":8},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG011","numEvents":2,"numAffected":2,"numAtRisk":18},{"groupId":"EG012","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":8},{"groupId":"EG007","numEvents":1,"numAffected":1,"numAtRisk":8},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Rash erythematous","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG012","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Rash maculo-papular","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG012","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG017","numEvents":1,"numAffected":1,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Rash papular","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":2,"numAffected":1,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Rash pruritic","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG017","numEvents":1,"numAffected":1,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Skin irritation","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG016","numEvents":1,"numAffected":1,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Skin wrinkling","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG014","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Flushing","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG008","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG014","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG015","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":11},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG007","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG008","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG009","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG010","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG011","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG012","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG013","numEvents":0,"numAffected":0,"numAtRisk":14},{"groupId":"EG014","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG015","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG016","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG017","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG018","numEvents":0,"numAffected":0,"numAtRisk":8}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines."},"pointOfContact":{"title":"Senior Vice President, Global Clinical Development","organization":"Merck Sharp & Dohme Corp.","email":"ClinicalTrialsDisclosure@merck.com","phone":"1-800-672-6372"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-10-09","removedCountries":["United States"]},"conditionBrowseModule":{"meshes":[{"id":"D003920","term":"Diabetes Mellitus"}],"ancestors":[{"id":"D044882","term":"Glucose Metabolism Disorders"},{"id":"D008659","term":"Metabolic Diseases"},{"id":"D009750","term":"Nutritional and Metabolic Diseases"},{"id":"D004700","term":"Endocrine System Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000069450","term":"Liraglutide"}],"ancestors":[{"id":"D052216","term":"Glucagon-Like Peptide 1"},{"id":"D004763","term":"Glucagon-Like Peptides"},{"id":"D052336","term":"Proglucagon"},{"id":"D005768","term":"Gastrointestinal Hormones"},{"id":"D006728","term":"Hormones"},{"id":"D006730","term":"Hormones, Hormone Substitutes, and Hormone Antagonists"}]}},"hasResults":true}